De-differentiated t cells, and restoration and uses thereof
Transient transcription factor reprogramming using OSKM factors addresses the inefficiencies of current immunotherapies by reversing T cell exhaustion and expanding tumor-specific CD8 T cells for effective tumor treatment.
Patent Information
- Application Number
- PCT/US2026/028050
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-13
- Filing Date
- 2026-05-13
- Publication Date
- 2026-11-19
AI Technical Summary
Current immunotherapies, such as adoptive cellular therapy (ACT) and immune checkpoint blockade (ICB), are limited by the irreversible exhaustion of terminally differentiated tumor-specific T cells, which hinders the expansion and clinical utility of these cells, and existing reprogramming methods are inefficient and often result in loss of tumor specificity.
A method involving transient transcription factor reprogramming using OSKM factors, such as Sendai-OSKM, to de-differentiate exhausted tumor-specific T cells into stem-like memory T cells, maintaining tumor specificity and reversing exhaustion without full dedifferentiation to iPSCs.
Reverses T cell exhaustion, enabling the rapid expansion of tumor-specific CD8 T cells that can be reinfused to treat solid tumors, thereby enhancing the efficacy of immunotherapy by preserving tumor specificity and cellular sternness.
Smart Images

Figure US2026028050_19112026_PF_FP_ABST
Abstract
Description
[UCLA 2024-240] P-638467-PC DE-DIFFERENTIATED T CELLS, AND RESTORATION AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims priority to U.S. provisional patent application serial no.63 / 805,021, filed May 13, 2025, which is incorporated herein by reference in its entirety.FIELD OF INTEREST
[0002] This disclosure relates to de-differentiated T cells, as well as restoration and uses thereof, including transient transcription factor reprogramming to rejuvenate exhausted tumor-specific T cells into stem-like memory T cells.BACKGROUND
[0003] Immunotherapy is a promising (neo)adjuvant treatment strategy for patients with solid tumors, but currently benefits only 10-20% of patients (Y. Mao et al., Cancer Immunol, hnmunother. 72: 2483-2498 (2023)). In addition, immunotherapy is often used to treat patients with diffusely metastatic disease, as they are often considered not surgical candidates.
[0004] In the case of adoptive cellular therapy (ACT), a cell-based form of immunotherapy, cells can be harvested from the circulation or tumor and manipulated. Circulating CD8 T cells can be isolated and engineered with a chimeric T cell receptor, allowing them to target a single tumor antigen. Importantly, T cells circulating in the blood comprise the entire T cell repertoire, estimated to represent 1010different antigen specificities (Lythe, 2016, JTheorBiol, 21:389:214-24), such that cells harvested in this manner are almost certainly not tumor-specific. If a T cell is not tumor-specific, or capable of recognizing tumor antigens, it has no therapeutic utility. Engineering with a chimeric antigen receptor targeting a known tumor antigen, then, is essential for T cells derived from blood. In contrast, T cells infiltrating the tumor mass are predominantly tumor-specific and represent a range of T cell clones targeting multiple tumor antigens, and knowledge of these specific antigens is not necessary for the success of this approach. Accordingly, a primary or metastatic tumor can be surgically resected, tumor-specific polyclonal CD8 T cells isolated, expanded, and reinfused into the patient, followed by T cell extravasation at remaining tumor sites. Therefore, among the benefits of patient ACT using tumor-derived T cells, the modified cells are from a tumor-specific, polyclonal population — often recognizing many tumor antigens — with minimal off target toxicity.[UCLA 2024-240] P-638467-PC
[0005] Complete and durable responses are possible with ACT; however, these are currently infrequent and, when they do occur, require engraftment of rare stem-like T cells that can persist and self-renew (L. Gattinoni et al., Nature Medicine 17: 1290-1297 (2011)). A critical limitation to this approach is that most of a patient’s tumor-specific T cells that can be harvested from a resected tumor are terminally differentiated, or “exhausted.” Repeated tumor cell / antigen encounter and suppressive signaling in the tumor microenvironment (TME) drive T cell exhaustion, first described as the progressive loss of proliferation and effector function with accumulation of inhibitory surface proteins (E. J. Wherry et al., J. Virol. 77: 4911-4927 (2003)). Exhaustion is now understood to be an epigenetically mediated differentiation step that constrains sternness, proliferation, and effector functions (M. Philip et al., Nature 545: 452-456 (2017)). Moreover, tumor-specific T cells adopt this program extremely rapidly, within hours of initial activation (M. W. Rudloff et al., Nature Immunology 24: 1527-1539 (2023)). Even after removal of cognate antigen — e.g., with surgical resection or complete pathologic response — exhausted CD8 T cells are unable to re-acquire the stem-like capacity of their less differentiated counterparts (M. S. Abdel-Hakeem et al., Nature Immunology 22: 1008-1019 (2021)). This in turn limits the ability of tumor-specific T cells harvested from a tumor to expand and to generate the billions of cells needed for ACT, and while CD8 T cells available in the blood are typically not exhausted, they are very rarely tumor-specific, restricting their clinical utility. So, while less differentiated stem-like T cells are required for successful ACT, most of a patient’s tumor-specific T cell repertoire is either exhausted (terminally differentiated) or has already initiated that program. Moreover, non-exhausted T cells available in the blood are not tumor-specific. Therefore, there is a critical need to develop strategies that overcome exhaustion and promote “sternness” of tumor-specific T cells.
[0006] Tumor-infiltrating lymphocyte (TIL) therapy — a form of ACT comprised of surgically resecting a tumor, isolating T cells, growing them to large numbers ex vivo, and transferring back to the patient — was recently FDA-approved as a potentially curative treatment for patients with advanced cancers. However, its success absolutely requires transfer of rare stem-like memory T cells. Unfortunately, the large majority of tumor-specific T cells are non-functional owing to suppressive signals within the tumor, driving “T cell exhaustion”. T cell exhaustion is an epigenetically mediated progressive differentiation wherein continuous T cell receptor signaling reshapes the chromatin landscape to constrain sternness, proliferation, and effector functions.[UCLA 2024-240] P-638467-PC
[0007] Previous attempts to overcome T cell exhaustion have involved reprogramming T cells of a known specificity using stem cell technology. The epigenome of terminally differentiated cells of any lineage can be reset through de-differentiation into induced pluripotent stem cells (iPSC) via transcription factor reprogramming by introducing Oct3 / 4, Sox2, KLF4, and c-Myc (OSKM) (Okita, 2007, Nature, 448(7151):313-7). T cell de-differentiation to iPSC (which includes loss of T cell lineage identity) is herein termed “full reprogramming” and requires an additional step to re-differentiate iPSC derived from CD8 T cells (CD8-iPSC) back into CD8 T cells. Attempts at re-differentiating CD8-iPSC back into mature CD8ab T cells have included provision of Notch signaling on two-dimensional stromal or feeder cell cultures (e.g., OP9-DLL1). These attempts, however, generated aberrant CD8aa cells with compromised yield, engraftment, and specificity (Vizcardo, 2018, Cell Rep, 22(12):3175-3190). Seet et al improved upon CD8-iPSC re-differentiation with description of an artificial thymic organoid (ATO) that provides Notch signaling on stromal cells (MS5-DLL1 / 4) in a three-dimensional structure in an air-liquid interface culture (Montel-Hagen, Cell Stem Cell, 2019, 24(3):376-389; Montel-Hagen, Cell Reports, 2020, 33(4): 108320). When taken collectively, T cells may conceptually be dedifferentiated to iPSC with OSKM to erase their epigenome and re-differentiated with Notch signaling in an attempt to recover cellular sternness. However, despite recent advances, both the T cell-to-iPSC reprogramming (de-differentiation) and iPSC-to-T cell differentiation (redifferentiation or re-maturation, or maturation) remain exceedingly challenging and prohibitively inefficient. Additionally, T cells can lose their antigen / tumor specificity during the redifferentiation process (Minagawa, Cell Stem Cell, 2018, 23(6):850-858), which would render the resultant T cell therapeutic product not tumor-specific and clinically ineffective.
[0008] Alternative approaches to immunotherapy are also complicated. Immune checkpoint blockade (ICB) drugs have been developed targeting checkpoints in tumor progression, e.g., immunomodulatory and / or antitumor immune mechanisms / signaling pathways, including, but not limited to cytotoxic T-lymphocyte associated protein-4 (CTLA-4), programmed cell death- 1 (PD-1), programmed death ligand-1 (PD-L1), and lymphocyte activation gene-3 (LAG-3 / CD223) (Sun et al., Signal Transduction & Targeted Therapy 8: 320 (2023)). Although these drugs have shown some success, e.g., in patients with aggressive melanoma or non-small cell lung cancer (NSCLC), in the larger field of solid tumors, inseparable immune response and side effects, unconfirmed progressive disease, and complex regulatory networks of immune resistance Emit the widespread application of this approach. Moreover, ICB drugs such as anti-PD(L)l do[UCLA 2024-240] P-638467-PC not stimulate a de novo anti-tumor response but rather, are contingent upon a patient’s preexisting anti-tumor immune response. Specifically, anti-PD(L)l expands existing less differentiated memory CD8 T cells but does not create these subsets (hn, 2016, Nature, 537(7620):417-421).
[0009] TIL therapy is an approach in which a tumor is resected from the patient, e.g., with advanced melanoma, and T cells are isolated from the tumor with high dose interleukin-2 (IL-2). After a few weeks of laboratory growth and expansion, the T cells are injected back into the same patient and traffic to eradicate other sites of disease. TIL therapy can cause side effects, including, but not limited to, high fevers, chills, nausea, loss of appetite, headaches, dizziness, effects on the nervous system, low blood counts, fluid buildup leading to stress on the heart and lungs, shortness of breath, rapid heartbeat, low blood pressure, trouble breathing, rash, exhaustion and weakness.
[0010] Importantly, T cell differentiation is in a one-way direction. Many attempts have been made to reverse cell differentiation with epigenetic modifiers and ICB. However, once established, exhaustion is irreversible. This represents a significant clinical challenge because current immunotherapies, cellular-based (ACT or TIL) or antibody-based(ICB), rely on the presence of less differentiated CD8 T cells.
[0011] Methods for improved tumor treatment using immune cells are needed.SUMMARY
[0012] Provided herein are de-differentiated T cells, as well as restoration and uses thereof.
[0013] In some aspects, disclosed herein are stem-like memory T cells.
[0014] In some aspects, disclosed herein are methods of transient transcription factor reprogramming to rejuvenate exhausted tumor-specific T cells into tumor-specific stem-like memory T cells.
[0015] In some aspects, disclosed herein are tumor-specific stem-like memory T cells rejuvenated from exhausted tumor-specific T cells.
[0016] In some aspects, disclosed herein is a method to rapidly expand tumor-specific CD8 T cells. In a related aspect, these expanded tumor-specific T cells can be used as a therapeutic[UCLA 2024-240] P-638467-PC product by re-infusing them into the patient.
[0017] In some aspects, disclosed herein is a method to reverse T cell exhaustion through transcription factor reprogramming.
[0018] In some aspects, disclosed herein is a method to de-differentiate tumor-derived T cells into induced pluripotent stem cells (iPSC). In a related aspect, this method can be used to partially or transiently de-differentiate T cells from a terminally differentiated exhaustion state to less differentiated stem-like memory T cells without de-differentiating all the way to an iPSC.
[0019] In one aspect, a method is provided for treating a solid tumor in a subject comprising the steps of:a) isolating CD8 T cells from the tumor, tumor environment, tumor microenvironment or blood;b) exposing the CD8 T cells to de-differentiation-inducing conditions; c) inducing de-differentiation of the CD8 T cells;d) halting de-differentiation of the CD8 T cells at temporally and / or phenotypically defined time at which stem-like memory features are reacquired; ande) administering the CD8 T cells to the subject;whereby the solid tumor is treated.
[0020] In some embodiments, the solid tumor is melanoma, a mesenchymal cancer such as a sarcoma or an epithelial cancer such as pancreatic cancer.
[0021] In some embodiments, exposing the CD8 T cells to de-differentiation-inducing conditions comprises exposing the T cells to OSKM, such as Sendai-OSKM, optionally at a 5 :5 :3, 3:3:2, 2:2:1 or 1:1:1 ratio of c-Myc:KLF4-Oct3 / 4-Sox2:KLF4. In some embodiments, the inducing de-differentiation comprises exposing cells to OSKM in 100% T cell medium on days 0-1, then over the next 5-6 days reducing the percent (v / v) T cell medium and increasing the percent (v / v) stem cell medium with cytokines, followed by 100% stem cell medium with cytokines. In some embodiments, the inducing de-differentiation comprises exposing cells to 100% T cell medium with cytokines, such as from about day 2 to about day 8. In some[UCLA 2024-240] P-638467-PC embodiments, the cytokines comprise IL-2, IL-7 and / or IL- 15, such as such as 10-3000 lU / mL IL-2, 10-20 ng / mL IL-7 and / or 10-20 ng / mL IL-15, for example, 12 lU / mL IL-2, 10 ng / mL IL-7 and 10 ng / mL IL-15.
[0022] In some embodiments, inducing de-differentiation of the CD8 T cells comprisesexposing the CD8 T cells to Sendai-OSKM and 100% T cell medium on days 0- 1;exposing the CD8 T cells to 75% T cell medium, 25% stem cell medium and cytokines on about day 2;exposing the CD8 T cells to 50% T cell medium, 50% stem cell medium and cytokines on about day 3exposing the CD8 T cells to 25% T cell medium, 75% stem cell medium and cytokines on about day 4;exposing the CD8 T cells to 100% stem cell medium and cytokines on about day 5; andexposing the CD8 T cells to 100% stem cell medium and cytokines starting on about day 6.
[0023] In some embodiments, The method of claim 1, wherein during and / or after any one or more steps, the CD8 T cells are expanded. In some embodiments, the expansion occurs in T cell medium.
[0024] In some embodiments, halting de-differentiation is carried out when the majority of tumor-specific T cells have gained stem-like T cell features, such as any one or more of: positive CD3, positive CD8, high %Tcm (CD45RO+, CD62L+, CD95+, CCR7+ and / or IL-2Rb+), low SSEA421, and / or high %Tscm (CD45RA+, CD62L+, CD95+, CCR7+ and / or IL-2Rb+); and / or at a defined time point corresponding with acquisition of stem-like T cell features without loss of T cell lineage identity. In some embodiments, halting de-differentiation is carried out after about day 2 and before about day 21, such as on any one of days 2-8, such as on day 2, 3, 4, 6 or 8. In some embodiments, halting de-differentiation comprises exposing the T cells to T cell stimulation conditions. In some embodiments, T cell stimulation conditions comprises TCR signaling with or without costimulation, with or without T cell medium, or T cell medium with or without[UCLA 2024-240] P-638467-PC cytokines. In some embodiments, TCR signaling comprises exposure to one or more small molecules, peptides, cytokines, growth factors, and / or antibodies, such as anti-CD3 antibodies, anti-CD28 antibodies, irradiated PBMCs, TLR agonist such as R848, Notch ligand such as DLL4-Fc, cognate peptide, tumor cells, tumor lysate, antigen presenting cells, or any combination thereof, to achieve T cell stimulation, such as the combination of irradiated PBMCs, anti-CD3, IL-2, IL-7, IL-15, optionally including IL-21, TLR agonist and / or Notch ligand.
[0025] In some embodiments, the halted de-differentiation comprises expression of NFkB, NFAT, AP-1, Runxl / 3 and / or GATA3, and continued expression of CD3 and CD8; and / or lack of upregulation of canonical iPSC markers, such as SSEA3, SSEA4, CD30, Tra-1-60, Tra-1-81, or any combination thereof.
[0026] In some embodiments, the expanding of the T cells comprises further incubation of the T cells in T cell stimulation conditions.
[0027] In some embodiments, the T cells are infused into the subject.
[0028] In some embodiments, the CD8 cells isolated from the tumor express CD39, CD69, CD103, CD137, PD-1, TIM3, or any combination thereof.
[0029] In some embodiments, inducing de-differentiation of the CD8 T cells further comprises including at least one epigenetic modifier. In some embodiments, inducing de-differentiation of the CD8 T cells further comprises including vitamin C, a histone deacetylase inhibitor such as valproic acid (VPA), a histone methyltransferase inhibitor, such as a DOT1L inhibitor, optionally EPZ-5676 (pinometostat), and / or a GSK3b inhibitor such as CHIR99021. In some embodiments, a modulator of signal strength of the TCR is included.
[0030] In one aspect, transiently reprogrammed, tumor-specific CD8 T cells prepared by:a) exposing CD8 T cells obtained from a tumor, a tumor microenvironment or blood to de-differentiation-inducing conditions;b) inducing de-differentiation of the CD8 T cells; and[UCLA 2024-240] P-638467-PC c) halting de-differentiation of the CD8 T cells at a temporally or phenotypically defined time at which stem-like memory features are reacquired.
[0031] In some embodiments, the cells are expanded.
[0032] In some embodiments, exposing the CD8 T cells to de-differentiation-inducing conditions comprises transducing the T cells with OSKM, such as Sendai-OSKM, optionally at a 5:5:3, 3:3:2, 2:2:1 or 1:1:1 ratio of c-Myc:KLF4-Oct3 / 4-Sox2:KLF4. In some embodiments, inducing de-differentiation comprises exposing cells to OSKM in 100% T cell medium on days 0-1, then over the next 5-6 days reducing the percent (v / v) T cell medium and increasing the percent ( / v) stem cell medium with cytokines, followed by 100% stem cell medium with cytokines. In some embodiments, the inducing de-differentiation comprises exposing cells to 100% T cell medium with cytokines, such as from about day 2 to about day 8.
[0033] In some embodiments, the cytokines comprise IL-2, IL-7 and / or IL- 15, such as 10-3000 HJ / mL IL-2, 10-20 ng / mL IL-7 and / or 10-20 ng / mL IL-15, for example, 12 HJ / mL IL-2, 10 ng / mL IL-7 and 10 ng / mL IL-15.
[0034] In some embodiments, inducing de-differentiation of the CD8 T cells comprisesa) exposing the CD8 T cells to Sendai-OSKM and 100% T cell medium on days 0-1;b) exposing the CD8 T cells to 75% T cell medium, 25% stem cell medium and cytokines on about day 2;c) exposing the CD8 T cells to 50% T cell medium, 50% stem cell medium and cytokines on about day 3d) exposing the CD8 T cells to 25% T cell medium, 75% stem cell medium and cytokines on about day 4;e) exposing the CD8 T cells to 100% stem cell medium and cytokines on about day 5; andf) exposing the CD8 T cells to 100% stem cell medium and cytokines starting on about day 6.[UCLA 2024-240] P-638467-PC
[0035] In some embodiments, during and / or after any one or more steps, the CD8 T cells are expanded. In some embodiments, the expansion occurs in T cell medium.
[0036] In some embodiments, the halting de-differentiation is carried out when the majority of tumor-specific T cells have gained stem-like T cell features, such as any one or more of: positive CD3, positive CD8, high %Tcm (CD45RO+, CD62L+, CD95+, CCR7+ and / or IL-2Rb+), low SSEA421, and / or high %Tscm (CD45RA+, CD62L+, CD95+, CCR7+ and / or IL-2Rb+); and / or at a defined time point corresponding with acquisition of stem-like T cell features without loss of T cell lineage identity. In some embodiments, the halting de-differentiation is carried out after about day 2 and before about day 21, such as on any one of days 2-8, such as on day 2, 3, 4, 6 or 8. In some embodiments, the T cell medium comprises TCR signaling. In some embodiments, the TCR signaling comprises exposure to anti-CD3 antibodies, anti-CD28 antibodies, irradiated PBMCs, TLR agonist such as R848, Notch ligand such as DLL4-Fc, cognate peptide, tumor cells, tumor lysate, antigen presenting cells, or any combination thereof, to achieve T cell stimulation, such as the combination of irradiated PBMCs, anti-CD3, IL-2, IL-7, IL-15, optionally including IL-21, TLR agonist and / or Notch ligand, or any combination thereof. In some embodiments, the halted de-differentiation comprises expression of NFkB, NFAT, AP-1, Runxl / 3 and / or GATA3, with continued expression of CD3 and CD8; and / or lack of upregulation of canonical iPSC markers, such as SSEA3, SSEA4, CD30, Tra-1-60, Tra-1-81, or any combination thereof.
[0037] In some embodiments, the expanding T cells in step e. comprises further incubation of the T cells in T cell medium.
[0038] In some embodiments, the transiently reprogrammed CD8 T cells are prepared for infusion into a subject. In some embodiments, the CD8 cells are obtained from a tumor, tumor environment, tumor microenvironment or blood. In some embodiments, the CD8 cells isolated form the tumor, tumor environment, tumor microenvironment or blood express CD39, CD69, CD103, CD137, PD-1, TIM3, or any combination thereof.
[0039] In one aspect, a method is provided for treating a solid tumor in a subject comprising the steps of:a) isolating CD8 T cells from the tumor, tumor environment, tumor microenvironment or blood;[UCLA 2024-240] P-638467-PC b) exposing the CD8 T cells to de-differentiation-inducing conditions; c) inducing full de-differentiation of the CD8 T cells to iPSCs; d) maturing the iPSCs back into CD8 T cells; ande) administering the CD8 T cells to the subject;whereby the solid tumor is treated.
[0040] In some embodiments, the solid tumor is melanoma, a mesenchymal cancer such as a sarcoma or an epithelial cancer such as pancreatic cancer.
[0041] In some embodiments, exposing the CD8 T cells to de-differentiation-inducing conditions comprises exposing the T cells to OSKM, such as Sendai-OSKM, optionally at a 5:5:3, 3:3:2, 2:2:1 or 1:1:1 ratio of c-Myc:KLF4-Oct3 / 4-Sox2:KLF4. In some embodiments, inducing dedifferentiation comprises exposing cells to OSKM in 100% T cell medium on days 0-1, then over the next 3-4 days reducing the percent (v / v) T cell medium and increasing the percent (v / v) stem cell medium with cytokines, followed by 100% stem cell medium without cytokines. In some embodiments, inducing de-differentiation comprises exposing cells to 100% T cell medium with cytokines from about day 2 to about day 5. In some embodiments, the cytokines comprise IL-2, IL-7 and / or IL-15, such as 10-3000 HJ / mL IL-2, 10-20 ng / mL IL-7 and / or 10-20 ng / mL IL-15, for example, 12 HJ / mL IL-2, 10 ng / mL IL-7 and 10 ng / mL IL- 15. In some embodiments, the T cells are exposed to 100% T cell medium without cytokines starting about day 6.
[0042] In some embodiments, inducing de-differentiation of the CD8 T cells comprises a) exposing the CD8 T cells to Sendai-OSKM and 100% T cell medium on days 0-1;b) exposing the CD8 T cells to 75% T cell medium, 25% stem cell medium and cytokines on about day 2;c) exposing the CD8 T cells to 50% T cell medium, 50% stem cell medium and cytokines on about day 3d) exposing the CD8 T cells to 25% T cell medium, 75% stem cell medium and cytokines on about day 4;e) exposing the CD8 T cells to 100% stem cell medium and cytokines on about day 5; and[UCLA 2024-240] P-638467-PC f) exposing the CD8 T cells to 100% stem cell medium without cytokines starting on about day 6; andg) exposing the CD8 T cells to 100% stem cell medium without cytokines for the reminder of culture.
[0043] In some embodiments, the full de-differentiation occurs over about 1-2 months. In some embodiments, during and / or after any one or more steps, the iPSC are expanded. In some embodiments, the expansion occurs in stem cell medium. In some embodiments, the maturing of the iPSCs to T cells is carried out by culturing the iPSCs in an ATO. In some embodiments, the culturing in an ATO is carried out for about 3-4 months. In some embodiments, the expanding T cells in step e. comprises further incubation of the T cells in T cell medium.
[0044] In some embodiments, the T cells are infused into the subject. In some embodiments, the CD8 cells isolated from the tumor, tumor environment, tumor microenvironment or blood express CD39, CD69, CD103, CD137, PD-1, TIM3, or any combination thereof.
[0045] In some embodiments, inducing de-differentiation of the CD8 T cells further comprises including at least one epigenetic modifier. In some embodiments, inducing de-differentiation of the CD8 T cells further comprises including vitamin C, a histone deacetylase inhibitor such as valproic acid (VPA), a histone methyltransferase inhibitor, such as a DOT1L inhibitor, optionally EPZ-5676 (pinometostat), and / or a GSK3b inhibitor such as CHIR99021.
[0046] In some embodiments, the iPSC are induced or matured into mesodermal progenitors followed by hematopoietic progenitor induction then differentiated into naive or stem-like T cells. In some embodiments, the iPSCs are exposed to Activin A, BMP4, VEGF, and FGF to induce mesodermal induction. In some embodiments, hematopoietic induction can then be accomplished by aggregating mesodermal progenitors with a mouse bone marrow stromal cell line expressing human delta-like ligand 4 (MS5-DLL4) and culturing resultant organoids initially in EGM2 media with a TGFb inhibitor then EGM2 media with a TGFb inhibitor plus SCF, FLT3L, and TPO. In some embodiments, T cell differentiation into naive or stem-like T cells can then be accomplished by continued organoid culture in RPMI media supplemented with ascorbic add, B27 supplement, SCF, FLT3L, IL-7.
[0047] In one aspect, provided are programmed, tumor-specific CD8 T cells prepared by:[UCLA 2024-240] P-638467-PC a) exposing CD8 T cells isolated from a tumor, a tumor microenvironment or blood to de-differentiation-inducing conditions;b) inducing full de-differentiation of the CD8 T cells to iPSCs; and c) re-maturing or re-differentiating the iPSCs to CD8 T cells.
[0048] In some embodiments, the fully reprogrammed CD8 T cells are expanded. In some embodiments, exposing the CD8 T cells to de-differentiation-inducing conditions comprises transducing the T cells with OSKM, such as Sendai-OSKM, optionally at a 5:5:3, 3:3:2, 2:2: 1 or 1:1:1 ratio of c-Myc:KLF4-Oct3 / 4-Sox2:KLF4. In some embodiments, the inducing dedifferentiation comprises exposing cells to OSKM in 100% T cell medium on days 0-1, then over the next 5-6 days reducing the percent (v / v) T cell medium and increasing the percent (v / v) stem cell medium with cytokines, followed by 100% stem cell medium without cytokines. In some embodiments, the inducing de-differentiation comprises exposing cells to 100% T cell medium with cytokines from about day 2 to about day 5. In some embodiments, the cytokines comprise IL-2, IL-7 and / or IL- 15, such as 10-3000 TU / mL IL-2, 10-20 ng / mL IL-7 and / or 10-20 ng / mL IL-15, for example, 12 TU / mL IL-2, 10 ng / mL IL-7 and 10 ng / mL IL-15. In some embodiments, the T cells are exposed to 100% T cell medium without cytokines starting about day 6.
[0049] In some embodiments, inducing de-differentiation of the CD8 T cells comprises:a) exposing the CD8 T cells to Sendai-OSKM and 100% T cell medium on days 0-1;b) exposing the CD8 T cells to 75% T cell medium, 25% stem cell medium and cytokines on about day 2;c) exposing the CD8 T cells to 50% T cell medium, 50% stem cell medium and cytokines on about day 3d) exposing the CD8 T cells to 25% T cell medium, 75% stem cell medium and cytokines on about day 4;e) exposing the CD8 T cells to 100% stem cell medium and cytokines on about day 5; andf) exposing the CD8 T cells to 100% stem cell medium without cytokines starting on about day 6; andg) exposing the CD8 T cells to 100% stem cell medium without cytokines for the reminder of culture.[UCLA 2024-240] P-638467-PC
[0050] In some embodiments, for the fully reprogrammed CD8 T cells, the de-differentiation occurs over about 2 months. In some embodiments, during and / or after any one or more steps, the iPSC are expanded. In some embodiments, the expansion occurs in stem cell medium. In some embodiments, the re-maturing of the iPSCs to T cells is carried out by culturing the iPSCs in an ATO. In some embodiments, the culturing is carried out for about 3-4 months.
[0051] In some embodiments, the T cells are prepared for infusion into a subject. In some embodiments, the CD8 cells isolated from the tumor, tumor microenvironment or blood express CD39, CD69, CD103, CD137, PD1, TIM3, or any combination thereof.
[0052] In one aspect, a method for partially reprogramming T cells is provided comprising the steps of:a. isolating CD8 T cells from a tumor, tumor environment, tumor microenvironment or blood;b. exposing the CD8 T cells to de-differentiation-inducing conditions;c. inducing de-differentiation of the CD8 T cells; andd. halting de-differentiation of the CD8 T cells at temporally and / or phenotypically defined time at which stem-like memory features are reacquired.
[0053] In some embodiments, the solid tumor is melanoma, a mesenchymal cancer such as a sarcoma or an epithelial cancer such as pancreatic cancer.
[0054] In some embodiments, exposing the CD8 T cells to de-differentiation-inducing conditions comprises exposing the T cells to OSKM, such as Sendai-OSKM, optionally at a 5:5:3, 3:3:2, 2:2:1 or 1:1:1 ratio of c-Myc:KLF4-Oct3 / 4-Sox2:KLF4. In some embodiments, the inducing de-differentiation comprises exposing cells to OSKM in 100% T cell medium on days 0- 1 , then over the next 5-6 days reducing the percent (v / v) T cell medium and increasing the percent (v / v) stem cell medium with cytokines, followed by 100% stem cell medium with cytokines. In some embodiments, the inducing de-differentiation comprises exposing cells to 100% T cell medium with cytokines, such as from about day 2 to about day 8.[UCLA 2024-240] P-638467-PC
[0055] In some embodiments, the cytokines comprise IL-2, IL-7 and / or IL- 15, such as such as 10-3000 lU / mL IL-2, 10-20 ng / mL IL-7 and / or 10-20 ng / mL IL-15, for example, 12 lU / mL IL-2, 10 ng / mL IL-7 and 10 ng / mL IL-15.
[0056] In some embodiments, inducing de-differentiation of the CD8 T cells comprises a. exposing the CD8 T cells to Sendai-OSKM and 100% T cell medium on days 0-1;b. exposing the CD8 T cells to 75% T cell medium, 25% stem cell medium and cytokines on about day 2;c. exposing the CD8 T cells to 50% T cell medium, 50% stem cell medium and cytokines on about day 3d. exposing the CD8 T cells to 25% T cell medium, 75% stem cell medium and cytokines on about day 4;e. exposing the CD8 T cells to 100% stem cell medium and cytokines on about day 5; andf. exposing the CD8 T cells to 100% stem cell medium and cytokines starting on about day 6.
[0057] In some embodiments, during and / or after any one or more steps, the CD8 T cells are expanded. In some embodiments, the expansion occurs in T cell medium.
[0058] In some embodiments, the halting de-differentiation is carried out when the majority of tumor-specific T cells have gained stem-like T cell features, such as any one or more of: positive CD3, positive CD8, high %Tcm (CD45RO+, CD62L+, CD95+, CCR7+ and / or IL-2Rb+), low SSEA421, and / or high %Tscm (CD45RA+, CD62L+, CD95+, CCR7+ and / or IL-2Rb+); and / or at a defined time point corresponding with acquisition of stem-like T cell features without loss of T cell lineage identity.
[0059] In some embodiments, the halting de-differentiation is carried out after about day 2 and before about day 21, such as on any one of days 2-8, such as on day 2, 3, 4, 6 or 8. In some embodiments, the halting de-differentiation comprises exposing the T cells to T[UCLA 2024-240] P-638467-PC cell stimulation conditions. In some embodiments, the T cell stimulation conditions comprises TCR signaling with or without costimulation, with or without T cell medium, or T cell medium with or without cytokines. In some embodiments, the TCR signaling comprises exposure to one or more small molecules, peptides, cytokines, growth factors, and / or antibodies, such as anti-CD3 antibodies, anti-CD28 antibodies, irradiated PBMCs, TLR agonist such as R848, Notch ligand such as DLL4-Fc, cognate peptide, tumor cells, tumor lysate, antigen presenting cells, or any combination thereof, to achieve T cell stimulation, such as the combination of irradiated PBMCs, anti-CD3, IL-2, IL-7, IL-15, optionally including IL-21, TLR agonist and / or Notch ligand.
[0060] In some embodiments, the halted de-differentiation comprises expression of NFkB, NFAT, AP-1, Runxl / 3 and / or GATA3, and continued expression of CD3 and CD8; and / or lack of upregulation of canonical iPSC markers, such as SSEA3, SSEA4, CD30, Tra-1-60, Tra-1-81, or any combination thereof.
[0061] In some embodiments, the expanding of the T cells comprises further incubation of the T cells in T cell stimulation conditions.
[0062] In some embodiments, the CD8 T cells isolated from the tumor express CD39, CD69, CD103, CD137, PD-1, TIM3, or any combination thereof.
[0063] In some embodiments, inducing de-differentiation of the CD8 T cells further comprises including at least one epigenetic modifier. In some embodiments, inducing de-differentiation of the CD8 T cells further comprises including vitamin C, a histone deacetylase inhibitor such as valproic add (VP A), a histone methyltransferase inhibitor, such as a DOT1L inhibitor, optionally EPZ-5676 (pinometostat), and / or a GSK3b inhibitor such as CHIR99021.
[0064] In some embodiments, inducing de-differentiation further comprising a modulator of signal strength of the TCR.
[0065] In one aspect, a method for fully reprogramming T cells is provided comprising the steps of:a. isolating CD8 T cells from a tumor, tumor environment, tumor microenvironment or blood;[UCLA 2024-240] P-638467-PC b. exposing the CD8 T cells to de-differentiation-inducing conditions;c. inducing full de-differentiation of the CD8 T cells to iPSCs; andd. maturing the iPSCs back into CD8 T cells.
[0066] In some embodiments, the solid tumor is melanoma, a mesenchymal cancer such as a sarcoma or an epithelial cancer such as pancreatic cancer.
[0067] In some embodiments, exposing the CD8 T cells to de-differentiation-inducing conditions comprises exposing the T cells to OSKM, such as Sendai-OSKM, optionally at a 5:5:3, 3:3:2, 2:2:1 or 1:1:1 ratio of c-Myc:KLF4-Oct3 / 4-Sox2:KLF4.
[0068] In some embodiments, inducing de-differentiation comprises exposing cells to OSKM in 100% T cell medium on days 0-1, then over the next 3-4 days reducing the percent (y / v) T cell medium and increasing the percent (v / v) stem cell medium with cytokines, followed by 100% stem cell medium without cytokines. In some embodiments, inducing de-differentiation comprises exposing cells to 100% T cell medium with cytokines from about day 2 to about day 5. In some embodiments, the cytokines comprise IL-2, IL-7 and / or IL- 15, such as such as 10-3000 lU / mL IL-2, 10-20 ng / mL IL-7 and / or 10-20 ng / mL IL-15, for example, 12 lU / mL IL-2, 10 ng / mL IL-7 and 10 ng / mL IL-15. In some embodiments, the T cells are exposed to 100% T cell medium without cytokines starting about day 6.
[0069] In some embodiments, inducing de-differentiation of the CD8 T cells comprises a. exposing the CD8 T cells to Sendai-OSKM and 100% T cell medium on days 0-1;b. exposing the CD8 T cells to 75% T cell medium, 25% stem cell medium and cytokines on about day 2;c. exposing the CD8 T cells to 50% T cell medium, 50% stem cell medium and cytokines on about day 3d. exposing the CD8 T cells to 25% T cell medium, 75% stem cell medium and cytokines on about day 4;[UCLA 2024-240] P-638467-PC e. exposing the CD8 T cells to 100% stem cell medium and cytokines on about day 5; andf. exposing the CD8 T cells to 100% stem cell medium without cytokines starting on about day 6; andg. exposing the CD8 T cells to 100% stem cell medium without cytokines for the reminder of culture.
[0070] In some embodiments, the full de-differentiation occurs over about 1-2 months.
[0071] In some embodiments, during and / or after any one or more steps, the iPSC are expanded. In some embodiments, the expansion occurs in stem cell medium.
[0072] In some embodiments, the maturing of the iPSCs to T cells is carried out by culturing the iPSCs in an ATO.
[0073] In some embodiments, the culturing is carried out for about 3-4 months.
[0074] In some embodiments, the CD8 T cells isolated from the tumor, tumor environment, tumor microenvironment or blood express CD39, CD69, CD103, CD137, PD-1, TIM3, or any combination thereof.
[0075] In some embodiments, inducing de-differentiation of the CD8 T cells further comprises including at least one epigenetic modifier. In some embodiments, inducing de-differentiation of the CD8 T cells further comprises including vitamin C, a histone deacetylase inhibitor such as valproic add (VP A), a histone methyltransferase inhibitor, such as a DOT1L inhibitor, optionally EPZ-5676 (pinometostat), and / or a GSK3b inhibitor such as CHIR99021.
[0076] In some embodiments, the iPSC are induced or matured into mesodermal progenitors (mesodermal induction), followed by induction into hematopoietic progenitors (hematopoietic induction), and then into differentiated into naive or stemlike T cells (T cell differentiation). In some embodiments, the iPSCs are sequentially exposed toa. activin A, BMP4, VEGF, and FGF (mesodermal induction);[UCLA 2024-240] P-638467-PC b. aggregating mesodermal progenitors with a MS5-DLL4 cells and culturing resultant organoids initially in EGM2 media with a TGFb inhibitor then EGM2 media with a TGFb inhibitor plus SCF, FLT3L, and TPO (hematopoietic induction); andc. cultured in RPMI media supplemented with ascorbic acid, B27 supplement, SCF, FLT3L, IL-7 (T cell differentiation).BRIEF DESCRIPTION OF THE DRAWINGS
[0077] The subject matter regarded as the invention is particularly pointed out and distinctly claimed in the concluding portion of the specification. The invention, however, both as to organization and method of operation, together with objects, features, and advantages thereof, may best be understood by reference to the following detailed description when read with the accompanying drawings in which:
[0078] FIGURE 1 shows a schematic representation of adoptive cellular therapy (ACT). Here, a tumor (primary or metastatic) can be surgically removed (step 1) and T cells isolated. CD4 and CD8 T cells that are present within a patient’s tumor are assumed to be largely tumor-specific because this is what causes them to remain in the tumor and respond to tumor antigen. Isolated CD4 or CD8 T cells can then be expanded ex vivo to generate the billions of cells needed for ACT (step 2). At this stage, T cells can also be manipulated with culture conditions (e.g., addition of small molecules, metabolites, other cell types, etc.) or through gene engineering approaches (e.g., introduction of genes or chimeric antigen receptors using CRISPR or other methods) to render cells more efficacious. Herein, T cell reprogramming is accomplished during step 2. Therapeutic T cells are then transferred back to the same patient in step 3 such that they can traffic through the blood to reach the tumor, extravasate, and kill tumor cells in step 4. Adapted from Crompton et al. 2017 (Crompton, Annals Surgical Oncology, 2017, 25(2):565-572).
[0079] FIGURE 2 shows a schematic representation of the linear model of T cell differentiation. Importantly, this differentiation is one-way (see arrow from left to right). As depicted by the arrow, the T cell differentiation stages proceed as follows (left to right): naive T cell, stem central memory T cell, central memory T cell, effector T cell, and exhausted T cell. As differentiation increases, left to right, sternness decreases. Many attempts have been made to reverse the process with epigenetic modifiers and ICB. However, once established, exhaustion has previously been[UCLA 2024-240] P-638467-PC irreversible.
[0080] FIGURE 3 shows a schematic representation depicting “full reprogramming” — exhausted T cell to iPSC to rejuvenated / reprogrammed T cell — an exemplary strategy for reversing T cell exhaustion. The images, left to right, depict a resected tumor; a representative exhausted T cell (red) isolated from the resected tumor; a representative induced pluripotent stem cell (iPSC) (purple) generated from the exhausted T cell using transcription factor reprogramming (however, this might also be accomplished with a constellation of small molecules (Liuyang, Cell Stem Cell, 2023, 30(4):450-459)); an artificial thymic organoid culture containing T cell-derived iPSC; and a representative reprogrammed T cell (blue) following artificial thymic organoid culture.
[0081] FIGURE 4 depicts an exemplary experimental design used for culture conditions over a thirty-day (30-day) period for the generation of iPSC from human CD8 (hCD8) T cells. Notably, TCR stimulation — represented here as anti-CD3 / anti-CD28 antibodies — is absent during T cell de-differentiation following infection with sendai-OSKM.
[0082] FIGURE 5 is a schematic depicting a strategy of “full reprogramming” of T cells using sendai-OSKM at various differentiation states to study the effect of starting T cell differentiation state on de-differentiation potential. Cells depicted are, left to right, iPSC, hematopoietic progenitor cells, naive T cells, stem central memory T cells, central memory T cells, effector T cells, and exhausted T cells. In this experimental design T cell subsets at various differentiation states — exhausted T cells, or effector T cells, or central memory T cells, or stem central memory T cells — will be sorted using FACS, transduced with sendai-OSKM, and then “full reprogramming” assessed. Here, as T cell de-differentiates beyond a naive T cell it begins to lose T cell lineage identity as it progresses toward hematopoietic progenitors or other intermediate cells in the process of becoming an iPSC.
[0083] FIGURES 6A-6F relate to a series of experiments concerning “full reprogramming” of CD8 T cells to iPSC. FIGURE 6A is a pair of flow cytometry plots comparing the starting differentiation states of bulk CD8 T cells isolated from blood (top) or human tumor (bottom) as measured by programmed cell death protein- 1 (PD-1) and T-cell immunoglobulin and mucindomain containing-3 (TIM-3) expression. Numbers represent frequency of double positive cells. Plots demonstrate increased PD1 and TIMS expression on CD8 T cells isolated from a tumor,[UCLA 2024-240] P-638467-PC consistent with a more differentiated, exhausted phenotype. FIGURE 6B is a series of immunofluorescence (IF) images of CD8-iPSC generated either from circulating CD8 T cells (blood) (top) or from tumor-infiltrating CD8 T cells (tumor) (bottom), left to right, stained with 4’,6-diamidino-2-phenylindole (DAPI) (left) or with an antibody targeting homeobox protein NANOG (NANOG or hNanog or Nanog; a transcriptional factor that helps stem cells maintain pluripotency by suppressing cell determination factors and associated with some cancers, used as a marker of iPSC in culture) (center) or as an overlay of the two detection methods (right). FIGURE 6C is a graph demonstrating “full reprogramming” efficiency at an early time point (day 7) when starting with bulk CD8 T cells isolated from blood or tumor and FIGURE 6D is a corresponding plot that shows the total number of iPSC-like colonies emerging at day 7. T cells from tumor do form iPSC colonies at later timepoints but this is notably slower than the rate at which T cells from blood are able to de-differentiate fully into iPSC. Next, a series of experiments were performed to test the de-differentiation potential of patient-matched CD8 T cell subsets sorted based on their differentiation state, from least to most differentiated: stem central memory (Tscm), central memory (Tcm), effector memory (Tern), effector (Teff), and exhausted (Tex). These sorted subsets were subjected to “full reprogramming”, as described above, via transduction with sendai-OSKM. After infection with sendai-OSKM, transduced T cells demonstrate a burst of proliferation. This is shown in FIGURE 6E, a graph depicting the fold expansion for, left to right, stem central memory (Tscm), central memory (Tcm), effector memory (Tern), effector (Teff), and exhausted (Tex) CD8 T cells measured 5 days after sendai-OSKM transduction. Less differentiated T cell subsets generally proliferate more than more differentiated subsets following OSKM transduction. FIGURES 6F-6G demonstrate “full reprogramming” efficiency when starting with T cell subsets at various differentiation states. In FIGURE 6F, CD8 T cells were sorted by FACS from blood and tumor of a patient with high-grade leiomyosarcoma (a high grade STS that usually penetrates beyond its compartment (stage HB)) and in FIGURE 6G, CD8 T cells were sorted from blood and tumor of a different patient with a well-differentiated liposarcoma (WDLPS; atypical lipomatous tumor and a less aggressive STS).
[0084] FIGURES 7A-7C depict the results of “full reprogramming” when starting with a polyclonal, exhausted CD8 T cell population isolated from a patient tumor (tumor infiltrating lymphocytes; TIL). FACS sorted CD8 T cells were transduced with sendai-OSKM and maintained in culture under stem cell conditions, as described above. FIGURE 7A is a graph showing expression of sialyl-glycolipid stage-specific embryonic antigen 4 (SSEA4) as measured[UCLA 2024-240] P-638467-PC by median fluorescence intensity (MFI) on flow cytometry. Expression of SSEA4 on CD8-iPSC is compared against a sample of peripheral blood mononuclear cells (which contain T cells) to demonstrate dramatic upregulation of this stem cell marker compared with non-transfected cells.FIGURE 7B is a graph showing expression of NANOG as measured by MFI on flow cytometry. Expression of NANOG on CD8-iPSC is compared against a sample of peripheral blood mononuclear cells to demonstrate dramatic upregulation of this stem cell marker compared with non-transfected cells. FIGURE 7C is a light microscopy image (4X magnification) showing a mature CD8-iPSC colony at approximately 60 days post sendai-OSKM. Note the cells are tightly packed in the colony and the colony edges are smooth without evidence of differentiation (which would appear as less dense solitary or small groups of larger cells breaking away from the colony), as is characteristic of a mature iPSC colony.
[0085] FIGURES 8A-8C demonstrate results of re-programming CD8-iPSC into mature CD8ab T cells using an ATO. For these experiments, CD8-iPSC were generated by starting with exhausted CD8 T cells isolated form a patient tumor and then “fully reprogrammed” with sendai-OSKM. CD8-iPSC were then cultured in an ATO and aliquots harvested at week 2, 3, and 4 for cell enumeration and characterization by flow cytometry. FIGURE 8A-8B are flow cytometry plots characterizing cell phenotype as they progress through the ATO culture. After 2 weeks of culture in the ATO (FIGURE 8A), CD8-iPSC are maturing back into T cells and demonstrating key components of the T cell lineage. From left to right: cells in the ATO are stained for CD45 expression (x-axis), CD45+ cells are then assessed for expression of CD5 (y-axis) and CD7 (x-axis), CD5+ cells are then assessed for TCRab (y-axis) and CD3 (x-axis) expression, CD3+ TCRab+ cells are then assessed for CD8 (y-axis) and CD4 (x-axis) expression. FIGURE 8B shows maturation of CD8-iPSC in the ATO culture at 4 weeks. From left to right: cells in the ATO are stained for CD45 expression (x-axis), CD45+ cells are then assessed for expression of TCRab (y-axis) and CD3 (x-axis), CD3+ TCRab-i- cells are then assessed for CD8 (y-axis) and CD4 (x-axis) expression. By 4 weeks of ATO culture, maturing T cells are largely CD8+ CD4- (single positives), consistent with native CD8 T cell development. CD8+ CD4- cells are then assessed for CD8b expression (x-axis), and CD8b+ cells are then assessed for CD45RO (y-axis) and CD45RA (x-axis) expression. FIGURE 8C shows enumeration of total cells present in four ATO cultures at 2, 3, and 4 weeks of culture. T9-1 and T9-2 are the ATO cultures starting with CD8-iPSC (originally generated from polyclonal, exhausted CD8 T cells) compared to Nll-WT, a control iPSC cell fine derived from less differentiated CD8 T cells that are known to progress though the[UCLA 2024-240] P-638467-PC ATO culture (used as a positive control).
[0086] FIGURE 9 is an example schematic representation of T cell de-differentiation using down titration of OSKM factors. Here, more differentiated T cells (effector or exhausted) are infected with sendai-OSKM in limiting concentrations — 5:5:3 (positive control, manufacturer recommended), 3:3:2, or 1:1:1 of c-Myc:KOS:KLF4. The schematic depicts a red “dedifferentiation” arrow pointing from right to left, or in the direction of reverse differentiation, to indicate that after sendai-OSKM T cells progressively de-differentiate. The arrow fades out as it progresses from left to right representing the idea that down titration of OSKM might allow cells to begin de-differentiation but not complete “full reprogramming” or progress all the way to iPSC. In this way, with down titration of OSKM, T cells might de-differentiate into less differentiated memory subsets but not so far as to lose lineage identity.
[0087] FIGURE 10 is a graph depicting post-infection cell counts as a function of a 10-day period for ratios of 5:5:3 (blue circles), 3:3:2 (green squares), or 1:1:1 (red triangles). Black vertical arrows indicate when the culture plates were split at approximately at 1 : 1 ratio.
[0088] FIGURES 11A-11H depict characterization of OSKM titration kinetics. FIGURE 11A is a reference schematic depicting exemplary stages of differentiation, left to right, induced pluripotent stem cells (iPSC), hematopoietic stem cells (HSC), stem central memory cells (SCM), central memory cells (CM), effector memory cells (EM), effector cells (Eft), and exhausted cells (EX). FIGURES 11B-11H are graphs wherein CD8 T cells are transduced with sendai-OSKM at different ratios using the previously described culture conditions to test if down titration of OSKM factors might achieve “transient reprogramming”. Here, down titration conditions are as follows: blue circles represent conditions having a 5:5:3 ratio of c-Myc:KOS:KLF4, green squares represent conditions having a 3:3:2 ratio, and red triangles represent conditions having a 1:1:1 ratio. FIGURE 11B is a graph depicting expression of CD3 in cells over time after transduction with sendai-OSKM by flow cytometry with staining intensity represented as the mean fluorescent intensity (MFI) of cells over time (day 2-day 15). FIGURE 11C is a graph depicting the MFI of CD8 expression following sendai-OSKM infection over time (day 2-day 15). FIGURE 11D is a graph depicting the percentage of Tcm cells in culture over time (day 2-day 15) after sendai-OSKM transduction under each of the three conditions. FIGURE HE is a graph depicting the frequency of Tscm cells in culture over time (day 2-day 15) under each of the three conditions, following sendai-OSKM transduction. FIGURE HF is a graph depicting the MFI of SSEA421[UCLA 2024-240] P-638467-PC expression on cells over time (day 2-day 15) under each of the three conditions, following sendai-OSKM transduction. FIGURE 11G is a bar graph depicting induced pluripotent stem cell colonies formed at a single time point — day 12 — under each of the three conditions, following sendai-OSKM transduction. CD8 T cells were transduced with sendai-OSKM at a 5:5:3, 3:3:2, or 1:1:1 ratio and cells were harvested at each timepoint listed between day 3 to day 15 and subjected to bulk RNA sequencing. FIGURE 11H is a principal component analysis of bulk-RNA sequencing at each time point when down titrating the OSKM ratio. At days 3-6 CD8 T cells remain largely similar to each other regardless what ratio of OSKM was used for transduction. By day 10, cells are becoming transcriptionally distinct from those at earlier time points (day 3-6) and the 5:5:3 and 3:3:2 conditions are also becoming distinct from the 1 : 1 : 1 condition. By day 15 these differences are more pronounced. Cells at day 15 are distinct from other time point and the 5:5:3 and 3:3:2 conditions are now notably separate from the 1:1:1 condition.
[0089] FIGURE 12 is a schematic depicting the transient reprogramming strategy for halting dedifferentiation reprogramming in order to retain lineage identity. Here, T cell receptor (TCR) signaling is introduced at a representative defined timepoint prior to loss of T cell lineage such that reprogrammed CD8 T cells never lose their T cell identity. This time point might be after cells de-differentiate to Tcm, after cells de-differentiate to Tscm, or after cells de-differentiate to naive T cells but before they progress further and lose T cell lineage identity. Thus, introduction of TCR signaling at defined time point halts de-differentiation at the T cells current differentiation state and does not allow it to continue de-differentiating.
[0090] FIGURE 13A is a schematic depicting a representative experimental design for arresting de-differentiation, or “transient reprogramming,” and the confirmation of the same. T cells are FACS sorted then infected with sendai-OSKM at a 5:5:3, 3:3:2, or 1:1:1 ratio. Cells are then cultured in reprogramming conditions as described above. At different times following sendai-OSKM infection, reprogramming T cells are harvested and transferred to T cell conditions with 100% cytokines (IL-2 at 12-2000IU / mL, IL-7 lOng / mL, IL- 15 at lOng / mL) and TCR stimulation (in some embodiments provided by plate bound anti-CD3 and anti-CD28, as indicated in the figure). In this series of experiments, cells were transferred from reprogramming conditions to T cell conditions on day 4 or day 6 or day 7 after sendai-OSKM. These time points precede the point at which the majority of the culture begins to adopt iPSC characteristics (represented by arrows from iPSC culture conditions down to T cell conditions prior to the far right image of an iPSC culture). “Transiently reprogrammed” CD8 T cells were then allowed to proliferate in T cell[UCLA 2024-240] P-638467-PC conditions for an additional two weeks of culture. After these two weeks of culture in T cell conditions, reprogrammed CD8 T cells were subjected to one of three experiments. (1) Reprogrammed CD8 T cells were harvested and stained with cell trace violet (CTV), placed back in T cell culture conditions for an additional 5 days for continued proliferation, then subjected to flow cytometry to quantify CTV dilution and thereby proliferation. (2) Reprogrammed CD8 T cells were harvested and subjected to a 6 hour stimulation using PMA / ionomydn (eBioscience™ Cell Stimulation Cocktail (500X)) in the presence of a golgi toxin such cytokines produced during the stimulation remain intracellular and can be stained for subsequent quantification by flow cytometry. This is a measure of effector capacity. (3) Reprogrammed CD8 T cells were harvested and immediately subjected to immunophenotyping by flow cytometry. These experiments demonstrate that “transient reprogramming” and providing TCR signaling prevent continued dedifferentiation of T cells. This is because after “transient reprogramming” for 4, 6, or 7 days, plus another 14 to 19 days of culture in T cell conditions, T cells are 18 to 26 days post sendai-OSKM infection. If de-differentiation had not been arrested, then cultures would be predominantly or entirely iPSC by these times (day 18 to 26). However, in these experiments, no examples of iPSC (or iPSC-like) colonies were observed when T cells were continued in T cell culture conditions.
[0091] FIGURE 13B is a schematic depicting another representative experimental design for arresting de-differentiation, or “transient reprogramming”, and the confirmation of the same. CD8+ T cells are sorted from patient tumors. T cells are partially reprogrammed with sendai-OSKM at various ratios for 2-8 days. Cells are then transferred to T cell conditions to halt de-differentiation and cultured to expand to clinically relevant numbers. T cell conditions are adapted from a “rapid expansion protocol,” wherein T cells are co-cultured with irradiated peripheral blood mononuclear cells (PBMCs), anti-CD3 antibody, IL-2, IL-7, and IL- 15. IL-21, TLR agonists, and notch ligands can additionally be added to culture media. Partially reprogrammed T cells are cultured under these conditions for an additional 1-2 weeks, or as needed to achieve necessary cell numbers. Additional assays testing partially reprogrammed T cell cytokine production and immunophenotype can be performed.
[0092] FIGURES 14A-14C are graphs, cell count tables, and fight microscopy photographs depicting the results of “transient reprogramming” as described in FIGURE 13A. FIGURES 14A-C represent results of experiment (1) in FIGURE 13A for the day 4 condition (FIGURE 14A), the day 6 condition (FIGURE 14B), or the day 7 condition (FIGURE 14C). In these respective experiments, cells were transferred from stem cell conditions to T cell conditions on[UCLA 2024-240] P-638467-PC day 4 or day 6 or day 7, allowed to proliferate for an additional 2 weeks, stained with CTV, allowed to proliferate an additional 5 days, then subjected to flow cytometry. The top image of FIGURE 14A is a flow cytometry plot of CTV dilution (a measure of cellular proliferation), where CTV dilution is shown for sendai-OSKM transduction conditions with ratios 5:5:3 (top graph and cell count), 3:3:2 (middle graph and cell count), and 1:1:1 (bottom graph and cell count). Below this is a light microscopy image (at 4X magnification) of the “transiently reprogrammed” CD8 T cell culture demonstrating characteristic T cell proliferation morphology with formation of clusters (or “rosettes) and absence of iPSC (or iPSC-like) appearing colonies.FIGURE 14B represents results of the day 6 condition and is a flow cytometry plot of CTV dilution (a measure of cellular proliferation), where CTV dilution is shown for sendai-OSKM transduction conditions with ratios 5:5:3 (top graph and cell count), 3:3:2 (middle graph and cell count), and 1:1:1 (bottom graph and cell count). FIGURE 14C represents results of the day 6 condition. The top image is a flow cytometry plot of CTV dilution (a measure of cellular proliferation), where CTV dilution is shown for sendai-OSKM transduction conditions with ratios 5:5:3 (top graph and cell count), 3:3:2 (middle graph and cell count), and 1:1:1 (bottom graph and cell count). Below this is a fight microscopy image (at 4X magnification) of the “transiently reprogrammed” CD8 T cell culture demonstrating characteristic T cell proliferation morphology with formation of clusters (or “rosettes) and absence of iPSC (or iPSC-like) appearing colonies.
[0093] FIGURES 15A-15D are flow cytometry plots depicting the results of “transient reprogramming” as described in FIGURE 13A-B. FIGURES 15A-D represent results of experiment (2) — cytokine production — in FIGURE 13A for the day 6 condition when sendai-OSKM transduction was done using the 5:5:3 condition (FIGURE 15A), the 3:3:2 condition (FIGURE 15B), or the 1:1:1 condition (FIGURE 15C). Cytokine production of “transiently reprogrammed” CD8 T cells is compared to production of non-reprogrammed T cells in peripheral blood mononuclear cells (PBMCs) in FIGURE 15D. Cells were transferred from stem cell conditions to T cell conditions on day 6, cultured for an additional 2 weeks, then subjected to stimulation with PMA / ionomycin (eBioscience™ Cell Stimulation Cocktail (500X)) in the presence of a golgi block (such that produced cytokines remain intracellular and are not secreted to permit staining), then subjected to flow cytometry. FIGURES 15A-D show production of IFNg (y-axis) versus granzyme B (x-axis) and numbers represent frequencies of cells falling within each quadrant gate.[UCLA 2024-240] P-638467-PC
[0094] FIGURES 16A-16B depict the results of “transient reprogramming” of CD8 T cells, and corresponds to experiment (3) — immunophenotyping — in FIGURE 13A. FIGURE 16A is an exemplary reference schematic of forward T cell differentiation and constituent T cell differentiation stages from left to right: naive, stem central memory, central memory, effector, and exhausted T cell. FIGURE 16B shows flow cytometry plots of CD8 T cell phenotype following “transient reprogramming”. Here, as shown in FIGURE 13A, cells were infected with sendai-OSKM at a 5:5:3, 3:3:2, or 1:1:1 ratio, cultured in stem cell conditions for 6 days, at which time cells were transferred to T cell conditions to halt de-differentiation, T cells were cultured for an additional 2 weeks, then harvested and subjected to flow cytometry for immunophenotyping. The left column shows staining for CCR7 (y-axis) and CD45RO (x-axis), where Tcm is CCR7+ CD45RO+. The right column shows staining for CD95 (y-axis) and CCR7 (x-axis), where Tscm is CCR7+ CD95+ and T naive are CCR7+ CD95-. The bottom row shows staining T cells present in peripheral blood mononuclear cells that were not reprogrammed, as a control. Numbers represent frequencies of cells falling within each gate.
[0095] FIGURES 17A-B show results of “transient reprogramming” of polyclonal, exhausted CD8 T cells isolated from a patient tumor (in this example a soft tissue sarcoma). Polyclonal CD8 T cells from a tumor were isolated using FACS to sort out terminally differentiated, exhausted PD1+ TIM3+ cells and these were used for “transient reprogramming” with OSKM as described above. FIGURE 17A shows the phenotype of the exhausted, starting population of CD8 T cells. On flow cytometric analysis, these cells are PD1+ and TIM3hi (left panel), are mostly CCR7-CD45RO+, and have essentially no stem central memory cells. FIGURE 17B shows the results of “transient reprogramming” of these cells using a 5:5:3 ratio of c-Myc:KOS:KLF4 (as described above) in the presence of small molecules as listed (CHIR990215uM, DOT1L 5uM, VPA 2mM, and / or Vitamin C 50ug / mL). Cells were transferred to T cell conditions with TCR stimulation provided by anti-CD3 (2ug / mL) and anti-CD28 (5ug / mL) antibodies on day 7 post sendai-OSKM infection. FIGURE 17B demonstrates T cell phenotypes at day 7 determined by flow cytometry. After 7 days of “transient reprogramming”, CD8 T cells retain PD1 expression (indicative of previously activated T cells) and have generally less TIM3 expression (left panel) compared to day 0 (see FIGURE 17 A). After “transient reprogramming” CD8 T cells acquire predominantly Tcm and Tscm phenotypes, staining for CCR7+ CD45RO+ or CCR7+ CD45RO-, respectively (middle panel). Following 7 days of “transient reprogramming”, a large population of stem central memory CD8 T cells is now present, whereas these cells are absent from the starting population[UCLA 2024-240] P-638467-PC of exhausted CD8 T cells (right panel). Thus, a polyclonal population of exhausted, tumor-specific CD8 T cells harvested from a patient tumor can be “transiently reprogrammed” into central memory and stem central memory CD8 T cells.
[0096] FIGURES 18A-18D are schematics depicting exemplary strategies of producing and / or using de-differentiated and reprogrammed cells in mice. This series of experiments is to test durability of anti-tumor immunity from transfer of “transiently” versus “fully reprogrammed” CD8 T cells is tested using mouse models. In Figure 18A STEMCCA mice, possessing OSKM under tetracycline-dependent promoter control (Stadtfeld et al., Nature Methods 7:53-55 (2010)), are crossed with R26-M2rtTA mice, harboring reverse tetracycline-controlled transactivator protein, both on a B6 background generating progeny with doxycycline-inducible OSKM in all cells. These mice are given TAO1 tumor cells — a murine STS (soft tissue sarcoma) model — in the subcutaneous flank. Tumors are harvested at day 21 and tumor-infiltrating exhausted CD8 T cells (PD1+, TIM3-I-) FACS sorted. Tumor control of fully (FIGURE 3) versus transiently (FIGURE 12) reprogramed cells is then compared. Fully reprogrammed cells have continuous doxycycline in ex vivo culture for 30 days until stable iPSC colonies are established, then subjected to re-differentiation with ATO, as described above. Transiently reprogrammed cells are exposed to doxycycline for 7 days, then doxycycline is removed and plate-bound anti-CD3 / CD28 and IL-2, IL-7, and IL-15 are added. IxlO6reprogrammed CD8 T cells are then transferred to secondary, sub-lethally irradiated B6 mice with established TAO1 tumors. Tumor growth is measured biweekly using calipers. In FIGURE 18B, This line of experimentation is repeated with human tissues. Exhausted CD8 T cells and tumor cells are two-way FACS sorted from resected STS. T cells undergo “full” or “transient reprogramming”. Tumor cells are injected into SCID mice to develop patient-derived xenografts (PDX). l-10xl06reprogrammed CD8 T cells are injected into PDX-bearing mice, and tumor growth is measured biweekly with calipers. FIGURE 18C shows an exemplary schematic to evaluate persistence of reprogrammed CD8 T cells using competitive and serial transfer experiments. Mouse CD8 T cells infiltrating TAO1 tumors in STEMCCA mice are harvested and “fully” or “transiently reprogrammed”, as described above. During culture, reprogrammed CD8 T cells are labeled with BrdU, while non-reprogrammed controls are not. For competitive transfer, reprogrammed CD8 T cells and controls (both CD45.2+) are transferred in a 1:1 ratio into a sub-lethally irradiated CD45.1+ Pepboy mouse bearing a TAO1 tumor. Tumor, draining lymph node, and spleen are harvested 3 weeks later and analyzed for reprogrammed (CD45.2+, BrdU+) and control CD8 T cells (CD45.2+, BrdU-), revealing which is better able to[UCLA 2024-240] P-638467-PC engraft in niches and persist. FIGURE 18D. Similarly, this experiment is repeated to compare persistence of “fully” versus “transiently reprogrammed” CD8 T cells. “Fully reprogrammed” T cells are labeled with BrdU during culture, while “transiently reprogrammed” T cells are not. “Fully” and “transiently reprogrammed” T cells (both CD45.2+) are transferred in a 1 : 1 ratio into a sub-lethally irradiated CD45.1+ Pepboy mouse bearing a TAO1 tumor. Tumor, draining lymph node, and spleen are harvested 3 weeks later and analyzed for “fully reprogrammed” (CD45.2+, BrdU+) and “transiently reprogrammed” CD8 T cells (CD45.2+, BrdU-), revealing which is better able to engraft in niches and persist. For serial transfer, CD45.2+ reprogrammed and control CD8 T cells are transferred into separate sub-lethally irradiated TAO 1 -bearing CD45.1+ Pepboy mice. Reprogrammed and control CD8 T cells are then isolated from each mouse 3 weeks later and transferred into a second TAO 1 -bearing mouse. These experiments are then repeated comparing “fully” (labeled BrdU+) versus “transiently reprogrammed” (BrdU-) CD8 T cells.
[0097] FIGURE 19 depicts CD8+ PD1+ TIM3-I- T cells sorted from patient tumors are partially reprogrammed with sendai-OSKM. CD8+ PD1+ TTM3+ exhausted T cells were sorted from patient tumors, melanoma (left) or liposarcoma (right). T cells were partially reprogrammed with sendai-OSKM at 5:5:3, 3:3:2, or 2:2:1 ratios for 4 days. Cells were then transferred to T cell conditions to halt de-differentiation and cultured for an additional 2 weeks. Samples were taken after 7 or 14 days to measure cell proliferation. Fold expansion is calculated as (number of cells in culture at each timepoint) / (number of cells put into culture).
[0098] It will be appreciated that for simplicity and clarity of illustration, elements shown in the figures have not necessarily been drawn to scale. For example, the dimensions of some of the elements may be exaggerated relative to other elements for clarity.DETAILED DESCRIPTION
[0099] It would be desirable to regenerate a tumor-specific stem-like memory T cell that can treat or reduce an established tumor. Although less differentiated stem-like memory CD8 T cells that recognize tumor antigens are absolutely required for the success of ACT, these cells are present at vanishingly low frequencies within resected tumors or blood. This in turn represents a substantial limitation to the current clinical utility of ACT and TIL therapy. A major gap in treatment exists, wherein there is an inability to provide a tumor-specific CD8 T cell therapy with stem-like properties able to self-renew, persist long-term within the patient, and enact cytotoxic[UCLA 2024-240] P-638467-PC functions to eliminate residual cancer within the body. Strategies to reverse exhaustion of tumorspecific CD8 T cells to restore their sternness and ability to control or eliminate cancer fill such a gap. The present disclosure is directed to, among other embodiments, transiently dedifferentiating exhausted, tumor-specific T cells using transcription factor reprogramming, rejuvenating such tumor-specific T cells into tumor-specific stem-like memory T cells and halting de-differentiation prior to loss of T cell lineage identity, expanding the T cells, then infusing them into the patient.
[0100] In another embodiment, full de-differentiation of exhausted, tumor-specific T cells is provided using transcription factor reprogramming, such that T cells are dedifferentiated to iPSCs, then re-differentiated to iPSCs, expanding the T cells, then infusing them into the patient.
[0101] The epigenome of terminally differentiated cells of any lineage can be reset through de-differentiation into iPSCs via transcription factor reprogramming with c-Myc, Oct4, Sox2, and KLF4 (OSKM) (K. Okita et al., Nature 448: 313-317 (2007)). In this way, the suppressive epigenome enforcing T cell exhaustion can be erased and sternness recovered. In one embodiment, for T cell reprogramming to be used as a clinical therapeutic strategy, de-differentiation of CD8 T cells into iPSC then requires re-differentiation or maturation back into mature CD8ab T cells. Prior attempts at re-differentiating CD8 T cell-derived iPSC (CD8-iPSC) into mature CD8 T cells by providing Notch signaling (on OP9-DLL1 stromal cells, or on other stromal cell models) have been met with remarkable inefficiency and generate aberrant CD8-alpha-alpha (CD8aa) cells with compromised engraftment and specificity (R. Vizcardo et al., Cell Rep. 22: 3175-3190 (2018)). However, use of an artificial thymic organoid (ATO) is able to produce canonical mouse or human CD8-alpha-beta (CD8a ) T cells (A. Montel-Hagen et al., Cell Rep. 33: 108320 (2020)), though this approach is still subject to remarkable inefficiency and months of cell culture. As described herein further below, in one embodiment, full de-differentiation and reprogramming of CD8 T cells obtained from the tumor or tumor microenvironment provides cells for treating a tumor. In one embodiment, transient de-differentiation of ULs obtained from the tumor or tumor microenvironment provides cells for treating a tumor.TRANSIENT T CELL DE-DIFFERENTIATION
[0102] In the following description, numerous specific details are set forth in order to provide a thorough understanding of transiently de-differentiated T cells, methods of making them, and[UCLA 2024-240] P-638467-PC methods of use thereof. However, it will be understood by those skilled in the art that the production of these transiently de-differentiated T cells, methods of making them, and uses thereof may be practiced without these specific details. In other instances, well-known methods, procedures, and components have not been described in detail so as not to obscure their description. In subsequent sections, a different aspect of the disclosure, full T cell reprogramming, is described, which shares certain aspects with the transient reprogramming described herein, such as but not limited to cancers that are treatable, certain steps in de-differentiation and reprogramming, and expansion. Such differences between transient and full reprogramming will be apparent from the ensuing descriptions.
[0103] Disclosed herein are techniques for transient reprogramming. Transient reprogramming refers to initiating OSKM reprogramming, as with de-differentiating T cells all the way to iPSC; however, de-differentiation is stopped before T cell identity is lost and before cells become iPSC.
[0104] To address certain limitations of full reprogramming strategies, a strategy of transient reprogramming of T cells has been utilized, not allowing them to de-differentiate all the way to iPSC, can reset the chromatin state and gene-regulatory networks that enforce T cell exhaustion, thereby restoring sternness and anti-tumor functionality. This de-differentiation strategy also preserves the original T cell receptor sequence, or the T cell’s ability to “see” the tumor.
[0105] Thus, provided herein are methods of utilizing T cell receptor signaling at specific times after OSKM reprogramming to halt reprogramming and maintain T cell lineage identity at tunable stages of differentiation, including stem-like memory (Tscm and Tcm). Therefore, the transient reprogramming approach can de-differentiate T cells from terminally exhausted to stem-like T cells with the full array of anti-tumor functionality, generating the T cell population (stem-like memory) that is required for patients to benefit from immunotherapy (including adoptive cellular transfer or TIL therapy and certain ICB strategies (e.g., anti-PD(L)l). The clinical impact of this immunotherapy is that non-responsive patients (e.g., the majority of patients) can be turned into immunotherapy responders.
[0106] Provided herein are tumor-specific CD8 T cells reprogrammed, with their sternness and anti-tumor functionality restored via transcription factor reprogramming. Provided herein are methods wherein the chromatin state and gene regulatory networks enforcing exhaustion of[UCLA 2024-240] P-638467-PC tumor-specific CD8 T cells are reset to a stem-like T cell state (e.g., that of a stem central memory T cells or central memory T cell) via transcription factor reprogramming. Provided herein are methods utilizing transcription factor reprogramming to reverse or overcome epigenetic and transcriptional programs enforcing exhaustion and cells resulting therefrom. Also provided herein are methods to improve the efficacy of T cell mediated therapies for patients with cancer and cells and materials used therein. Also provided herein are strategies to protect ACT products from exhaustion and the ACT products therefrom.
[0107] Provided herein are de-differentiated T cells, as well as restoration and uses thereof.
[0108] In some aspects, disclosed herein are stem-like memory T cells.
[0109] In some aspects, disclosed herein are methods of transient transcription factor reprogramming to rejuvenate exhausted tumor-specific T cells into stem-like memory T cells.
[0110] In some aspects, disclosed herein are stem-like memory T cells rejuvenated from reprogrammed exhausted tumor-specific T cells.
[0111] In some embodiments, T cell receptor signaling at specific times after OSKM reprogramming is utilized to halt reprogramming and maintain T cell identity at tunable stages of differentiation, including stem-like memory. In some embodiments, transient reprogramming can de-differentiate T cells from terminally exhausted to stem-like T cells with the full array of antitumor functionality, e.g., to generate the T cell population (stem-like memory) that is required for patients to benefit from immunotherapy (including adoptive cellular transfer or TIL therapy and certain ICB strategies (e.g. anti-PD(L)l)), thereby turning an immunotherapy non-responder into a responder.Cancers
[0112] In some embodiments, the methods disclosed herein are useful for treating cancer. In some embodiments, the methods disclosed herein are useful for treating any cancer or tumor. In some embodiments, the tumor is derived from the embryonic endoderm, mesoderm, or ectoderm. In some embodiments, the methods disclosed herein are useful for treating any solid cancer that can elicit a T cell response.
[0113] In some embodiments, the cancer is a solid tumor or a hematologic cancer. In some[UCLA 2024-240] P-638467-PC embodiments, the cancer is melanoma. In some embodiments, the cancer is a mesenchymal cancer. In some embodiments, the cancer is an epithelial cancer. In some embodiments, the cancer is pancreatic cancer.
[0114] In some embodiments, the tumor is a solid tumor. In some embodiments, the tumor is a hematological cancer. In some embodiments, the tumor, suspected tumor, or resected tumor comprises a cancerous, pre-cancerous, or non-cancerous tumor. Non-limiting examples of types of tumors from which T cells may be obtained (from the tumor, tumor microenvironment or blood) include any of those described herein.
[0115] In some embodiments, the tumor is a solid tumor. In some embodiments, the tumor is a hematological cancer. In some embodiments, the tumor, suspected tumor, or resected tumor comprises a cancerous, pre-cancerous, or non-cancerous tumor. In some embodiments, the tumor comprises a sarcoma or a carcinoma, a fibrosarcoma, a myxosarcoma, a liposarcoma, a chondrosarcoma, an osteogenic sarcoma, a chordoma, an angiosarcoma, an endotheliosarcoma, a lymphangiosarcoma, a lymphangioendotheliosarcoma, a synovioma, a mesothelioma, an Ewing’s tumor, a leiomyosarcoma, a rhabdomyosarcoma, a colon carcinoma, a pancreatic cancer or tumor, a breast cancer or tumor, an ovarian cancer or tumor, a prostate cancer or tumor, a squamous cell carcinoma, a basal cell carcinoma, an adenocarcinoma, a sweat gland carcinoma, a sebaceous gland carcinoma, a papillary carcinoma, a papillary adenocarcinomas, a cystadenocarcinoma, a medullary carcinoma, a bronchogenic carcinoma, a renal cell carcinoma, a hepatoma, a bile duct carcinoma, a choriocarcinoma, a seminoma, an embryonal carcinoma, a Wihn's tumor, a cervical cancer or tumor, a uterine cancer or tumor, a testicular cancer or tumor, a lung carcinoma, a small cell lung carcinoma, a bladder carcinoma, an epithelial carcinoma, a glioma, an astrocytoma, a medulloblastoma, a craniopharyngioma, an ependymoma, a pinealoma, a hemangioblastoma, an acoustic neuroma, an oligodendroglioma, a schwannoma, a meningioma, a melanoma, a neuroblastoma, or a retinoblastoma, esophageal cancer, pancreatic cancer, metastatic pancreatic cancer, metastatic adenocarcinoma of the pancreas, bladder cancer, stomach cancer, fibrotic cancer, glioma, malignant glioma, diffuse intrinsic pontine glioma, recurrent childhood brain neoplasm renal cell carcinoma, clear-cell metastatic renal cell carcinoma, kidney cancer, prostate cancer, metastatic castration resistant prostate cancer, stage IV prostate cancer, metastatic melanoma, melanoma, malignant melanoma, recurrent melanoma of the skin, melanoma brain metastases, stage HIA skin melanoma; stage LLLB skin melanoma, stage IHC skin melanoma; stage IV skin melanoma, malignant melanoma of head and neck, lung[UCLA 2024-240] P-638467-PC cancer, non-small cell lung cancer (NSCLC), squamous cell non-small cell lung cancer, breast cancer, recurrent metastatic breast cancer, hepatocellular carcinoma, Hodgkin’s lymphoma, follicular lymphoma, non-Hodgkin’s lymphoma, advanced B-cell NHL, HL including diffuse large B-cell lymphoma (DLBCL), multiple myeloma, chronic myeloid leukemia, adult acute myeloid leukemia in remission; adult acute myeloid leukemia with Inv(16)(pl3.1q22); CBFB-MYH11; adult acute myeloid leukemia with t(16;16)(pl3.1;q22); CBFB-MYH11; adult acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1; adult acute myeloid leukemia with t(9; 11)(p22;q23); MLLT3-MLL; adult acute promyelocytic leukemia with t(15;17)(q22;ql2); PML-RARA; alkylating agent-related acute myeloid leukemia, chronic lymphocytic leukemia, Richter’s syndrome; Waldenstrom’s macroglobulinemia, adult glioblastoma; adult gliosarcoma, recurrent glioblastoma, recurrent childhood rhabdomyosarcoma, recurrent Ewing sarcoma / peripheral primitive neuroectodermal tumor, recurrent neuroblastoma; recurrent osteosarcoma, colorectal cancer, MSI positive colorectal cancer; MSI negative colorectal cancer, nasopharyngeal nonkeratinizing carcinoma; recurrent nasopharyngeal undifferentiated carcinoma, cervical adenocarcinoma; cervical adenosquamous carcinoma; cervical squamous cell carcinoma; recurrent cervical carcinoma; stage IVA cervical cancer; stage IVB cervical cancer, anal canal squamous cell carcinoma; metastatic anal canal carcinoma; recurrent anal canal carcinoma, recurrent head and neck cancer; carcinoma, squamous cell of head and neck, head and neck squamous cell carcinoma (HNSCC), ovarian carcinoma, colon cancer, gastric cancer, advanced GI cancer, gastric adenocarcinoma; gastroesophageal junction adenocarcinoma, bone neoplasms, soft tissue sarcoma; bone sarcoma, thymic carcinoma, urothelial carcinoma, recurrent Merkel cell carcinoma; stage HI Merkel cell carcinoma; stage IV Merkel cell carcinoma, myelodysplastic syndrome and recurrent mycosis fungoides and Sezary syndrome.T Cells
[0116] Provided herein are de-differentiated T cells, methods of making them, and methods of use thereof. Such T cells are obtained from a patient’s tumor or the tumor microenvironment, for example from a solid tumor or blood.
[0117] In some embodiments, the T cells obtained from a tumor and used to carry out the methods disclosed herein may be obtained by biopsy (comprising tumor, tumor environment, tumor microenvironment or blood), or surgical resection of a primary tumor or metastatic tumor[UCLA 2024-240] P-638467-PC (metastectomy). Such biopsy may be referred to as containing tumor infiltrating lymphocytes (TILs).
[0118] In some embodiments, the T cells are obtained from a patient’s blood.
[0119] In some embodiments, tumor-specific TILs may be identified by expression of biomarkers including but not limited to one or more of PD1, TIM3, CD39, CD69, CD103 and / or CD137.De-differentiation and De-Differentiated Cells
[0120] In some embodiments, disclosed herein is a method for de-differentiating T cells obtained from a tumor (e.g., exhausted, tumor-specific T cells) or blood (e.g., effector T cells) then halting de-differentiation to provide less differentiated tumor-specific T cells that can be expanded then used to treat the tumor. As will be described herein, the method as well as the state of the T cells at the various steps of the method, are described by either or both of conditions for progressing the T cells though the steps (e.g., duration, conditions such as medium components, etc.) as well as expression or lack of expression of certain T cell markers. One of skill in the art will readily identify from the guidance herein various ways to achieve the desired population of expanded T cells using any of these indicators (e.g., duration, medium, biomarker expression) or any combination thereof. Below is provided guidance for each of the steps and the biomarker expression of the T cells thereof, but such guidance is merely non-limiting and exemplary and other means to achieve them are fully embraced herein.Isolating CD8 T cells from the tumor, tumor environment, tumor microenvironment or blood
[0121] In some embodiments, T cells obtained from a tumor and used to carry out the methods disclosed herein are obtained by biopsy (comprising tumor or blood), or surgical resection of a primary tumor or metastatic tumor (metastectomy).
[0122] In some embodiments, tumor-specific TILs may be identified by expression of biomarkers including but not limited to one or more of PD1, TIM3, CD39, CD69, CD103 and / or CD137.Exposing the CD8 T cells to de-differentiation-inducing conditions[UCLA 2024-240] P-638467-PC
[0123] In some embodiments, de-differentiation-inducing conditions comprises exposing (e.g., transducing, transfecting, electroporating or by mechanical introduction) the T cells with OSKM, which comprises c-Myc, Oct3 / 4, Sox2, and KLF4 (see K. Okita et al., Nature 448: SISSI? (2007)). Non-limiting examples of OSKM include Sendai-OSKM, such as available commercially (CYTOTUNE™-iPS 2.0 Sendai Reprogramming Kit from THERMO FISHER SCIENTIFIC INC.™). In some embodiments, the ratio of OSKM components is optionally at a 5:5:3, 3:3:2, 2:2:1 or 1:1:1 ratio of c-Myc:KLF4-Oct3 / 4-Sox2:KLF4. In some embodiments, any multiplicity of infection intermediate to these ratios is suitable.Inducing de-differentiation of the CD8 T cells
[0124] In some embodiments, de-differentiating-inducing conditions comprises exposing cells to OSKM in 100% T cell medium in the absence of T cell receptor (TCR) signaling (e.g. absence of anti-CD3 and anti-CD28, peptide stimulation, or other forms of antigen presentation) on days 0-1, then over the next 5-6 days reducing the percent (v / v) T cell medium and increasing the percent (v / v) stem cell medium with cytokines, followed by 100% stem cell medium with cytokines, again in the absence of TCR signaling. In another embodiment, the CD8 T cells can be maintained in 100% T cell medium with cytokines. In some embodiments, cytokines comprise IL-2, IL-7 and / or IL-15, such as 10-3000 lU / mL IL-2, 10-20 ng / mL IL-7 and 10-20 ng / mL IL-15. In some embodiments, cytokines at 10-20 ng / mL are used. Cells are cultured on a surface coated with extracellular matrix, including but not limited to rhLaminin521, vitronectin, etc.
[0125] For example, in one embodiment, T cell medium comprises 90% defined base medium (e.g., RPMI 1640) and 10% fresh human serum from healthy donors or a defined serum replacement (e.g., KnockOut™ Serum Replacement, THERMOFISHER).
[0126] For example, in one embodiment, stem cell medium comprises 100% defined medium (e.g., TeSR™-E8™ basal medium, STEMCELL TECHNOLOGIES, Essential 8™ Medium, THERMOFISHER, or StemFit Basic04 Complete Type AJINOMOTO CO. INC, AminoScience Division).
[0127] Cytokines may include one or more gamma-chain cytokines, such as one or more of IL-2, IL-4, IL-7, IL-9, IL- 15, IL- 18, and / or IL-21. Typically, IL-2 is used in combination with one or more other gamma-chain cytokines, such as IL-7 and IL-15. Typically, concentrations of about 10-20 ng / mL are used. In some embodiments, IL- 10 may be included; in some[UCLA 2024-240] P-638467-PC embodiments, an antibody to IL- 10 may be included. In some embodiments, anti-interferon gamma antibody may be included.
[0128] Inclusion of cytokines comprises, in some embodiments, the combination of IL-2 at 12 lU / mL, IL-7 at lOng / mL, and IL- 15 at lOng / mL. Other single or combination of other cytokines may also be used.
[0129] As will be described here and elsewhere herein, guidance for the duration of dedifferentiating and the appropriate point to halt de-differentiation of T cells may be provided in temporal terms, such as based on days and conditions such T cells are exposed to each day, and / or may be provided by characterization of the T cells, such as analysis of expressed markers by flow cytometry or flow assisted cell sorting. The disclosure is not limited to specific days or durations, which are merely provided herein as guidance for the duration of de-differentiating and point of halting thereof; the characterization of the cells, changes therein and the appropriate point to halt de-differentiation and start re-differentiating is based on the teachings herein and is not intended to be limited. Examples of protocols based on time of incubation in various media are exemplary only and based on the teachings here, the skilled artisan will identify variations therein that are fully encompassed by the present disclosure.
[0130] Thus, as disclosed herein, a method for the transient reprogramming of T cells isolated from a tumor, tumor microenvironment or blood comprises exposing the CD8 T cells to dedifferentiation-inducing conditions, then halting de-differentiation of the CD8 T cells. The timing of exposure to de-differentiating conditions, and the point to halt such de-differentiation will be apparent from the description and the examples herein, which are not intended to be limiting.
[0131] For example, a protocol to achieve de-differentiation may comprise:exposing the CD8 T cells to Sendai-OSKM and 100% T cell medium on days 0- 1;exposing the CD8 T cells to 75% T cell medium, 25% stem cell medium and cytokines on about day 2;exposing the CD8 T cells to 50% T cell medium, 50% stem cell medium and cytokines on about day 3[UCLA 2024-240] P-638467-PC exposing the CD8 T cells to 25% T cell medium, 75% stem cell medium and cytokines on about day 4;exposing the CD8 T cells to 100% stem cell medium and cytokines on about day5; andexposing the CD8 T cells to 100% stem cell medium and cytokines starting on about day 6.
[0132] Variations in the number of steps with changes in medium compositions, and / or duration of time under each condition, may be used to achieve the same results. For example, an alternative protocol comprises maintaining cells in 100% T cell medium with cytokines from days 2-6. The skilled artisan by following the teachings herein will readily identify conditions for achieving these results, all of which are embraced herein.
[0133] For example, the CD8 T cells may be maintained up to about 21 days in 100% stem cell medium with cytokines, before halting de-differentiation as described below.
[0134] In some embodiments, during or after the step following exposure to OSKM in 100% T cell medium, the T cells exposed to these conditions are rapidly expanded. Such expansion may be achieved by expansion in T cell medium with cytokines or progressive exposure to increasing concentrations of stem cell medium with cytokines, as above. This expansion is accomplished in the absence of TCR signaling (e.g., anti-CD3 and anti-CD28, peptide stimulation, or other forms of antigen presentation) and on a surface coated with extracellular matrix proteins, including but not limited to rhLaminin521, vitronectin, etc.
[0135] In some embodiments, if T cells exposed to the protocol to achieve de-differentiation described above are continued in culture with stem cell media and removal of cytokines on a surface coated with extracellular matrix, including but not limited to rhLaminin521, vitronectin, etc., then CD8-derived iPSC colonies will begin to be formed in the culture. The timing of de-differentiation to iPSC and appearance of iPSC colonies depends on the source of starting T cells used (e.g., blood or tumor) and the starting differentiation state of these T cells (e.g., Tscm, Tcm, Tern, Teff, Tex). Allowing T cells exposed to OSKM under the above described conditions is termed full reprogramming. Such use of full reprogramming is described separately below as another aspect of the present disclosure as an alternate method for deriving tumor-killing T cells[UCLA 2024-240] P-638467-PC from tumor-obtained T cells, tumor environment, tumor microenvironment or blood, by taking such T cells back to iPSCs then reprogramming them.
[0136] While the duration of de-differentiation is provided as a number of days in certain guidance and examples herein, such duration of de-differentiation before it is halted and / by TCR stimulation started may be guided by any one or more characteristics of the T cells, and determination of the duration in days may be superseded or confirmed by such characterization. In some embodiments, once the conditions for de-differentiation protocol to a certain T cell characterization is identified, such protocol may be conducted using duration (in days) in place of characterization, although in some embodiments, the duration may be checked by characterization, for example, as an in-process control. For example, in one embodiment, the exact day of when to begin TCR stimulation / halt reprogramming can be guided by taking culture aliquots and running flow cytometry for any one or more of CD3, CD4 or CD8, PD1, TIM3, CCR7, CD27, CD95, CD45RA, CD45RO, among other markers. In one embodiment, the halting de-differentiation and starting TCR stimulation may be guided by when the majority of the culture adopts stem-like memory phenotypes on flow cytometry without losing T cell lineage, or expression of CD3 and CD4 or CD8. In other embodiments, identifying iPSC surface markers such as SSEA4 to confirm that these have not started to increase.
[0137] In some embodiments, one or more additional compounds may be included to induce de-differentiation. In some embodiments, such compounds are epigenetic modifiers. In some embodiments, the compound is vitamin C. In some embodiments, such a compound is a histone deacetylase inhibitor such as valproic acid (VP A). In some embodiments, such a compound is a histone methyltransferase inhibitor, such as a DOT1L inhibitor, optionally EPZ-5676 (pinometostat). In some embodiment, such compound is a GSK3b inhibitor such as CHIR99021. Inclusion or other compounds including small molecule epigenetic modifiers are fully embraced herein.
[0138] In some embodiments, a compound such as a small molecules may also be included to modulate signaling strength of various receptors, including the TCR.Halting de-differentiation of the CD8 T cells
[0139] Halting de-differentiation comprises interrupting the protocol to achieve de-differentiation (as described above) by removing any adherent, loosely adherent, or non-adherent[UCLA 2024-240] P-638467-PC T cells from any extracellular matrix protein coated surface and exposing them to T cell stimulating conditions, such as but not limited to TCR stimulation / signaling conditions. In some embodiments, the T cell stimulation conditions comprises TCR signaling, with or without costimulation, with or without T cell medium, or T cell medium with or without cytokines. In some embodiments, such conditions include 100% T cell medium with cytokines additionally in the presence of TCR signaling, which can be accomplished by addition of anti-CD3, anti-CD28, peptide, antigen presenting cells, etc. Cytokines may include one or more gamma-chain cytokines, such as one or more of IL-2, IL-4, IL-7, IL-9, IL- 15, IL- 18, and / or IL-21. Typically, IL-2 is used in combination with one or more other gamma-chain cytokines, such as IL-7 and IL-15. Typically, concentrations of about 10-20 ng / mL are used. In some embodiments, IL-10 may be included; in some embodiments, an antibody to IL- 10 may be included. In some embodiments, anti-interferon gamma antibody may be included.
[0140] In some embodiments, for halting de-differentiation, the T cell medium comprises one or more agents that induce TCR signaling, such as exposure to anti-CD3 and / or anti-CD28 antibodies, these may be soluble in the medium, bound to beads or other structures, or adhered to the culture surface, or any combination thereof. Halted de-differentiation of T cells comprises continued expression of NFkB, NFAT, AP-1, Runxl / 3, etc.
[0141] TCR stimulation may also be provided by culturing partially reprogrammed T cells with irradiated peripheral blood mononuclear cells (PBMCs) and soluble anti-CD3 (as above) with or without soluble anti-CD28.
[0142] In some embodiments, additional agents that can be added to T cell conditions to preserve T cell lineage and maintain sternness can include: IL-21 (10-20ng / mL); TLR agonists (such as R848, a synthetic TLR7 / 8 ligand); Notch ligands (e.g., DLL4-Fc), or any combination thereof. Thus, in some embodiments, the T cell medium comprises irradiated peripheral blood mononuclear cells (PBMCs), anti-CD3 antibody, IL-2, IL-7, and IL-15. Thus, in some embodiments, the T cell medium comprises irradiated peripheral blood mononuclear cells (PBMCs), anti-CD3 antibody, IL-2, IL-7, IL- 15 and IL-21. In some embodiments, the T cell medium comprises irradiated peripheral blood mononuclear cells (PBMCs), anti-CD3 antibody, IL-2, IL-7, IL- 15, and TLR agonist. In some embodiments, the T cell medium comprises irradiated PBMCs, anti-CD3 antibody, IL-2, IL-7, IL- 15 and Notch ligand. In some embodiments, the T cell medium comprises irradiated PBMCs, anti-CD3 antibody, IL-2, IL-7, IL- 15, IL-21 and[UCLA 2024-240] P-638467-PC TLR agonist. In some embodiments, the T cell medium comprises irradiated PBMCs, anti-CD3 antibody, IL-2, IL-7, IL- 15, TLR agonist and Notch ligand. In some embodiments, the T cell medium comprises irradiated PBMCs, anti-CD3 antibody, IL-2, IL-7, IL- 15, IL-21 and Notch ligand. In some embodiments, the T cell medium comprises irradiated PBMCs, anti-CD3 antibody, IL-2, IL-7, IL- 15, IL-21, TLR agonist and Notch ligand.
[0143] As noted herein, halting de-differentiation of the CD8 T cells may be started based on duration of time of de-differentiation, based on culture medium conditions during the last step(s) of de-differentiation, based on expression of biomarkers, or any combination or combinations thereof. For example, halting de-differentiation may be started when the T cells have any one or more of: high CD8, high %Tcm (CD45RO+, CD62L+, CD95+, CCR7+ and / or IL-2Rb+), low SSEA421, high CD3 and / or high %Tscm (CD45RA+, CD62L+, CD95+, CCR7+ and / or IL-2Rb+). These and other methods for identifying the time and / or conditions for halting de-differentiation, and halting de-differentiation based thereon, are fully embraced herein.
[0144] In addition to or alternatively, halting de-differentiation may be started after about day 3 and before about day 21 of incubation in 100% stem cell medium with cytokines. However, the duration (in days) of de-differentiation is not a limiting aspect of the disclosure and may be selected based on other features to guide the decision of when to begin TCR stimulation. For example, in one embodiment, the exact day of when to begin TCR stimulation / halt reprogramming can be guided by taking culture aliquots and running flow cytometry for any one or more of CD3, CD4 or CD8, PD1, TIM3, CCR7, CD27, CD95, CD45RA, CD45RO, among other markers. In other embodiments, additional stimuli that may assist halting de-differentiation include addition of Notch ligands (e.g., delta-like ligand 1 or 4, DLL1 / 4), TLR ligands (e.g., R848, CpG, LPS, etc), and / or certain cytokines (e.g., IL-2, IL-7, IL-15, IL-18, IL-21). In one embodiment, the halting de-differentiation and starting TCR stimulation may be guided by when the majority of the culture adopts stem-like memory phenotypes on flow without losing T cell lineage, or expression of CD3 and CD4 or CD8. In other embodiments, identifying iPSC surface markers such as SSEA4 is performed to confirm that these have not started to increase.Expanding the CD8 T cells
[0145] As noted herein above, expansion of the T cells may occur during or after the step following exposure to OSKM in 100% T cell medium. T cells exposed to these conditions are[UCLA 2024-240] P-638467-PC rapidly expanded. Such expansion may be achieved by expansion in T cell medium with cytokines or progressive exposure to increasing concentrations of stem cell medium with cytokines, as above. This expansion is accomplished in the absence of TCR signaling (e.g., anti-CD3 and anti-CD28, peptide stimulation, or other forms of antigen presentation) and on a surface coated with extracellular matrix, including but not limited to rhLaminin521, vitronectin, etc.
[0146] After halting de-differentiation, the T cells may be expanded to obtain a sufficient population for efficacious treatment of the patient’s tumor. In one embodiment, expansion is achieved by incubation of the T cells in T cell medium with cytokines and provision of TCR signaling, which may include but is not limited to anti-CD3 and anti-CD28 (soluble in the medium, bound to beads or other structures, or adhered to the culture surface), cognate peptide(s), antigen presenting cells, etc. In some embodiments, expansion is continued for 2-4 weeks. In some embodiments, such expansion may achieve 400-fold expansion or more in one week and continued expansion is dependent upon conditions used.Other factors
[0147] As disclosed herein, halting de-differentiation is dependent predominantly upon TCR stimulation, e.g., placing the cells in culture vessels coated with anti-CD3 / anti-CD28 or in culture conditions with presentation of specific, cognate antigens or peptides or potentially addition of PMA / ionomycin or a combination thereof (e.g., rapid expansion protocols, for reference M. Dudley et al., J Immunother. 26: 332-342 (2003)). Additional stimuli that may assist halting de-differentiation include addition of Notch ligands (e.g., delta-like ligand 1 or 4, DLL1 / 4), TLR ligands (e.g., R848, CpG, LPS, etc), and / or certain cytokines (e.g., IL-2, IL-7, IL-15, IL-18, IL-21).
[0148] In some embodiments, IL-2 concentration can range from 10-3000 lU / mL. Anti-CD3 concentration can range from 30ng / mL (soluble) to l-10ug / mL (coating concentration if plate bound).
[0149] TCR stimulation may also be provided by culturing partially reprogrammed T cells with irradiated peripheral blood mononuclear cells (PBMCs) and soluble anti-CD3 (as above) with or without soluble anti-CD28.[UCLA 2024-240] P-638467-PC
[0150] In some embodiments, additional agents that can be added to T cell conditions to preserve T cell lineage and maintain sternness can include: IL-21 (10-20ng / mL); TLR agonists (such as R848, a synthetic TLR7 / 8 ligand); Notch ligands (e.g., DLL4-Fc), or any combination thereof. Thus, in some embodiments, the T cell medium comprises irradiated peripheral blood mononuclear cells (PBMCs), anti-CD3 antibody, IL-2, IL-7, and IL-15. Thus, in some embodiments, the T cell medium comprises irradiated peripheral blood mononuclear cells (PBMCs), anti-CD3 antibody, IL-2, IL-7, IL- 15 and IL-21. In some embodiments, the T cell medium comprises irradiated peripheral blood mononuclear cells (PBMCs), anti-CD3 antibody, IL-2, IL-7, IL- 15, and TLR agonist. In some embodiments, the T cell medium comprises irradiated PBMCs, anti-CD3 antibody, IL-2, IL-7, IL- 15 and Notch ligand. In some embodiments, the T cell medium comprises irradiated PBMCs, anti-CD3 antibody, IL-2, IL-7, IL- 15, IL-21 and TLR agonist. In some embodiments, the T cell medium comprises irradiated PBMCs, anti-CD3 antibody, IL-2, IL-7, IL- 15, TLR agonist and Notch ligand. In some embodiments, the T cell medium comprises irradiated PBMCs, anti-CD3 antibody, IL-2, IL-7, IL- 15, IL-21 and Notch ligand. In some embodiments, the T cell medium comprises irradiated PBMCs, anti-CD3 antibody, IL-2, IL-7, IL-15, IL-21, TLR agonist and Notch ligand. In some embodiments, anti-CD28 antibody may be included in any of the foregoing conditions.
[0151] In some embodiments, partially reprogrammed T cells can be transferred to "T cell conditions" after 2-8 days of partial reprogramming with sendai-OSKM.
[0152] In some embodiments, partial reprogramming can be accomplished in T cell media (TCM) tapering to stem cell media (SCM) or in TCM alone without tapering.
[0153] The partial reprogramming scheme depicted in Figure 13B reflects inclusion of some of the aforementioned embodiments. In some embodiments, the T cell medium comprises irradiated PBMCs, anti-CD3, IL-2, IL-7, IL-15, and optionally including IL-21, TLR agonist (e.g., R848) and / or Notch ligand (e.g., DLL4-Fc). Other factors can be included that provide costimulation (e.g., T cell activation through a receptor / pathway distinct from the TCR) to help maintain T lineage identity, sternness, and cell expansion, and are fully embraced herein.Administering the CD8 T cells to the subject[UCLA 2024-240] P-638467-PC
[0154] T cells obtained by the foregoing methods are infused into the patient. In some embodiments, a total of about 3 x 106to about 3 x 107cells are infused per kg body weight. In some embodiments, such infusion is in divided, escalating doses.Monitoring efficacy of treatment
[0155] Effectiveness of the treatment disclosed herein may be monitored by methods including but not limited to evaluating the size of the tumor, measuring tumor markers, and identifying tumor-specific TILs from a biopsy sample, or any combination thereof. In other embodiments, such efficacy may be determined by radiographic characteristics of the primary and / or metastatic tumor (e.g., by ultrasound, CT, MRI, PET); radiographic characteristics of the resection bed (in the case of surgery) or surrounding tissue; tumor characteristics on biopsy (in addition to T cell characteristics on biopsy, e.g., TCR repertoire, functional analysis, etc.) determined by next generation sequencing techniques, high resolution imaging techniques (referring to histologic or pathologic analysis), flow cytometry, cytometry by time-of-flight (CyTOF), spectral cytometry, image stream; antigen expression; T cell (co-)culture assays, tumor (co-)culture assays; ELISA; Luminex; extracellular vesicles; exosomes; tumor-derived nanoparticles; circulating tumor cells; circulating cell-free DNA. Any biopsy or radiographic technique or other technique used to assess efficacy of tumor treatment is fully embraced herein.
[0156] The foregoing description of methods for transiently reprogramming T cells and exemplary ways of preparing them are merely illustrative and non-limiting, and one of skill in the art following the teachings herein will readily prepare such transiently reprogrammed T cells. Reference is made to Figure 1 and the aspects relating to transient reprogramming in Figures 4, 9, 10, 12, 13-17, 18C and l8D.TRANSIENTLY REPROGRAMMED T CELLS
[0157] In some embodiments, the disclosure embraces transiently reprogrammed T cells prepared in accordance with the teachings herein. In some embodiments, such transiently reprogrammed T cells are prepared by:i. exposing the CD8 T cells to de-differentiation-inducing conditions;ii. inducing de-differentiation of the CD8 T cells; and[UCLA 2024-240] P-638467-PC iii. halting de-differentiation of the CD8 T cells.
[0158] In some embodiments, the transiently reprogrammed T cells are prepared using T cells obtained from a tumor or tumor microenvironment. In some embodiments, the T cells are obtained from blood. In some embodiments, the T cells obtained from the tumor, tumor microenvironment or blood express CD39, CD69, CD103, CD137, or any combination thereof.
[0159] In some embodiments, the transiently reprogrammed T cell are expanded, such that the expanded, transiently reprogrammed T cells are embraced by the disclosure. In some embodiments, the expanded transiently reprogrammed T cells are administered to a subject.
[0160] In some embodiments, exposing the CD8 T cells to de-differentiation-inducing conditions comprises transducing the T cells with OSKM, such as Sendai-OSKM, optionally at a 5:5:3, 3:3:2, 2:2:1 or 1:1:1 ratio of c-Myc:KLF4-Oct3 / 4-Sox2:KLF4. In some embodiments, any multiplicity of infection intermediate to these ratios is suitable.
[0161] In some embodiments, exposing the CD8 T cells to de-differentiation-inducing conditions comprises exposing cells to OSKM in 100% T cell medium on days 0-1, then over the next 5-6 days reducing the percent (v / v) T cell medium and increasing the percent (v / v) stem cell medium with cytokines, followed by 100% stem cell medium without cytokines. In some embodiments, the cytokines comprise IL-2, IL-7 and / or IL- 15, such as 10-3000 lU / mL IL-2, 10-20 ng / mL IL-7 and 10-20 ng / mL IL- 15.
[0162] By way of non-limiting example, in one embodiment, transiently reprogrammed T cells may be prepared by the de-differentiating steps of:a) exposing the CD8 T cells to Sendai-OSKM and 100% T cell medium on days 0- 1;b) exposing the CD8 T cells to 75% T cell medium, 25% stem cell medium and cytokines on about day 2;c) exposing the CD8 T cells to 50% T cell medium, 50% stem cell medium and cytokines on about day 3;d) exposing the CD8 T cells to 25% T cell medium, 75% stem cell medium and cytokines on about day 4;[UCLA 2024-240] P-638467-PC e) exposing the CD8 T cells to 100% stem cell medium and cytokines on about day 5; andf) exposing the CD8 T cells to 100% stem cell medium with cytokines starting on about day 6.
[0163] Halting de-differentiation may be started from about day 2 and beyond, and up to around day 21. In some embodiments, halting occurs on day 2, 3, 4, 6 or 8. Such duration of time before halting de-differentiation may be based on biomarkers expressed by the cells, to provide the basis for a protocol such as that above, using time duration. This and other examples of timebased durations of de-differentiation before halting are exemplary and non-limiting.
[0164] In some embodiments, during and / or after step b., the CD8 T cells are expanded. In some embodiments, the expansion occurs in T cell medium.
[0165] In some embodiments, the halting de-differentiation is carried out when the T cells have any one or more of: high CD8, high %Tcm (CD45RO+, CD62L+, CD95+, CCR7+ and / or IL-2Rb+), low SSEA421, high CD3 and / or high %Tscm (CD45RA+, CD62L+, CD95+, CCR7+ and / or IL-2Rb+). In some embodiments, the halting de-differentiation is carried out after about day 3 and before about day 21. In some embodiments, the foregoing markers will guide the day selected for halting de-differentiation. In some embodiments, the halting de-differentiation comprises exposing the T cells to T cell medium. In some embodiments, the T cell medium comprises TCR signaling. In some embodiments, the TCR signaling comprises exposure to anti-CD3 and / or anti-CD28 antibodies.
[0166] In some embodiments, the reprogrammed T cells comprise expression of NFkB, NFAT, AP-1, Runxl / 3 and / or GATA3. In some embodiments, the transiently reprogrammed CD8 T cells lack upregulation of canonical iPSC markers, such as SSEA3, SSEA4, CD30, Tra-1-60, Tra-1-81, or any combination thereof.
[0167] In some embodiments, the reprogrammed cells comprise one or more of: expression of CD3 (hi), CD4 or CD8 (hi), CCR7 (hi / upregulated), PD1 (may be down regulated but still positive), TIM3 (down regulated). In some embodiments, the reprogrammed cells comprise one or more of no expression (or at least not higher than non-reprogrammed T cell controls) of iPSC surface proteins including SSEA3, SSEA4, Tra-1-60, Tra-1-80 and / or CD30. In some[UCLA 2024-240] P-638467-PC embodiments, the reprogrammed cells comprise one or more of: negative or low expression of the transcription factor Nanog relative to fully reprogrammed iPSC (in which Nanog is high).
[0168] In some embodiments, the reprogrammed cells comprise one or more of: ability to proliferate robustly, ability to robustly produce canonical T cell cytokines (IFNg, granzyme B, perforin, TNFa), retained characteristic T cell morphology in culture upon TCR (re.) stimulation. In some embodiments, the reprogrammed cells comprise antigen-specific or non-specific tumor cell killing in assays or co-cultures, using, for example, annexin V vs. viability (e.g., propidium iodide (PI)) stain), or Incucyte.
[0169] The foregoing examples of phenotypic and functional assays for reprogrammed cells may be used individually or in any combination of phenotypic and / or functional assays, to characterize the transiently reprogrammed cells described herein.
[0170] In some embodiments, expanding the T cells in step e. comprises further incubation of the T cells in T cell medium.
[0171] In some embodiments, the CD8 cells isolated from the tumor express CD39, CD69, CD103, CD137, PD1, TIM3 or any combination thereof.
[0172] The foregoing description of transiently reprogrammed T cells and exemplary ways of preparing them are merely illustrative and non-limiting, and one of skill in the art following the teachings herein will readily prepare such transiently reprogrammed T cells. Reference is made to Figure 1 and the aspects relating to transient reprogramming in Figures 4, 9, 10, 12, 13-17, 18C and 18D.FULL T CELL REPROGRAMMING
[0173] In the following description, numerous specific details are set forth in order to provide a thorough understanding methods for making fully de-differentiated T cells from T cells obtained from a tumor, a tumor microenvironment or from blood, then maturing the resulting iPSC cells to T cells targeting the tumor, and methods of use thereof. However, it will be understood by those skilled in the art that the production of these fully reprogrammed T cells, methods of making them, and uses thereof may be practiced without these specific details. In other instances, well-known methods, procedures, and components have not been described in detail so as not to obscure their description.[UCLA 2024-240] P-638467-PC
[0174] Disclosed herein are techniques for full reprogramming of T cells. Full reprogramming refers to initiating OSKM reprogramming, de-differentiating T cells all the way to iPSC, and maturing these iPSC back to T cells. As will be described herein, such full reprogramming of tumor-specific T cells taken from the tumor, tumor microenvironment, or blood, retain their previously rearranged T cell receptor sequence, and thus the fully reprogrammed T cells retain original antigen specificity and the ability to target the tumor.
[0175] Thus, provided herein are methods of utilizing transcription factor-mediated cellular reprogramming to de-differentiate T cells from terminally exhausted T cells to iPSCs, then using these iPSC to generate the less differentiated T cell populations (e.g. naive, stem central memory, or central memory) that are required for patients to benefit from immunotherapy (including adoptive cellular transfer or TIL therapy and certain ICB strategies (e.g., anti-PD(L)l), with the full array of anti-tumor functionality. The clinical impact of this strategy is that immunotherapy non-responsive patients (e.g., the majority of patients) can be turned into immunotherapy responders.
[0176] Provided herein are tumor-specific CD8 T cells reprogrammed, with their sternness and anti-tumor functionality restored via transcription factor reprogramming. Provided herein are methods wherein the chromatin state and gene regulatory networks enforcing exhaustion of tumor-specific CD8 T cells are reset to an embryonic-like state and sternness restored via transcription factor reprogramming. Provided herein are methods utilizing transcription factor reprogramming to reverse or overcome epigenetic and transcriptional programs enforcing exhaustion and cells resulting therefrom. Also provided herein are methods to improve the efficacy of T cell mediated therapies for patients with cancer and cells and materials used therein. Also provided herein are strategies to protect ACT products from exhaustion and the ACT products therefrom.
[0177] Provided herein are de-differentiated T cells obtained from a tumor, tumor microenvironment or blood, as well as restoration and uses thereof.
[0178] In some aspects, disclosed herein are methods of full transcription factor reprogramming to rejuvenate exhausted tumor-specific T cells into stem-like memory T cells.
[0179] In some aspects, disclosed herein are stem-like memory T cells rejuvenated by reprogramming exhausted tumor-specific T cells.[UCLA 2024-240] P-638467-PC Cancers
[0180] In some embodiments, the methods disclosed herein are useful for treating cancer. In some embodiments, the methods disclosed herein are useful for treating any cancer. In some embodiments, the tumor is derived from the embryonic endoderm, mesoderm, or ectoderm. In some embodiments, the methods disclosed herein are useful for treating any solid cancer that can elicit a T cell response.
[0181] In some embodiments, the cancer is a solid tumor or a hematologic cancer. In some embodiments, the cancer is melanoma. In some embodiments, the cancer is a mesenchymal cancer. In some embodiments, the cancer is an epithelial cancer.
[0182] In some embodiments, the tumor is a solid tumor. In some embodiments, the tumor is a hematological cancer. In some embodiments, the tumor, suspected tumor, or resected tumor comprises a cancerous, pre-cancerous, or non-cancerous tumor. Non-limiting examples of types of tumors from which T cells may be obtained (from the tumor, tumor microenvironment or blood) include any of those described herein.
[0183] In some embodiments, the cancer is a solid tumor or a hematologic cancer. In some embodiments, the cancer is melanoma. In some embodiments, the cancer is a mesenchymal cancer. In some embodiments, the cancer is an epithelial cancer. In some embodiments, the cancer is pancreatic cancer.
[0184] In some embodiments, the tumor is a solid tumor. In some embodiments, the tumor is a hematological cancer. In some embodiments, the tumor, suspected tumor, or resected tumor comprises a cancerous, pre-cancerous, or non-cancerous tumor. In some embodiments, the tumor comprises a sarcoma or a carcinoma, a fibrosarcoma, a myxosarcoma, a liposarcoma, a chondrosarcoma, an osteogenic sarcoma, a chordoma, an angiosarcoma, an endotheliosarcoma, a lymphangiosarcoma, a lymphangioendotheliosarcoma, a synovioma, a mesothelioma, an Ewing’s tumor, a leiomyosarcoma, a rhabdomyosarcoma, , a colon carcinoma, a pancreatic cancer or tumor, a breast cancer or tumor, an ovarian cancer or tumor, a prostate cancer or tumor, a squamous cell carcinoma, a basal cell carcinoma, an adenocarcinoma, a sweat gland carcinoma, a sebaceous gland carcinoma, a papillary carcinoma, a papillary adenocarcinomas, a cystadenocarcinoma, a medullary carcinoma, a bronchogenic carcinoma, a renal cell carcinoma, a hepatoma, a bile duct carcinoma, a choriocarcinoma, a seminoma, an embryonal carcinoma, a[UCLA 2024-240] P-638467-PC Wilm's tumor, a cervical cancer or tumor, a uterine cancer or tumor, a testicular cancer or tumor, a lung carcinoma, a small cell lung carcinoma, a bladder carcinoma, an epithelial carcinoma, a glioma, an astrocytoma, a medulloblastoma, a craniopharyngioma, an ependymoma, a pinealoma, a hemangioblastoma, an acoustic neuroma, an oligodendroglioma, a schwannoma, a meningioma, a melanoma, a neuroblastoma, or a retinoblastoma, esophageal cancer, pancreatic cancer, metastatic pancreatic cancer, metastatic adenocarcinoma of the pancreas, bladder cancer, stomach cancer, fibrotic cancer, glioma, malignant glioma, diffuse intrinsic pontine glioma, recurrent childhood brain neoplasm renal cell carcinoma, clear-cell metastatic renal cell carcinoma, kidney cancer, prostate cancer, metastatic castration resistant prostate cancer, stage IV prostate cancer, metastatic melanoma, melanoma, malignant melanoma, recurrent melanoma of the skin, melanoma brain metastases, stage HIA skin melanoma; stage LLLB skin melanoma, stage me skin melanoma; stage IV skin melanoma, malignant melanoma of head and neck, lung cancer, non-small cell lung cancer (NSCLC), squamous cell non-small cell lung cancer, breast cancer, recurrent metastatic breast cancer, hepatocellular carcinoma, Hodgkin’s lymphoma, follicular lymphoma, non-Hodgkin’s lymphoma, advanced B-cell NHL, HL including diffuse large B-cell lymphoma (DLBCL), multiple myeloma, chronic myeloid leukemia, adult acute myeloid leukemia in remission; adult acute myeloid leukemia with Inv(16)(pl3.1q22); CBFB-MYH11; adult acute myeloid leukemia with t(16;16)(pl3.1;q22); CBFB-MYH11; adult acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1; adult acute myeloid leukemia with t(9; 11)(p22;q23); MLLT3-MLL; adult acute promyelocytic leukemia with t(15;17)(q22;ql2); PML-RARA; alkylating agent-related acute myeloid leukemia, chronic lymphocytic leukemia, Richter’s syndrome; Waldenstrom’s macroglobulinemia, adult glioblastoma; adult gliosarcoma, recurrent glioblastoma, recurrent childhood rhabdomyosarcoma, recurrent Ewing sarcoma / peripheral primitive neuroectodermal tumor, recurrent neuroblastoma; recurrent osteosarcoma, colorectal cancer, MSI positive colorectal cancer; MSI negative colorectal cancer, nasopharyngeal nonkeratinizing carcinoma; recurrent nasopharyngeal undifferentiated carcinoma, cervical adenocarcinoma; cervical adenosquamous carcinoma; cervical squamous cell carcinoma; recurrent cervical carcinoma; stage IVA cervical cancer; stage IVB cervical cancer, anal canal squamous cell carcinoma; metastatic anal canal carcinoma; recurrent anal canal carcinoma, recurrent head and neck cancer; carcinoma, squamous cell of head and neck, head and neck squamous cell carcinoma (HNSCC), ovarian carcinoma, colon cancer, gastric cancer, advanced GI cancer, gastric adenocarcinoma; gastroesophageal junction adenocarcinoma, bone neoplasms, soft tissue sarcoma; bone sarcoma, thymic carcinoma,[UCLA 2024-240] P-638467-PC urothelial carcinoma, recurrent Merkel cell carcinoma; stage HI Merkel cell carcinoma; stage IV Merkel cell carcinoma, myelodysplastic syndrome and recurrent mycosis fungoides and Sezary syndrome.
[0185] Provided herein are fully de-differentiated and rematured T cells, methods of making them, and methods of use thereof. Such T cells isolated for reprogramming are originally obtained from a patient’s tumor or the tumor microenvironment, for example from a solid tumor or from blood.
[0186] In some embodiments, the T cells obtained from a tumor and used to carry out the methods disclosed herein may be obtained by biopsy (comprising tumor, tumor environment, tumor microenvironment or blood), or surgical resection of a primary tumor or metastatic tumor (metastectomy). Such biopsy may be referred to as containing tumor infiltrating lymphocytes (TILs).
[0187] In some embodiments, the T cells are obtained from a patient’s blood.
[0188] In some embodiments, tumor-specific TILs may be identified by expression of biomarkers including but not limited to one or more of PD1, TIM3, CD39, CD69, CD103 and / or CD137.De-differentiation and De-Differentiated Cells
[0189] In some embodiments, disclosed herein is a method for fully de-differentiating T cells obtained from a tumor or tumor microenvironment (e.g., exhausted, tumor-specific T cells) or blood (e.g., effector or exhausted T cells, potentially tumor-specific) to iPSCs then expanding the cells, and re-maturing them into functional, stem-like T cells for use to treat the tumor. As will be described herein, the method as well as the state of the T cells at the various steps of the method, are described by either or both of conditions for progressing the T cells though the steps (e.g., duration, conditions such as medium components, etc.) as well as expression or lack of expression of certain T cell markers and response to TCR stimulation (or typical T cell stimulatory factors) in culture. One of skill in the art will readily identify from the guidance herein various ways to achieve the desired population of expanded T cells using any of these indicators (e.g., duration, medium, biomarker expression, performance in culture) or any combination thereof. Below is provided guidance for each of the steps and the biomarker expression of the T cells thereof, but[UCLA 2024-240] P-638467-PC such guidance is merely non-limiting and exemplary and other means to achieve them are fully embraced herein.Isolating CD8 T cells from the tumor, tumor environment, tumor microenvironment or blood
[0190] In some embodiments, T cells obtained from a tumor and used to carry out the methods disclosed herein are obtained by biopsy (comprising tumor or blood), or surgical resection of a primary tumor or metastatic tumor (metastectomy).
[0191] In some embodiments, tumor-specific TILs may be identified by expression of biomarkers including but not limited to one or more of PD1, TIM3, CD39, CD69, CD103 and / or CD137.Exposing the CD8 T cells to fully de-differentiation-inducing conditions
[0192] In some embodiments, de-differentiation-inducing conditions comprises exposing (e.g., transducing, transfecting, electroporating or by mechanical introduction) the T cells with OSKM, which comprises c-Myc, Oct3 / 4, Sox2, and KLF4 (see K. Okita et al., Nature 448: SISSI? (2007)). Non-limiting examples of OSKM include Sendai-OSKM, such as available commercially (CYTOTUNE™-iPS 2.0 Sendai Reprogramming Kit from THERMO FISHER SCIENTIFIC INC.™), adenoviral, lentiviral, or retroviral formats. Also included are polydstronic mRNA formats, such as the commercially available Simplicon® RNA Reprogramming Kit (OSKG; available from MILLIPORE SIGMA). In some embodiments, the ratio of OSKM components is optionally at a multiplicity of infection (MOI) of 5:5:3, 3:3:2, 2:2:1 or 1:1:1 ratio of c-Myc:KLF4-Oct3 / 4-Sox2:KLF4. In some embodiments, any multiplicity of infection intermediate to these ratios is suitable.Inducing de-differentiation of the CD8 T cells
[0193] In some embodiments, fully de-differentiating-inducing conditions comprises exposing cells to OSKM in 100% T cell medium in the absence of T cell receptor (TCR) signaling (e.g. absence of anti-CD3 and anti-CD28, peptide stimulation, or other forms of antigen presentation or T cell stimulation) on days 0-1, then over the next 5-6 days reducing the percent (v / v) T cell medium and increasing the percent (v / v) stem cell medium with cytokines, followed by 100% stem cell medium with cytokines, again in the absence of TCR signaling. In another[UCLA 2024-240] P-638467-PC embodiment, the CD8 T cells can be maintained in 100% T cell medium with cytokines. Cytokines comprise IL-2, IL-7 and / or IL-15, such as 10 - 2000 lU / mL IL-2, 10-20 ng / mL IL-7 and 10-20 ng / mL IL- 15. Cells are cultured on a surface coated with extracellular matrix, including but not limited to rhLaminin521, vitronectin, etc.
[0194] For example, in one embodiment, T cell medium comprises 90% defined base medium (e.g., RPMI 1640) and 10% fresh human serum from healthy donors or a defined serum replacement (e.g., KnockOut™ Serum Replacement, THERMOFISHER).
[0195] For example, in one embodiment, stem cell medium comprises 100% defined medium (e.g., TeSR™-E8™ basal medium, STEMCELL TECHNOLOGIES, Essential 8™ Medium, THERMOFISHER, or StemFit Basic04 Complete Type AJINOMOTO CO. INC, AminoScience Division).
[0196] Cytokines may include one or more gamma-chain cytokines, such as one or more of IL-2, IL-4, IL-7, IL-9, IL- 15, IL- 18, and / or IL-21. Typically, IL-2 is used in combination with one or more other gamma-chain cytokines, such as IL-7 and IL-15. Typically, concentrations of about 10-20 ng / mL are used. In some embodiments, IL- 10 may be included; in some embodiments, an antibody to IL- 10 may be included. In some embodiments, anti-interferon gamma antibody may be included. Inclusion of cytokines comprises, in some embodiments, the combination of IL-2 at 12 lU / mL, IL-7 at lOng / mL, and IL- 15 at lOng / mL. Other single or combination of other cytokines may also be used. As will be described here and elsewhere herein, guidance for the duration of de-differentiating to iPSCs then maturing these iPSC back to T cells may be provided in temporal terms, such as based on days and conditions such T cells are exposed to each day, and / or may be provided by characterization of the T cells, such as analysis of expressed markers by flow cytometry or flow assisted cell sorting. The disclosure is not limited to specific days or durations, which are merely provided herein as guidance for the duration of de-differentiating and point of reprogramming the iPSCs thereof; the characterization of the cells, changes therein and the appropriate point to reprogram is based on the teachings herein and is not intended to be limited. Examples of protocols based on time of incubation in various media are exemplary only and based on the teachings here, the skilled artisan will identify variations therein that are fully encompassed by the present disclosure.[UCLA 2024-240] P-638467-PC
[0197] Thus, as disclosed herein, a method for the full reprogramming of T cells isolated from a tumor, tumor microenvironment of blood comprises exposing the CD8 T cells to dedifferentiation-inducing conditions to iPSCs, then maturing the resultant iPSCs back to CD8 T cells. The timing of exposure to de-differentiating conditions, and the point to start reprogramming the iPSCs will be apparent from the description and the examples herein, which are not intended to be limiting. As used herein, re-differentiating iPSCs into CD8 T cells is also referred to as maturing, rematuring, and syntactic variants thereof.
[0198] For example, a protocol to achieve full de-differentiation may comprise:exposing the CD8 T cells to Sendai-OSKM and 100% T cell medium on days 0- 1;exposing the CD8 T cells to 75% T cell medium, 25% stem cell medium and cytokines on about day 2;exposing the CD8 T cells to 50% T cell medium, 50% stem cell medium and cytokines on about day 3exposing the CD8 T cells to 25% T cell medium, 75% stem cell medium and cytokines on about day 4;exposing the CD8 T cells to 100% stem cell medium and cytokines on about day 5; andexposing the CD8 T cells to 100% stem cell medium without cytokines starting on about day 6; andexposing the CD8 T cells to 100% stem cell medium without cytokines for the remainder of culture.
[0199] Variations in the number of steps with changes in medium compositions, and / or duration of time under each condition, may be used to achieve the same results. For example, an alternative protocol comprises maintaining cells in 100% T cell medium with cytokines from days 2-6. The skilled artisan by following the teachings herein will readily identify conditions and variations in the stated conditions for achieving these results, all of which are embraced herein.[UCLA 2024-240] P-638467-PC
[0200] In some embodiments, during or after the step following exposure to OSKM in 100% T cell medium, the T cells exposed to these conditions are rapidly expanded. Such expansion may be achieved by culture in T cell medium with cytokines or progressive exposure to increasing concentrations of stem cell medium with cytokines, as above. This expansion is accomplished in the absence of TCR signaling (e.g., absence of anti-CD3 and anti-CD28, peptide stimulation, or other forms of antigen presentation) or other T cell intrinsic inflammatory signaling pathways, for example those that culminate with expression of NFkB, NFAT, AP-1 or the interferon response family members by way of non-limiting examples, which may be activated for example through Toll-Like Receptor (TLR) ligands, PMA / ionomycin, etc. Cells are cultured on a surface coated with extracellular matrix, including but not limited to rhLaminin521, vitronectin, etc.
[0201] In some embodiments, if T cells exposed to the protocol to achieve full de-differentiation described above are continued in culture with stem cell media and removal of cytokines on a surface coated with extracellular matrix, including but not limited to rhLaminin521, vitronectin, etc., then CD8-derived iPSC colonies will begin to be formed in the culture. The timing of dedifferentiation to iPSC and appearance of iPSC colonies depends on the source of starting T cells used (e.g., blood or tumor) and the starting differentiation state of these T cells (e.g., Tscm, Tcm, Tern, Teff, Tex).
[0202] While the duration of de-differentiation is provided as a number of days in certain guidance and examples herein, such duration of de-differentiation before the iPSCs are re-matured to T cells may be guided by any one or more characteristics of the cells, and determination of the duration in days may be superseded or confirmed by such characterization. In some embodiments, once the conditions for de-differentiation protocol to a certain iPSC characterization is identified, such protocol may be conducted using duration (in days) in place of characterization, although in some embodiments, the duration may be checked by characterization, for example, as an in-process control. For example, in one embodiment, the exact day or characterization to determine when reprogramming to iPSC has completed can be accomplished by staining cells for any one or more of SSEA3, SSEA4, Tra-1-60, Tra-1-81, CD30, etc and performing, for example, flow cytometry or microscopy-based imaging techniques to determine their expression on the surface of iPSC.
[0203] In some embodiments, one or more additional compounds may be included to induce de-differentiation. In some embodiments, such compounds are epigenetic modifiers. In some[UCLA 2024-240] P-638467-PC embodiments, the compound is vitamin C. In some embodiments, such a compound is a histone deacetylase inhibitor such as valproic acid (VP A). In some embodiments, such a compound is a histone methyltransferase inhibitor, such as a DOT1L inhibitor, optionally EPZ-5676 (pinometostat). In some embodiment, such compound is a GSK3b inhibitor such as CHIR99021. Inclusion or other compounds including small molecule epigenetic modifiers are fully embraced herein.
[0204] In some embodiments, a compound such as a small molecules may also be included to modulate signaling strength of various receptors, including the TCR.Re-maturing iPSCs to memory or naive T cells
[0205] In some embodiments, iPSCs are re-matured to T cells using an artificial thymic organoid (ATO) that allows re-differentiation into mature TCRa0 T cells. A description of the ATO and methods for achieving re-differentiation have been recently described (Montel-Hagen, Cell Stem Cell, 2019, 24(3):376-389; Montel-Hagen, Cell Reports, 2020, 33(4): 108320). In some embodiments, early maturation of iPSCs into T cells in the ATO are obtained when harvested at week 2 of ATO culture. Thus, in some embodiments, at week 2 of ATO culture, iPSC derived from CD8 cells have begun committing to the T cell lineage (CD3+ and TCRab+) but remain immature, expressing both CD4 and CD8. In some embodiments, maturation of iPSC into T cells in the ATO has occurred when harvested at week 4 of ATO culture. Monitoring for markers as described herein may be performed to optimize the incubation time and harvesting cells for infusion into the patient.Expanding the CD8 T cells
[0206] As noted herein above, expansion of the T cells may occur during or after the step following exposure to OSKM in 100% T cell medium. T cells exposed to these conditions are rapidly expanded. Such expansion may be achieved by expansion in T cell medium with cytokines or progressive exposure to increasing concentrations of stem cell medium with cytokines, as above. This expansion is accomplished in the absence of TCR signaling (e.g., anti-CD3 and anti-CD28, peptide stimulation, or other forms of antigen presentation) and on a surface coated with extracellular matrix, including but not limited to rhLaminin521, vitronectin, etc.[UCLA 2024-240] P-638467-PC
[0207] Following reprogramming to iPSC and re-maturation to T cells, the rejuvenated T cells may be expanded to obtain a sufficient population for efficacious treatment of the patient’ s tumor. In one embodiment, expansion is achieved by incubation of the T cells in T cell medium with cytokines and provision of TCR signaling, which may include but is not limited to anti-CD3 and anti-CD28 (soluble in the medium, bound to beads or other structures, or adhered to the culture surface), cognate peptide(s), antigen presenting cells, etc, or some combination thereof. In some embodiments, expansion is continued for 2-4 weeks, or more. In some embodiments, such expansion may achieve 400 fold expansion or more in one week and continued expansion is dependent upon conditions used.Administering the CD8 T cells to the subject
[0208] T cells obtained by the foregoing methods are infused into the patient. In some embodiments, a total of about 3 x 106to about 3 x 107cells are infused per kg body weight. In some embodiments, such infusion is in divided, escalating doses.Monitoring efficacy of treatment
[0209] Effectiveness of the treatment disclosed herein may be monitored by methods including but not limited to evaluating the size of the tumor, measuring tumor markers, and identifying tumor-specific TILs from a biopsy sample, or any combination thereof. In other embodiments, such efficacy may be determined by radiographic characteristics of the primary and / or metastatic tumor (e.g., by ultrasound, CT, MRI, PET); radiographic characteristics of the resection bed (in the case of surgery) or surrounding tissue; tumor characteristics on biopsy (in addition to T cell characteristics on biopsy, e.g., TCR repertoire, functional analysis, etc.) determined by next generation sequencing techniques, high resolution imaging techniques (referring to histologic or pathologic analysis), flow cytometry, cytometry by time-of-flight (CyTOF), spectral cytometry, image stream; antigen expression; T cell (co-)culture assays, tumor (co-)culture assays; ELISA; Luminex; extracellular vesicles; exosomes; tumor-derived nanoparticles; circulating tumor cells; circulating cell-free DNA. Any biopsy or radiographic technique or other technique used to assess efficacy of tumor treatment is fully embraced herein.
[0210] The foregoing description of fully reprogrammed T cells and exemplary ways of preparing them are merely illustrative and non-limiting, and one of skill in the art following the[UCLA 2024-240] P-638467-PC teachings herein will readily prepare such fully reprogrammed T cells. Reference is made to Figure 1 and the aspects relating to full reprogramming in Figures 3, 4, 5, 11, and 18A and 18B.Fully reprogrammed T cells
[0211] In some embodiments, the disclosure embraces transiently reprogrammed T cells prepared in accordance with the teachings herein. In some embodiments, such fully reprogrammed T cells are prepared by:i. exposing the CD8 T cells to full de-differentiation-inducing conditions to generate CD8 T cell-derived iPSC;ii. culturing CD8 T cell-derived iPSC for a desired period; andiii. inducing re-differentiation or maturation into mature CD8 T cells.
[0212] In some embodiments, the fully reprogrammed T cells are prepared from T cells obtained from a tumor or tumor microenvironment, or blood. In some embodiments, the T cells obtained from the tumor or tumor microenvironment express CD39, CD69, CD103, CD137, PD-1 , or TIM3 or any combination thereof.
[0213] In some embodiments, the fully reprogrammed T cell are expanded, such that the expanded fully reprogrammed T cells are embraced by the disclosure. In some embodiments, the expanded fully reprogrammed T cells are administered to a subject.
[0214] In some embodiments, exposing the CD8 T cells to de-differentiation-inducing conditions comprises transducing the T cells with OSKM, such as Sendai-OSKM, optionally at a MOI of 5:5:3, 3:3:2, 2:2:1 or 1:1:1 ratio of c-Myc:KLF4-Oct3 / 4-Sox2:KLF4. In some embodiments, any multiplicity of infection intermediate to these ratios is suitable.
[0215] In some embodiments, exposing the CD8 T cells to de-differentiation-inducing conditions comprises exposing cells to OSKM in 100% T cell medium on days 0-1, then over the next 5-6 days reducing the percent (v / v) T cell medium and increasing the percent (v / v) stem cell medium with cytokines, followed by 100% stem cell medium without cytokines. In some embodiments, the cytokines comprise IL-2, IL-7 and / or IL- 15, such as 10-3000 lU / mL IL-2, 10-20 ng / mL IL-7 and 10-20 ng / mL IL- 15.[UCLA 2024-240] P-638467-PC
[0216] By way of non-limiting example, in one embodiment, fully reprogrammed T cells may be prepared by the steps of:a) exposing the CD8 T cells to Sendai-OSKM and 100% T cell medium on days 0- 1;b) exposing the CD8 T cells to 75% T cell medium, 25% stem cell medium and cytokines on about day 2;c) exposing the CD8 T cells to 50% T cell medium, 50% stem cell medium and cytokines on about day 3;d) exposing the CD8 T cells to 25% T cell medium, 75% stem cell medium and cytokines on about day 4;e) exposing the CD8 T cells to 100% stem cell medium and cytokines on about day 5; andf) exposing the CD8 T cells to 100% stem cell medium without cytokines starting on about day 6;g) exposing the CD8 T cells to 100% stem cell medium without cytokines for the remainder of culture; andh) re-maturing CD8 T cell-derived iPSC back into mature CD8 T cells, which may be accomplished using an artificial thymic organoid.
[0217] In an alternative protocol, cells are maintained in 100% T cell medium with cytokines from days 2-6.
[0218] In some embodiments, during and / or after any step, the CD8 T cells or CD8 T cell-derived iPSC are expanded. In some embodiments, the expansion occurs in stem cell medium.
[0219] In some embodiments, the CD8 T cell-derived iPSC are induced toward mesodermal differentiation then incubated in an ATO that reprograms the iPSCs to T cells. Such incubation may comprise from about 3 to about 4 months.[UCLA 2024-240] P-638467-PC
[0220] In some embodiments, the iPSC are induced or matured into mesodermal progenitors followed by hematopoietic progenitor induction. In some embodiments, the iPSCs are exposed to Activin A, BMP4, VEGF, and FGF to induce mesodermal induction. Hematopoietic induction can then be accomplished by aggregating mesodermal progenitors with a mouse bone marrow stromal cell line expressing human delta-like ligand 4 (MS5-DLL4) and culturing resultant organoids initially in EGM2 media with a TGFb inhibitor then EGM2 media with a TGFb inhibitor plus SCF, FLT3L, and TPO. T cell differentiation into naive or stem-like T cells can then be accomplished by continued organoid culture in RPMI media supplemented with ascorbic add, B27 supplement, SCF, FLT3L and IL-7, as previously described (Montel-Hagen, Cell Stem Cell, 2019, 24(3):376-389).
[0221] In some embodiments, the CD8 cells isolated from the tumor express CD39, CD69, CD103, CD137, PD-1, or TIM3 or any combination thereof.
[0222] The foregoing description of fully reprogrammed T cells and exemplary ways of preparing them are merely illustrative and non-limiting, and one of skill in the art following the teachings herein will readily prepare such fully reprogrammed T cells. Reference is made to Figure 1 and the aspects relating to full reprogramming in Figures 3, 4, 5, 11, and 18A and 18B.Definitions
[0223] The term "operably linked" encompasses components to which the term is applied are in a relationship that allows them to carry out their inherent functions under suitable conditions. For example, a transcription control sequence "operably linked" to a protein coding sequence is ligated thereto so that expression of the protein coding sequence is achieved under conditions compatible with the transcriptional activity of the control sequences.
[0224] The term "control sequence" as used herein encompasses polynucleotide sequences that can affect expression or processing of coding sequences to which they are ligated or operably linked. The nature of such control sequences may depend upon the elements included in the cell-free transcription and translation system. In particular embodiments, transcription control sequences may include a promoter, ribosomal binding site, and transcription termination sequence. In some embodiments, transcription control sequences may include promoters comprising one or a plurality of recognition sites for transcription factors, transcription enhancer sequences, transcription termination sequences and polyadenylation sequences. In certain[UCLA 2024-240] P-638467-PC embodiments, "control sequences" can include leader sequences and / or fusion partner sequences.
[0225] The term "polynucleotide" as used herein encompasses single-stranded or doublestranded nucleic acid polymers. In certain embodiments, the nucleotides comprising the polynucleotide can be ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide. The term "polynucleotide" specifically includes single and double stranded forms ofDNA.
[0226] In some embodiments, an expression vector may contain a variety of elements for controlling expression, including without limitation, promoter sequences, transcription initiation sequences, enhancer sequences, selectable markers, and signal sequences. These elements may be selected as appropriate by a person of ordinary skill in the art. For example, the promoter sequences may be selected to promote the transcription of the polynucleotide in the vector. Suitable promoter sequences include, without limitation, T7 promoter, T3 promoter, SP6 promoter, beta-actin promoter, EFla promoter, CMV promoter, and SV40 promoter, or any promotor sequence known in the art. Enhancer sequences may be selected to enhance the transcription of the polynucleotide.
[0227] Transcription and translation of an encoded peptide or protein by the cell-free machinery are ATP-dependent processes. Therefore, availability of ATP, may in certain embodiments, regulate expression of a peptide or protein encoded by a plasmid vector. Caged ATP molecules may be used to regulate ATP release rapidly at sites of biological interest, at a desired time. A skilled artisan would appreciate and know how to select a caged ATP molecule, wherein they are well known in the art. In some embodiments, a caged ATP molecule may encompass a photoactivatable ATP molecule, for example but not limited to DMNPE-caged ATP (Adenosine 5'-Triphosphate, P3-(l-(4,5-Dimethoxy-2-Nitrophenyl)ethyl) Ester, Disodium Salt; THERMO FISHER SCIENTIFIC™ Cat No. A1049) or NPE-caged ATP (Adenosine 5'-Triphosphate, P3-(l-(2-Nitrophenyl)Ethyl) Ester, Disodium Salt; THERMO FISHER SCIENTIFIC™ Cat No. A1048; Jena Science, Germany Cat. No. NU-301S).
[0228] As used herein, a “targeting agent,” or “affinity reagent,” is a molecule that binds to an antigen or receptor or other molecule. In some embodiments, a “targeting agent” is a molecule that specifically binds to an antigen or receptor or other molecule. In certain embodiments, some or all of a targeting agent is composed of amino acids (including natural, non-[UCLA 2024-240] P-638467-PC natural, and modified amino acids), nucleic adds, or saccharides. In certain embodiments, a “targeting agent” is a small molecule.
[0229] As used herein, the term “antibody” encompasses the structure that constitutes the natural biological form of an antibody. In most mammals, including humans, and mice, this form is a tetramer and consists of two identical pairs of two immunoglobulin chains, each pair having one fight and one heavy chain, each light chain comprising immunoglobulin domains VL and CL, and each heavy chain comprising immunoglobulin domains VH, C-gamma-1 (Cyl), C-gamma-2 (Cy2), and C-gamma-3 (Cy3). In each pair, the light and heavy chain variable regions (VL and VH) are together responsible for binding to an antigen, and the constant regions (CL, Cyl, Cy2, and Cy3, particularly Cy2, and Cy3) are responsible for antibody effector functions. In some mammals, for example in camels and llamas, full-length antibodies may consist of only two heavy chains, each heavy chain comprising immunoglobulin domains VH, Cy2, and Cy3. By “immunoglobulin (Ig)” herein is meant a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes. Immunoglobulins include but are not limited to antibodies. Immunoglobulins may have a number of structural forms, including but not limited to full-length antibodies, antibody fragments, and individual immunoglobulin domains including but not limited to VH, Cyl, Cy2, Cy3, VL, and CL.
[0230] Depending on the amino add sequence of the constant domain of their heavy chains, intact antibodies can be assigned to different “classes”. There are five-major classes (isotypes) of intact antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into “subclasses”, e.g., IgGl, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy-chain constant domains that correspond to the different classes of antibodies are called alpha, delta, epsilon, gamma, and mu, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known to one skilled in the art.
[0231] As used herein, the term “immunoglobulin G” or “IgG” refers to a polypeptide belonging to the class of antibodies that are substantially encoded by a recognized immunoglobulin gamma gene. In humans this class comprises IgGl, IgG2, IgG3, and IgG4. In mice this class comprises IgGl, IgG2a, IgG2b, IgG3. As used herein, the term “modified immunoglobulin G” refers to a molecule that is derived from an antibody of the “G” class. As used herein, the term “antibody” refers to a protein consisting of one or more polypeptides substantially encoded by all or part of the recognized immunoglobulin genes. The recognized[UCLA 2024-240] P-638467-PC immunoglobulin genes, for example in humans, include the kappa (K ), lambda (1), and heavy chain genetic loci, which together comprise the myriad variable region genes, and the constant region genes mu (p), delta (8), gamma (y), sigma (o), and alpha (a) which encode the IgM, IgD, IgG, IgE, and IgA isotypes or classes, respectively.
[0232] The term “antibody” is meant to include full-length antibodies, and may refer to a natural antibody from any organism, an engineered antibody, or an antibody generated recombinandy for experimental, therapeutic, or other purposes as further defined below. Furthermore, full-length antibodies comprise conjugates as described and exemplified herein. As used herein, the term “antibody” comprises monoclonal and polyclonal antibodies. Antibodies can be antagonists, agonists, neutralizing, inhibitory, or stimulatory. Specifically included within the definition of “antibody” are full-length antibodies described and exemplified herein. By “full length antibody” herein is meant the structure that constitutes the natural biological form of an antibody, including variable and constant regions.
[0233] The “variable region” of an antibody contains the antigen binding determinants of the molecule, and thus determines the specificity of an antibody for its target antigen. The variable region is so named because it is the most distinct in sequence from other antibodies within the same isotype. The majority of sequence variability occurs in the complementarity determining regions (CDRs). There are 6 CDRs total, three each per heavy and fight chain, designated VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. The variable region outside of the CDRs is referred to as the framework (FR) region. Although not as diverse as the CDRs, sequence variability does occur in the FR region between different antibodies. Overall, this characteristic architecture of antibodies provides a stable scaffold (the FR region) upon which substantial antigen binding diversity (the CDRs) can be explored by the immune system to obtain specificity for a broad array of antigens.
[0234] Furthermore, antibodies may exist in a variety of other forms including, for example, Fv, Fab, and (Fab’)2, as well as bi-functional (i.e., bi-specific) hybrid antibodies (see, e.g., Lanzavecchia et al., Eur. J. Immunol. 17, 105 (1987)) and in single chains (see, e.g., Huston et al., Proc. Natl. Acad. Sci. U.S.A., 85, 5879-5883 (1988) and Bird et al., Science, 242, 423-426 (1988)). (See, generally, Hood et al., “Immunology”, Benjamin, N.Y., 2nd ed. (1984), and Hunkapiller and Hood, Nature, 323, 15-16 (1986)).[UCLA 2024-240] P-638467-PC
[0235] The term “epitope” as used herein refers to a region of the antigen that binds to the antibody or antigen-binding fragment. It is the region of an antigen recognized by a first antibody wherein the binding of the first antibody to the region prevents binding of a second antibody or other bivalent molecule to the region. The region encompasses a particular core sequence or sequences selectively recognized by a class of antibodies. In general, epitopes are comprised by local surface structures that can be formed by contiguous or noncontiguous amino add sequences.
[0236] As used herein, the terms “selectively recognizes”, “selectively bind” or “selectively recognized” mean that binding of the antibody, antigen-binding fragment or other bivalent molecule to an epitope is at least 2-fold greater, preferably 2-5 fold greater, and most preferably more than 5-fold greater than the binding of the molecule to an unrelated epitope or than the binding of an antibody, antigen-binding fragment or other bivalent molecule to the epitope, as determined by techniques known in the art and described herein, such as, for example, ELISA or cold displacement assays.
[0237] As used herein, the term “Fc domain” encompasses the constant region of an immunoglobulin molecule. The Fc region of an antibody interacts with a number of Fc receptors and ligands, imparting an array of important functional capabilities referred to as effector functions, as described herein. For IgG, the Fc region comprises Ig domains CH2 and CH3. An important family of Fc receptors for the IgG isotype are the Fc gamma receptors (FcyRs). These receptors mediate communication between antibodies and the cellular arm of the immune system.
[0238] As used herein, the term “Fab domain” encompasses the region of an antibody that binds to antigens. The Fab region is composed of one constant and one variable domain of each of the heavy and the light chains.
[0239] In one embodiment, the term “antibody” or “antigen-binding fragment” respectively refer to intact molecules as well as functional fragments thereof, such as Fab, a scFv-Fc bivalent molecule, F(ab’)2, and Fv that are capable of specifically interacting with a desired target. In some embodiments, the antigen-binding fragments comprise:
[0240] (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, which can be produced by digestion of whole antibody with the enzyme papain to yield an intact fight chain and a portion of one heavy chain;[UCLA 2024-240] P-638467-PC
[0241] (2) Fab’, the fragment of an antibody molecule that can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab’ fragments are obtained per antibody molecule;
[0242] (3) (Fab’)2, the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab’)2 is a dimer of two Fab’ fragments held together by two disulfide bonds;
[0243] (4) Fv, a genetically engineered fragment containing the variable region of the fight chain and the variable region of the heavy chain expressed as two chains; and
[0244] (5) Single chain antibody (“SCA”), a genetically engineered molecule containing the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.
[0245] (6) scFv-Fc, is produced in one embodiment, by fusing single-chain Fv (scFv) with a hinge region from an immunoglobulin (Ig) such as an IgG, and Fc regions.
[0246] In some embodiments, an antibody provided herein is a monoclonal antibody. In some embodiments, the antigen-binding fragment provided herein is a single chain Fv (scFv), a diabody, a tri(a)body, a di-or tri-tandem scFv, a scFv-Fc bivalent molecule, an Fab, Fab’, Fv, F(ab’)2 or an antigen binding scaffold (e.g., affibody, monobody, anticalin, DARPin, Knottin, etc.). “Affibodies” are small proteins engineered to bind to a large number of target proteins or peptides with high affinity, often imitating monoclonal antibodies, and are antibody mimetics.
[0247] As used herein, the terms “bivalent molecule” or “BV” refer to a molecule capable of binding to two separate targets at the same time. The bivalent molecule is not limited to having two and only two binding domains and can be a polyvalent molecule or a molecule comprised of linked monovalent molecules. The binding domains of the bivalent molecule can selectively recognize the same epitope or different epitopes located on the same target or located on a target that originates from different species. The binding domains can be linked in any of a number of ways including, but not limited to, disulfide bonds, peptide bridging, amide bonds, and other natural or synthetic linkages known in the art (see, e.g., Spatola et al., “Chemistry and Biochemistry of Amino Adds, Peptides and Proteins,” B. Weinstein, eds., Marcel Dekker, New York, p. 267 (1983); Morley, J. S., “Trends Pharm Sci.” (1980) pp. 463-468 ; Hudson et al., hit.[UCLA 2024-240] P-638467-PC J. Pept. Prot. Res. (1979) 14, 177-185; Spatola et al., Life Sci. (1986) 38, 1243-1249; Hann, M. M., J. Chem. Soc. Perkin Trans. I (1982) 307-314; Almquist et al., J. Med. Chem. (1980) 23, 1392-1398; Jennings- White et al., Tetrahedron Lett. (1982) 23, 2533; Szelke et al., European Application EP 45665; Chemical Abstracts 97, 39405 (1982); Holladay, et al., Tetrahedron Lett. (1983) 24, 4401-4404; and Hruby, V. J., Life Sci. (1982) 31, 189-199).
[0248] As used herein, the terms “binds” or “binding” or grammatical equivalents, refer to compositions having affinity for each other. “Specific binding” is where the binding is selective between two molecules. A particular example of specific binding is that which occurs between an antibody and an antigen. Typically, specific binding can be distinguished from non-specific when the dissociation constant (KD) is less than about 1x10-5 M or less than about 1x10-6 M or 1x10-7 M. Specific binding can be detected, for example, by ELISA, immunoprecipitation, coprecipitation, with or without chemical crosslinking, two-hybrid assays and the like. Appropriate controls can be used to distinguish between “specific” and “non-specific” binding.
[0249] In addition to antibody sequences, an antibody according to the present invention may comprise other amino adds, e.g., forming a peptide or polypeptide, such as a folded domain, or to impart to the molecule another functional characteristic in addition to ability to bind antigen. For example, antibodies of the invention may carry a detectable label, such as fluorescent or radioactive label, or may be conjugated to a toxin (such as a holotoxin or a hemitoxin) or an enzyme, such as beta-galactosidase or alkaline phosphatase (e.g., via a peptidyl bond or linker).
[0250] In one embodiment, an antibody of the invention comprises a stabilized hinge region. The term "stabilized hinge region" will be understood to mean a hinge region that has been modified to reduce Fab arm exchange or the propensity to undergo Fab arm exchange or formation of a half-antibody or a propensity to form a half-antibody. "Fab arm exchange" refers to a type of protein modification for human immunoglobulin, in which a human immunoglobulin heavy chain and attached fight chain (half-molecule) is swapped for a heavy-light chain pair from another human immunoglobulin molecule. Thus, human immunoglobulin molecules may acquire two distinct Fab arms recognizing two distinct antigens (resulting in bispecific molecules). Fab arm exchange occurs naturally in vivo and can be induced in vitro by purified blood cells or reducing agents such as reduced glutathione. A "half-antibody" forms when a human immunoglobulin antibody dissociates to form two molecules, each containing a single heavy chain and a single[UCLA 2024-240] P-638467-PC light chain. In one embodiment, the stabilized hinge region of human immunoglobulin comprises a substitution in the hinge region.
[0251] In one embodiment, the term "hinge region" as used herein refers to a proline-rich portion of an immunoglobulin heavy chain between the Fc and Fab regions that confers mobility on the two Fab arms of the antibody molecule. It is located between the first and second constant domains of the heavy chain. The hinge region includes cysteine residues which are involved in inter-heavy chain disulfide bonds. In one embodiment, the hinge region includes cysteine residues which are involved in inter-heavy chain disulfide bonds.
[0252] In one embodiment, the antibody or antigen-binding fragment binds its target with a KD of 0.1 nM - 10 mM. In one embodiment, the antibody or antigen-binding fragment binds its target with a KD of 0.1 nM - 1 mM. In one embodiment, the antibody or antigen-binding fragment binds its target with a KD within the 0.1 nM range. In one embodiment, the antibody or antigenbinding fragment binds its target with a KD of 0.1-2 nM. In another embodiment, the antibody or antigen-binding fragment binds its target with a KD of 0.1-1 nM. In another embodiment, the antibody or antigen-binding fragment binds its target with a KD of 0.05-1 nM. In another embodiment, the antibody or antigen-binding fragment binds its target with a KD of 0.1-0.5 nM. In another embodiment, the antibody or antigen-binding fragment binds its target with a KD of 0.1-0.2 nM.
[0253] In some embodiments, the antibody or antigen-binding fragment thereof provided herein comprises a modification. In another embodiment, the modification minimizes conformational changes during the shift from displayed to secreted forms of the antibody or antigen-binding fragment. It is to be understood by a skilled artisan that the modification can be a modification known in the art to impart a functional property that would not otherwise be present if it were not for the presence of the modification. Encompassed are antibodies which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting / blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH4, acetylation, formylation, oxidation, reduction, metabolic synthesis in the presence of tunicamycin, etc.[UCLA 2024-240] P-638467-PC
[0254] In some embodiments, the modification is one as further defined herein below. In some embodiments, the modification is a N-terminus modification. In some embodiments, the modification is a C-terminal modification. In some embodiments, the modification is an N-terminus biotinylation. In some embodiments, the modification is an C-terminus biotinylation. In some embodiments, the secretable form of the antibody or antigen-binding fragment comprises an N-terminal modification that allows binding to an Immunoglobulin (Ig) hinge region. In some embodiments, the Ig hinge region is from but is not limited to, an IgA hinge region. In some embodiments, the secretable form of the antibody or antigen-binding fragment comprises an N-terminal modification that allows binding to an enzymatically biotinylatable site. In some embodiments, the secretable form of the antibody or antigen-binding fragment comprises an C-terminal modification that allows binding to an enzymatically biotinylatable site. In some embodiments, biotinylation of said site functionalizes the site to bind to any surface coated with streptavidin, avidin, avidin-derived moieties, or a secondary reagent.
[0255] It will be appreciated that the term “modification” can encompass an amino add modification such as an amino add substitution, insertion, and / or deletion in a polypeptide sequence.
[0256] In a further embodiment, the amino acid sequences of the invention may be homologues, variants, isoforms, or fragments of the sequences presented. The term "homolog" as used herein refers to a polypeptide having a sequence homology of a certain amount, namely of at least 70%, e.g., at least 80%, 90%, 95%, 96%, 97%, 98%, or 99% of the amino acid sequence it is referred to. Homology refers to the magnitude of identity between two sequences. Homolog sequences have the same or similar characteristics, in particular, have the same or similar property of the sequence as identified. The term 'variant' as used herein refers to a polypeptide wherein the amino add sequence exhibits substantially 70, 80, 95, or 99% homology with the amino add sequence as set forth in the sequence listing. It should be appreciated that the variant may result from a modification of the native amino acid sequences, or by modifications including insertion, substitution or deletion of one or more amino adds. The term “isoform” as used herein refers to variants of a polypeptide that are encoded by the same gene, but that differ in their isoelectric point (pl) or molecular weight (MW), or both. Such isoforms can differ in their amino add composition (e.g., as a result of alternative splicing or limited proteolysis) and in addition, or in the alternative, may arise from differential post-translational modification (e.g., glycosylation, acylation, phosphorylation deamidation, or sulphation). As used herein, the term “isoform” also refers to a[UCLA 2024-240] P-638467-PC protein that exists in only a single form, i.e., it is not expressed as several variants. The term "fragment" as used herein refers to any portion of the full-length amino add sequence of protein of a polypeptide of the invention which has less amino adds than the full-length amino add sequence of a polypeptide of the invention. The fragment may or may not possess a functional activity of such polypeptides.
[0257] As used herein, “majority” refers to or at least the values of: 51%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%.Pharmaceutically Acceptable Compositions
[0258] In some embodiments, the T cells prepared by the methods disclosed herein are infused into the patient in a pharmaceutical composition comprising one or more of electrolytes, albumin, culture medium, human serum, one or more buffers, etc.Methods of Use
[0259] In some embodiments, “treating” comprises therapeutic treatment including prophylactic or preventive measures, wherein the object is to prevent or lessen the targeted pathologic condition or disorder, for example to treat, suppress, inhibit, prevent, reduce the inddence or severity of, delay the onset of, or reduce symptoms associated with cancer such as a solid tumor. Thus, in some embodiments, treating may include directly affecting or curing, suppressing, inhibiting, preventing, redudng the severity of, delaying the onset of, reducing symptoms assodated with cancer, or a combination thereof. Thus, in other embodiments, treating may include directly affecting or curing, suppressing, inhibiting, preventing, reducing the severity of, delaying the onset of, reducing symptoms assodated with cancer, or a combination thereof. Thus, in some embodiments, “treating,” “ameliorating,” and “alleviating” refer inter alia to delaying progression, expediting remission, inducing remission, augmenting remission, speeding recovery, increasing efficacy of or decreasing resistance to alternative therapeutics, or a combination thereof. In some embodiments, “preventing” refers, inter alia, to delaying the onset of symptoms, preventing relapse to a disease, decreasing the number or frequency of relapse episodes, increasing latency between symptomatic episodes, or a combination thereof. In some embodiments, “suppressing” or “inhibiting”, refers inter alia to reducing the severity of symptoms, redudng the severity of an acute episode, reducing the number of symptoms, reducing the inddence of disease-related symptoms, reducing the latency of symptoms, ameliorating[UCLA 2024-240] P-638467-PC symptoms, reducing secondary symptoms, reducing secondary infections, prolonging patient survival, or a combination thereof.
[0260] In some embodiments, the transiently reprogrammed T cells as prepared herein may be utilized as a means “preventing,” “inhibiting,” or “reducing the incidence of’ cancer of one or more cells, tissues, organs, or organisms brought into contact with the transiently reprogrammed T cells.
[0261] In some embodiments, administration comprises injection and / or infusion directly into an organism. In some embodiments, administration comprises injection and / or infusion directly into the blood or circulation. In some embodiments, administration comprises injection and / or infusion directly into a tumor mass, surgical resection bed, or the tissue adjacent to a tumor. In some embodiments, administration comprises injection and / or infusion into tissues not involved by cancer including subcutaneous, muscle, fat, peri-lymphatic tissue, or tissues that drain into the tumor lymphatic drainage basin, transiently reprogrammed T cells for injection may be in the form of a pharmaceutical composition formulated as a sterile injectable solution.
[0262] In some embodiments, injection comprises subcutaneous injection. In some embodiments, the T cells are is administered via an image guided catheter, e.g., comprising ultrasound, radiofrequency, stereotactic, computed tomography (CT), or magnetic resonance imaging (MRI) source. In some embodiments, the T cells are administered through a surgical approach, including open, laparoscopy, minimally invasive and / or robotic.
[0263] In some embodiments, “administering” comprises bringing a cell, a tissue, an organ, or an organism into contact with the T cells or with a composition (e.g., a pharmaceutical composition) comprising the T cells. In some embodiments, a cell, a tissue, an organ, or an organism is perfused with a composition comprising the T cells. In some embodiments, a cell, a tissue, an organ, or an organism is grown in media comprising the T cells. Other methods will occur to those of ordinary skill in the art.
[0264] In some embodiments, “treating” comprises therapeutic treatment including prophylactic or preventive measures, wherein the object is to prevent or lessen the targeted pathologic condition or disorder, for example to treat or prevent cancer. Thus, in some embodiments, treating may include directly affecting or curing, suppressing, inhibiting, preventing, reducing the severity of, delaying the onset of, reducing symptoms associated with a[UCLA 2024-240] P-638467-PC cancer or tumor. Thus, in some embodiments, “treating,” “ameliorating,” and “alleviating” refer inter alia to delaying progression, expediting remission, inducing remission, augmenting remission, speeding recovery, increasing efficacy of or decreasing resistance to alternative therapeutics, or a combination thereof. In some embodiments, “preventing” refers, inter alia, to delaying the onset of symptoms, preventing relapse to a disease, decreasing the number or frequency of relapse episodes, increasing latency between symptomatic episodes, or a combination thereof. In some embodiments, “suppressing” or “inhibiting”, refers inter alia to reducing the severity of symptoms, reducing the severity of an acute episode, reducing the number of symptoms, reducing the incidence of disease-related symptoms, reducing the latency of symptoms, ameliorating symptoms, reducing secondary symptoms, reducing secondary infections, prolonging patient survival, or a combination thereof.
[0265] A “focus of interest” a “localized environment,” or a “localized site” comprises a site in which the disease, reaction, infection, injury, or other medical condition is specific to one part or area of the body; in which a symptom or condition of the medical condition is specific to one part or area of the body; or in which treatment is desired for one part or area of the body (even if the disease, reaction, infection, injury, or other medical condition affects other parts or areas of the body or the body as a whole).
[0266] In some embodiments, methods disclosed herein treat cancer. In some embodiments, provided herein is a method of treating cancer, in a subject in need thereof, comprising the step of administering to said subject transiently reprogrammed T cells, as described above. In some embodiments, provided herein is a method of treating cancer, in a cell, tissue, organ, or organism in need thereof, comprising the step of administering to said cell, tissue, organ, or organism transiently reprogrammed T cells, as described above.
[0267] In some embodiments, methods disclosed herein treat cancer or a tumor. In some embodiments, provided herein is a method of treating cancer or a tumor, in a subject in need thereof, comprising the step of administering to said subject transiently reprogrammed T cells, as described above. In some embodiments, provided herein is a method of treating cancer or a tumor, in a cell, tissue, organ, or organism in need thereof, comprising the step of administering to said cell, tissue, organ, or organism transiently reprogrammed T cells, as described above.
[0268] In some embodiments, methods disclosed herein treat a focus of interest of a localized[UCLA 2024-240] P-638467-PC site of a dysproliferative disease such as cancer or a tumor.
[0269] In some embodiments, administration comprises injection and / or infusion directly into a cell, tissue, organ, or organism. In some embodiments, administration comprises injection and / or infusion directly into a localized site of a cancer or tumor. In some embodiments, administration comprises injection and / or infusion adjacent to a localized site of a cancer or tumor. The transiently reprogrammed T cells may be administered in the form of a pharmaceutical composition formulated as a sterile injectable solution. In some embodiments, injection comprises intravenous injection. In some embodiments, injection comprises subcutaneous injection. In some embodiments, injection comprises intratumoral, paratumoral or paracanceral injection.
[0270] As used herein, the terms “composition” and “pharmaceutical composition” may in some embodiments, be used interchangeably having all the same qualities and meanings. In some embodiments, disclosed herein is a pharmaceutical composition for the treatment of a cancer or tumor as described herein. In some embodiments, disclosed herein is a pharmaceutical composition for the treatment of cancer or tumor. In some embodiments, disclosed herein is a pharmaceutical composition for the use in methods locally regulating an immune response. In some embodiments, disclosed herein are pharmaceutical compositions for the treatment of a systemic bacterial infection or bacterial disease, a localized bacterial infection or bacterial disease, an injury or other damage, a transplant or other surgical site, or a symptom of any of these, or a combination of any of these.
[0271] In still another embodiment, a pharmaceutical composition for the treatment of a cancer or tumor, as described herein, comprises an effective amount of transiently reprogrammed T cells and a pharmaceutically acceptable excipient.
[0272] In some embodiments, a method of use of transiently reprogrammed T cells further comprises a step of administering activated T cells to said subject. Methods of preparing T cells are known in the art. In some embodiments, these cells may be administered prior to or after administering said transiently reprogrammed T cells. In some embodiments, T cells are administered by intravenous (i.v.) injection.
[0273] In some embodiments, the transiently reprogrammed T cells is administered to an animal, a cell, tissue, or an organ derived from an animal. In some embodiments, the transiently reprogrammed T cells is administered to an animal. In some embodiments, the animal is a[UCLA 2024-240] P-638467-PC vertebrate. In some embodiments, the vertebrate is a homeothermic vertebrate (e.g., a mammal or a bird). In some embodiments, the mammal is a human mammal. In some embodiments, the mammal is a non-human mammal.
[0274] Unless otherwise indicated, all numbers expressing quantities, ratios, and numerical properties of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about". All parts, percentages, ratios, etc. herein are by weight unless indicated otherwise.
[0275] As used herein, the singular forms "a" or "an" or "the" are used interchangeably and intended to include the plural forms as well and fall within each meaning, unless expressly stated otherwise or unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.
[0276] Also as used herein, "at least one" is intended to mean "one or more" of the listed elements. Singular word forms are intended to include plural word forms and are likewise used herein interchangeably where appropriate and fall within each meaning, unless expressly stated otherwise. Except where noted otherwise, capitalized and non-capitalized forms of all terms fall within each meaning.
[0277] “Consisting of’ shall thus mean excluding more than traces of other elements. The skilled artisan would appreciate that while, in some embodiments the term “comprising” is used, such a term may be replaced by the term “consisting of’, wherein such a replacement would narrow the scope of inclusion of elements not specifically recited. The terms "comprises", "comprising", "includes", "including", “having” and their conjugates encompass "including but not limited to".
[0278] The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined. In some embodiments, the term “about” refers to a deviance of between 0.0001-5% from the indicated number or range of numbers. In some embodiments, the term “about” refers to a deviance of between 1-10% from the indicated number or range of numbers. In some embodiments, the term “about” refers to a deviance of up to 25%[UCLA 2024-240] P-638467-PC from the indicated number or range of numbers. In some embodiments, the term “about” refers to ± 10 %.
[0279] Throughout this application, various embodiments may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of certain embodiments. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
[0280] Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging / ranges between” a first indicate number and a second indicate number and “ranging / ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
[0281] Any patent, patent application pubheation, or scientific pubheation, cited herein, is incorporated by reference herein in its entirety.
[0282] The following examples are presented in order to more fully illustrate some embodiments of the invention. They should, in no way be construed, however, as limiting the broad scope of the invention. One skilled in the art can readily devise many variations and modifications of the principles disclosed herein without departing from the scope of the invention.EXAMPLES
[0283] Tumor-infiltrating lymphocyte (TIL) therapy — surgically resecting a tumor, isolating T cehs, growing them to large numbers ex vivo, and transferring back to the patient — was recently FDA-approved as a potentially curative treatment for patients with advanced cancers. A schematic representation of this approach is provided in FIGURE 1. However, its success absolutely requires transfer of rare stem-like memory T cehs. Unfortunately, the large majority of tumorspecific T cehs are non-functional owing to chronic antigen stimulation and suppressive signals within the tumor, driving “T ceh exhaustion”. T ceh exhaustion is an epigeneticahy mediated[UCLA 2024-240] P-638467-PC differentiation step wherein continuous T cell receptor signaling reshapes the chromatin landscape to constrain sternness, proliferation, and effector functions. Previous attempts to overcome T cell exhaustion have involved reprogramming to induced pluripotent stem cells (iPSCs) and then redifferentiation of iPSCs into mature T cells. However, both the T cell-to-iPSC reprogramming and iPSC-to-T cell differentiation are challenging and prohibitively inefficient. Additionally, T cells can lose their antigen / tumor specificity during full reprogramming. Many attempts have been made to reverse the process, e.g., with epigenetic modifiers and ICB. However, once established, exhaustion is irreversible.
[0284] FIGURE 2 shows a schematic representation of the linear model of T cell differentiation (see, e.g., J.G. Crompton et al., Immunol Rev. 257(1): 264—276 (2014)). Importantly, this differentiation is one-way and irreversible (see arrow from left to right). As depicted by the arrow, the T cell differentiation stages proceed as follows (left to right): naive T cell, stem central memory T cell, central memory T cell, effector T cell, and exhausted T cell. As differentiation increases, left to right, sternness decreases. TABLE 1 fists examples of markers expressed at each stage of T cell differentiation.
[0285] TABLE 1. Examples of markers expressed at each stage of T cell differentiation.Stage of T Cell Differentiation MarkersCD45RA+CD45RO- Naive T cell CD95- CCR7+CD27+CD45RA+CD45RO- Stem central memory T cell CD95+CCR7+CD27+CD45RA / 10CD45RO+Central memory T cell CD95+CCR7+CD27+p£j_ lo / intermediateEffector T cell TIM3neg / 10IFNg+[UCLA 2024-240] P-638467-PC Stage of T Cell Differentiation MarkersGranzyme+PD-1UTIM3+Exhausted T cell CTLA-4+TOX+
[0286] Many atempts have been made to reverse the process, e.g., with epigenetic modifiers and ICB. However, once established, exhaustion is irreversible.
[0287] Most T cells that are injected (for example, as a component of ACT or TIL therapy) are exhausted, as illustrated by the exhausted T cell (red) on the right of FIGURE 2, meaning they have poor anti-tumor function, do not persist long-term in the patient after injection, and fail to provide durable clinical benefit. The cells on the left side of FIGURE 2, namely, naive T cells (white) and memory T cells (blues), have improved efficacy because they are not exhausted but rather, they are less differentiated T cells that are able to persist long-term, self-renew, and asymmetrically divide to generate many tumor-specific highly potent cytotoxic T cells capable of controlling and eliminating tumors.
[0288] Tumor-infiltrating T cells are almost entirely tumor-specific, but the large majority of T cells in a tumor, such as a resected tumor, are exhausted.
[0289] To address these limitations, a strategy of “transient reprogramming” of T cells has been utilized — not allowing them to de-differentiate all the way to iPSC can reset the chromatin state and gene-regulatory networks that enforce T cell exhaustion, thereby restoring sternness and anti-tumor functionality. This dedifferentiation strategy also preserves the original T cell receptor sequence, or the T cell’s ability to “see” the tumor.Example 1: Production of Reprogrammed T Cells and Methods of Use
[0290] Strategies for the production of reprogrammed T cells and methods of making and using them were developed.
[0291] FIGURE 3 shows a schematic representation depicting an exemplary strategy, disclosed herein, for reversing T cell exhaustion using OSKM de-differentiation to CD8-iPSC[UCLA 2024-240] P-638467-PC (full reprogramming) followed by CD8-iPSC re-differentiation to mature CD8a0 T cells using the ATO. The images, left to right, depict a resected tumor; a representative exhausted T cell (red) derived from the resected tumor; a representative CD8-iPSC (purple); co-culture of CD8-iPSCs with Notch-ligand expressing stromal cells (which may consist of MS5-DLL1 / 4 cells) in the ATO; and a representative reprogrammed stem-like CD8a0 T cell (blue).
[0292] The strategy of T cell reprogramming depicted in FIGURE 3 is combined with adoptive cellular therapy (ACT) or tumor infiltrating lymphocyte (TIL) therapy depicted in FIGURE 1. Using induced pluripotent stem cells (iPSC) technology and the artificial thymic organoid (ATO) to overcome T cell exhaustion and recover sternness and functionality of a polyclonal tumor-specific T cell population may, for example, be accomplished during step 2 “ex vivo T cell expansion” of ACT or TIL therapy as represented in FIGURE 1.
[0293] The method utilizes transcription factor reprogramming (for example with the originally described OSKM factors but also inclusive of additional transcription factor combinations that achieve reprogramming to iPSC) to reset the epigenome. After introducing OSKM into a T cell (or somatic cell of any lineage), the cells will progressively de-differentiate under permissive conditions until they reach a stem cell, or iPSC (other transcription factor combinations may also be used to achieve de-differentiation). Herein, we term this “full reprogramming”, allowing the T cell to progressively de-differentiate into a stem cell (i.e., iPSC) with loss of T cell identity. De-differentiation takes approximately 1-2 months. Then the T cell-derived iPSC are re-differentiated into mature T cells using an artificial thymic organoid, (as described in Montel-Hagen, Cell Stem Cell, 2019, 24(3):376-389; Montel-Hagen, Cell Reports, 2020, 33(4): 108320), resulting in reprogrammed T cells. Reprogramming takes approximately 3-4 months. The resulting reprogrammed T cells are then administered to the patient in need. In this way, the chromatin state and gene regulatory networks enforcing exhaustion of tumor-specific CD8 T cells are reset and sternness is restored via transcription factor reprogramming and subsequent re-differentiation using an ATO.
[0294] To overcome exhaustion and restore a patient’s tumor-specific T cells to a stem-like state, induced pluripotent stem cell (iPSC) technology is used. Here, T cells are reprogrammed to iPSC and then re-differentiated into mature T cells (FIGURE 3). The efficacy of T cell mediated therapies for patients with cancer and cells is improved.[UCLA 2024-240] P-638467-PC Example 2: “Full Reprogramming” of CD8 T Cells
[0295] An exemplary method for T cell reprogramming to iPSC (or “full reprogramming”) is as follows. Human T cells are isolated from blood or tumor using FACS and the surface markers CD45, CD4, CD8, PD1, and TIM3 as well as live / dead staining. CD3 is not used for FACS of T cells as this frequently induces activation induced cell death (AICD). From FACS, T cells are collected into a defined medium in some embodiments comprised of a defined base medium (e.g., RPMI 1640), fresh human serum from healthy donors or a defined serum replacement (e.g. KnockOut™ Serum Replacement, THERMOFISHER), and IL-2 at 12-2000 lU / mL, with or without IL-7 (lOng / mL), with or without IL-15 (lOng / mL). Sorted T cells may then be “rested” in medium for 0- 12 hours at 4C. Alternatively, T cells can be cultured with TCR stimulation to induce proliferation prior to reprogramming. T cells are then infected with octamer-binding protein 3 / 4 (OCT3 / 4), sex determining region Y-box 2 (SOX2), Krueppel-like factor 4 (KLF4), c-MYC (OSKM) packaged in Sendai virus (Sendai-OSKM) using the CYTOTUNE™-iPS 2.0 Sendai Reprogramming Kit (THERMO FISHER SCIENTIFIC INC.™) at a manufacturer recommended 5:5:3 ratio of constituent plasmids: c-Myc : KLF4-Oct3 / 4-Sox2 (KOS) : KLF4. Infection is done in T cell medium, which in some embodiments may be comprised of 90% defined base medium (e.g., RPMI 1640), 10% fresh human serum from healthy donors or a defined serum replacement (e.g., KnockOut™ Serum Replacement, THERMOFISHER), and IL-2 at 12-2000 lU / mL, with IL-7 at lOng / mL, and with IL- 15 at lOng / mL. Immediately following infection / transduction, T cells are transferred to a culture surface coated with extracellular matrix proteins to support de-differentiation to iPSC, which in some embodiments is recombinant human Laminin or vitronectin. Importantly, and in contrast to other published strategies, TCR stimulation (e.g., anti-CD3 and anti-CD28 or MHC-bound peptides, etc.) are not present during reprogramming. 100% daily media exchanges are performed starting day 2 after infection with Sendai-OSKM and culture conditions are shown in TABLE 2 and schematically represented in FIGURE 4. Here, medium is progressively changed from T cell medium (TCM) to Stem cell medium (SCM). SCM in some embodiments is comprised of 100% defined medium (e.g., TeSR™-E8™ basal medium, STEMCELL TECHNOLOGIES, Essential 8™ Medium, THERMOFISHER, or StemFit Basic04 Complete Type AJINOMOTO CO. INC, AminoScience Division). Cytokines IL-2 at 12-2000 lU / mL, with IL-7 at lOng / mL, and with IL-15 at lOng / mL are included in the medium until day 5, after which they are removed from culture medium for “full reprogramming” (but continued for “transient reprogramming”).[UCLA 2024-240] P-638467-PC
[0296] TABLE 2. Culture conditions for iPSC generation from hCD8 T cells.Day(s) Culture ConditionsSendai T cell Stem *Cytokines rh Anti- Antibiotics containing media cell Laminin CD3 / media (TCM) media CD28 PRIMOCIN) (SCM)0-1 Yes 100% 0% 100% present absent + / - 2 No 75% 25% 100% present absent + / - 3 No 50% 50% 100% present absent + / - 4 No 25% 75% 100% present absent + / - 5 No 0% 100% 100% present absent + / -6 No 0% 100% 0% present absent + / -
[0297] A schematic of the method used is depicted in FIGURE 4. Essentially, the method proceeded as follows:
[0298] 1. CD8 T cells were isolated from a patient tumor or patient blood using conventional methods and then bulk CD8 T cells or CD8 T cell subsets are purified using FACS.
[0299] 2. CD8 T cells were transduced with Sendai-OSKM, cMyc:KOS:KLF4. This drives significant expansion of transduced T cells.
[0300] 3. CD8 T cells were transitioned from T cell media to stem cell media over the 5 days after transduction.
[0301] 4. Continuing cells in 100% SCM without cytokines and in the absence of stimulation through TCR (or other inflammatory pathways, for example TLR-MyD88 signaling, that upregulate transcription factors associated with a T cell fate) leads to development of stable iPSC colonies with culture medium changing every 1-2 days.
[0302] 5. CD8-iPSC colonies are passaged in accordance with conventional techniques.
[0303] 6. CD8-iPSC can be harvested and subjected to re-programming using an ATO. Example 3: “Full Reprogramming” CD8 T Cells at Varying Stages of Differentiation
[0304] As shown in FIGURE 5, experiments were designed to determine if reprogramming initially proceeds as reverse or pseudo reverse differentiation, or, for example, from right to left[UCLA 2024-240] P-638467-PC in FIGURE 2. In some embodiments, this would be reflected if less differentiated T cell subsets (i.e., those closer to hematopoietic stem cells and therefore iPSC) were able to form iPSC more rapidly and efficiently than more differentiated subsets.
[0305] To test this, CD8 T cells at varying stages of differentiation were isolated from a patient with soft tissue sarcoma. All T cells in each iteration of the experiment were from a single patient to control for inter-patient biological differences. Importantly, different T cell subsets are present at different frequencies in the blood and tumor. T cells in the blood are primarily comprised of naive, stem central memory, central memory, and effector memory subsets. As shown in Figure 6A, less differentiated naive T cells stain PD1- TIM3- and stem central memory and central memory T cells are PDllo / + TIM3-, while T cells in the tumor are primarily comprised of more differentiated effector (PD1+TIM3-) and exhausted (PDl+ / hi TIM3-I-) T cells. A bulk strategy was first employed wherein CD8 T cells were sorted from blood or tumor, but not sorted into further subsets. Because T cells in the blood are generally less differentiated than those in the tumor (Figure 6A), this approach tests the collective reprogramming of less differentiated (naive, stem central memory, central memory) versus more differentiated (effector, exhausted) CD8 T cells. CD8 T cells sorted from blood or tumor were then subjected to OSKM reprogramming. Here, T cells were infected with octamer-binding protein 3 / 4 (OCT3 / 4), sex determining region Y-box 2 (SOX2), Krueppel-like factor 4 (KLF4), c-MYC (OSKM) packaged in Sendai virus (Sendai-OSKM) using the CYTOTUNE™-iPS 2.0 Sendai Reprogramming Kit (THERMO FISHER SCIENTIFIC INC.™) at a manufacturer recommended 5:5:3 ratio of constituent plasmids: c-Myc, KLF4-Oct3 / 4-Sox2 (KOS), and KLF4. The results are depicted in FIGURE 6B-C.
[0306] Shown in FIGURE 6B is immunofluorescence images of CD8-iPSC generated either from circulating CD8 T cells (blood) (top) or from tumor-infiltrating CD8 T cells (tumor) (bottom), left to right, stained with 4’,6-diamidino-2-phenylindole (DAPI) (left) or with homeobox protein NANOG (NANOG or hNanog or Nanog; a transcriptional factor that helps stem cells maintain pluripotency by suppressing cell determination factors and associated with some cancers) (center) or as an overlay of the two detection methods (right). However, the rate and efficiency of iPSC colony formation were significantly greater when using CD8 T cells from blood, particularly at early timepoints (FIGURE 6C).
[0307] Both CD8 T cells isolated from patient blood or matched patient tumor were able to[UCLA 2024-240] P-638467-PC form iPSC colonies as demonstrated by immunofluorescence staining (IF) for Nanog, a canonical stem cell transcription factor that is commonly used as a marker of iPSC formation (FIGURE 6B). However, when the number of colonies with iPSC morphology emerging in culture was enumerated at an early timepoint after OSKM transduction (day 7), we observed that CD8 T cells isolated from blood form iPSC colonies much more rapidly than CD8 T cells isolated from tumor (FIGURE 6C). This is consistent with historical reports claiming that less differentiated somatic cells are able to reprogram to iPSC with greater efficiency than more differentiated cells (e.g., fibroblasts) (Feng, Cell Stem Cell, 2009, 4($):301-312).
[0308] Next, we tested whether individual T cell subsets at various differentiation states from patients with soft tissue sarcoma would also reprogram with greater efficiency and more rapid kinetics depending on their degree of differentiation. We hypothesized that less differentiated T cells (stem central memory, central memory, effector memory) are epigenetically more similar to stem cells and therefore would be able to reprogram to iPSC with greater efficiency and faster kinetics than more differentiated T cells (effector and exhausted), which are epigenetically more dissimilar to stem cells (FIGURE 5). To acquire sufficient numbers of each T cell subset for experimentation, lymphocytes were isolated from patient-matched blood or tumor and subjected to flow-assisted cell sorting (FACS) such that the CD8 T cells were sorted into stem central memory, central memory, effector memory, effector, and exhausted subsets using markers outlined in TABLE 1 (effector memory is defined as (CD45RA-, CD45RO+, CCR7-, CD95+).
[0309] Then, the T cells of each subset were de-differentiated to iPSC using OSKM transcription factor reprogramming (as above), by infecting with Sendai-OSKM at a manufacturer recommended 5:5:3 ratio of c-Myc, KLF4-Oct3 / 4-Sox2 (KOS), and KLF4. This experiment was repeated twice using patient-matched CD8 T cells from two separate patients with soft tissue sarcoma (FIGURE 6D-E). The subset stages studied were stem central memory (SCM) cells, central memory (CM) cells, effector memory (EM) cells, effector (Eff) cells, and exhausted (EX) cells. FIGURE 6D is a graph depicting reprogramming efficiency in a patient with high grade leiomyosarcoma, a high grade STS that usually penetrates beyond its compartment (stage IIB).FIGURE 6E is a graph depicting reprogramming efficiency in a patient with well-differentiated liposarcoma (WDLS; atypical lipomatous tumor), a less aggressive STS. Less differentiated CD8 T cells were much more readily reprogrammed to iPSC in a pattern consistent with recently described epigenetic remodeling transitions between different T cell subsets (Giles, Immunity, 2022, 55(3):557-574).[UCLA 2024-240] P-638467-PC Example 4: Production of iPSC from exhausted CD8 T cells using “full reprogramming”
[0310] Following OSKM transduction of CD8 T cells, fully reprogrammed cells were then characterized by morphology and expression of typical iPSC proteins, as shown in FIGURE 7.CD8-iPSC generated from exhausted CD8 T cells (Tex) as outlined in FIGURE 6 were subjected to flow cytometry for characterization. Cells were stained with antibodies targeting sialyl-glycolipid stage-specific embryonic antigen 4 (SSEA4), a surface protein used as a marker of iPSC de-differentiation, and antibodies targeting the transcription factor Nanog, similarly used to confirm de-differentiation to a stem cell / iPSC. Mean fluorescent intensity of SSEA4 (FIGURE 7A) and Nanog (FIGURE 7B) are plotted against expression of these proteins in unselected peripheral blood mononuclear cells, demonstrating upregulation of these markers in generated CD8-iPSC versus typical somatic hematogenous cells. Morphologic characterization of CD8-iPSC generated from Tex after approximately two months of culture is shown in FIGURE 7C at 4X magnification on light microscopy. These CD8-iPSC colonies are consistent with expected iPSC morphology, as they have clearly demarcated boarder of densely packed iPSC. Importantly, the boarder is sharp and without examples of differentiating cells that would appear as a blurred boarder with single or clusters of cells appearing to emigrate or bud off the larger colony.Example 5: Re-differentiation of CD84PSC into mature CD8ab T cells using an artificial thymic organoid (ATO)
[0311] Polyclonal, exhausted T cells were sorted from the tumor of a patient with soft tissue sarcoma and reprogrammed to a iPSC (CD8-iPSC), as described above. These CD8-iPSC were then subjected to re-programming into mature CD8ab T cells using an ATO. A description of the ATO and methods for achieving re-differentiation have been recently described (Montel-Hagen, Cell Stem Cell, 2019, 24(3):376-389; Montel-Hagen, Cell Reports, 2020, 33 (4): 108320). Multiple ATOs were cultured simultaneously using these CD8-iPSC (generated from polyclonal exhausted CD8 T cells) such that they could be harvested and subjected to flow cytometry at different times. Data from week 2-4 of ATO culture is presented in FIGURE 8. Notably, ATO culture can be continued without harvesting to allow continued maturation of CD8-iPSC (as they mature into CD8 T cells at different rates) and continued proliferation of emerging mature CD8ab T cells.FIGURE 8A shows early maturation of CD8-iPSC into T cells in the ATO when harvested at week 2 of ATO culture. From left to right: five cells staining for CD45 (x-axis), cells positive for CD45 are shown in the next panel staining for CD5 (y-axis) and CD7 (x-axis), cells positive for[UCLA 2024-240] P-638467-PC CD5 (a marker turned on early in T cell development) are shown in the next panel staining for TCRab (y-axis) and CD3 (x-axis), with cells positive for TCRab and CD3 shown in the next panel staining for CD8 (y-axis) and CD4 (x-axis). Numbers represent the frequencies of cells that fall into each gate. This demonstrates that at an early timepoint — week 2 of ATO culture — CD8-iPSC have begun committing to the T cell lineage (CD3+ and TCRab+) but remain immature, expressing both CD4 and CD8 (a known step in T cell development termed “double positive”).FIGURE 8B shows maturation of CD8-iPSC into T cells in the ATO when harvested at week 4 of ATO culture. From left to right: live cells staining for CD45 (x-axis), cells positive for CD45 are shown in the next panel staining for TCRab (y-axis) and CD3 (x-axis), with cells positive for TCRab and CD3 shown in the next panel staining for CD8 (y-axis) and CD4 (x-axis), with cells positive for CD8 shown in the next panel staining for CD8 (y-axis) and CD8b (x-axis), with cells positive for CD8 and CD8b shown in the next panel staining for CD45RO (y-axis) and CD45RA (x-axis). Numbers represent the frequencies of cells that fall into each gate. This demonstrates that by week 4 CD8-iPSCs in the ATO culture have predominantly re-differentiated into mature CD8ab T cells. FIGURE 8C shows enumeration of total cells present in four ATO cultures at 2, 3, and 4 weeks of culture. T9- 1 and T9-2 are the ATO cultures starting with CD8-iPSC (originally generated from polyclonal, exhausted CD8 T cells) compared to N11-WT, a control iPSC cell line derived from less differentiated CD8 T cells that are known to progress though the ATO culture (used as a positive control). This demonstrates that CD8-iPSC generated from a polyclonal, exhausted population of human CD8 T cells can be re-differentiated into mature CD8ab T cells with comparable efficacy to known controls.Example 6: Effects of OSKM Titration on “Transient Reprogramming”, or Dedifferentiation, of CD8 T Cells
[0312] Considering a linear model of T cell differentiation, namely, less differentiated CD8 T cell subsets more readily de-differentiate to achieve pluripotency, it was proposed that reprogramming initially could proceed along a reverse trajectory of normal T cell differentiation (see, e.g., FIGURE 5). This would suggest that following OSKM transduction, de-differentiation may be able to be arrested prior to loss of T cell lineage and progression to iPSC. Therefore, we next tested whether human CD8 T cells from cancer patients might be “transiently reprogrammed” to a stem-like CD8 T cell without losing lineage identity. Because Sendai-OSKM does not integrate into the host cell genome it is progressively lost with proliferation. We therefore reasoned that down titration of OSKM factors from the typical 5:5:3 ratio , or the additionally tested 3:3:2[UCLA 2024-240] P-638467-PC ratio, of c-Myc:KOS:KLF4 might initiate T cell reprogramming but that with fewer copies of sendai-OSKM in each cell and loss of sendai-OSKM with proliferation, transcription factors (e.g. OSKM) required to restructure the cell’s epigenome and achieve pluripotency would become limiting and therefore the CD8 T cell would not be able to complete “full reprogramming” (FIGURE 9). This represents an example of “transient reprogramming”, which in contrast to “full reprogramming”, T cells de-differentiate from Tex or Teff to Tcm or Tscm but do not further dedifferentiate into iPSC nor do they lose T cell lineage identity.
[0313] “Transient reprogramming” represents a significant improvement over “full reprogramming” in several regards . First, in the case of “transient reprogramming”, approximately 1-3 weeks is required for more differentiated T cells (Tex or Teff) to de-differentiate to less differentiated subsets (Tcm or Tscm) versus approximately 5-6 months for both “full reprogramming” and ATO re-differentiation. In patients with advanced cancers, this represents a significant amount of time, particularly with respect to anticipated disease progression. In addition to time expenditures, the shorter culture needed for “transient reprogramming” requires less resource expenditure and is logistically more feasible. Second, in the case of “full reprogramming”, tumor-specificity can be lost rendering T cells that have undergone “full reprogramming” and ATO re-differentiation therapeutically ineffective. This is because during re-differentiation of CD8-iPSC to mature CD8a0 T cells (using ATO or other methods) recombination-activating genes (RAG) 1 / 2 are reactivated and can lead to additional rounds of TCR editing and consequent alteration of antigen spedficity / loss of tumor-specificity (Minagawa, Cell Stem Cell, 2018, 23 (6): 850-858).
[0314] OSKM factors are commercially packaged in three vectors and given in a 5:5:3 ratio of c-Myc : KLF4-Oct3 / 4-Sox2 : KLF4 (CYTOTUNE™-iPS 2.0 Sendai Reprogramming Kit (THERMO FISHER SCIENTIFIC INC.™)) to create the Sendai-OSKM virus for infection / transduction. 3:3:2 and 1:1:1 ratios were additionally tested to determine if OSKM downtitration might result in “transient reprogramming” of CD8 T cells.
[0315] The hCD8 T cells were isolated from blood and infected with Sendai-octamer-binding protein 3 / 4 (OCT3 / 4) / sex determining region Y-box 2 (SOX2) / Krueppel-like factor 4 (KLF4) / MYC (OSKM) (Sendai-OSKM) using a CYTOTUNE™-iPS 2.0 Sendai Reprogramming Kit (THERMO FISHER SCIENTIFIC INC.™) at ratios of (a) 5:5:3, (b) 3:3:2, or (c) 1:1:1, using the following methods.[UCLA 2024-240] P-638467-PC
[0316] A schematic of the method used is depicted in FIGURE 4. Essentially, the method proceeded as follows:
[0317] 1. CD8 T cells were isolated from a patient tumor or patient blood using conventional methods and then bulk CD8 T cells or CD8 T cell subsets are purified using FACS.
[0318] 2. CD8 T cells were transduced with Sendai-OSKM, cMyc:KOS:KLF4. This drives significant expansion of transduced T cells.
[0319] 3. CD8 T cells were transitioned from T cell media to stem cell media over the 5 days after transduction. For “transient reprogramming”, T cells can also be continued in 100% TCM without transition to SCM; see Example 7.
[0320] 4. Between days 3-21 (depending on the starting T cell differentiation state), CD8 T cells were removed from stem cell media and placed back into T cell culture conditions. This included T cell media, 100% cytokines, and T cell receptor stimulation (which may be provided by anti-CD3 and anti-CD28, antigen presenting cells, etc.).
[0321] 5. T cell receptor signaling halts the de-differentiation process to lock cells into their differentiation state at that time. This maintained cells in the CD8 T cell lineage, now as dedifferentiated stem-like memory and central memory CD8 T cells.
[0322] 6. CD8 T cells continued to expand under T cell culture conditions.
[0323] 7. CD8 T cells can be harvested and transferred back into the patient as a “living drug”. Importantly, the use of CD8 T cells harvested from a tumor as an adoptive cellular therapy recently received FDA approval (February 2024).
[0324] Following Sendai-OSKM infection, T cells proliferate robustly for about 1 week, whether transduced with OSKM in a 5:5:3, 3:3:2, or 1:1:1 ratio. FIGURE 10 is a graph depicting post-infection cell counts as a function of a 10-day period for ratios of 5:5:3 (blue circles), 3:3:2 (green squares), or 1:1:1 (red triangles). Black vertical arrows indicate when the culture plates were split, and the splits were used to make frozen stocks, stored at -80°C. During this week of rapid proliferation, the T cells exposed to Sendai-OSKM have initiated de-differentiation but are still non-adherent in culture (whereas iPSCs are adherent to the culture surface), as is typical of T cells in culture (that is, T cells are non-adherent). This enables serial aliquots of non-adherent[UCLA 2024-240] P-638467-PC cells in culture to be taken every few days for flow cytometry analysis.Example 7. Transient reprogramming in 100% TCM without transition to SCM
[0325] In Example 6, CD8 T cells were transitioned from T cell media (TCM) to stem cell media (SCM) over the 5 days after transduction. For transient reprogramming, T cells can also be continued in 100% TCM without transition to SCM. Such protocol is described in the table below and ensuing steps. As noted herein, a protocol using 100% TCM without transition to SCM may rely on characterization of the cells rather than duration (e.g., days) for each step; in some embodiments, once the optimal protocol is identified using cell characterization, ensuing carrying out of the same or similar protocol may be simplified to using durations (e.g., in days) to achieve the desired outcome.Day(s) Culture ConditionsSendai TceU Stem *Cytokines rh Anti- Antibiotics containing media cell Laminin CD3 / media (TCM) media CD28(SCM)0-1 Yes 100% 0% 100% + / - absent + / - 2 No 100% 0% 100% + / - absent + / - 3 No 100% 0% 100% + / - + / - + / - 4 No 100% 0% 100% + / - + / - + / - 5 No 100% 0% 100% + / - + / - + / -6+ No 100% 0% 100% + / - + / - + / -
[0326] By way of non-limiting example, in one embodiment, transiently reprogrammed T cells may be prepared by the steps of:a) exposing the CD8 T cells to Sendai-OSKM and 100% T cell medium on days 0- 1;b) exposing the CD8 T cells to 100% T cell medium and cytokines on about day 2; c) exposing the CD8 T cells to 100% T cell medium and cytokines on about day 3, and TCR stimulation (for example with anti-CD3 / anti-CD28) can be added; d) exposing the CD8 T cells to 100% T cell medium and cytokines on about day 4, and TCR stimulation (for example with anti-CD3 / anti-CD28) can be added;[UCLA 2024-240] P-638467-PC e) exposing the CD8 T cells to 100% T cell medium and cytokines on about day 5, and TCR stimulation (for example with anti-CD3 / anti-CD28) can be added; and f) exposing the CD8 T cells to 100% T cell medium and cytokines on about day 6, and TCR stimulation (for example with anti-CD3 / anti-CD28) can be added. g) exposing the CD8 T cells to 100% T cell medium and cytokines on about day 7, and TCR stimulation (for example with anti-CD3 / anti-CD28) is optimally started at this time depending on the T cell differentiation state in culture. h) exposing the CD8 T cells to 100% T cell medium and cytokines for the remainder of culture, and TCR stimulation (for example with anti-CD3 / anti-CD28) can be added starting on day 8-21 depending on the T cell differentiation state in culture and kinetics thereof.i) Following addition of TCR stimulation, T cell culture can be maintained in the presence of continued TCR stimulation, or removed from TCR stimulation for a period of 2-7 days, then TCR stimulation resumed, such that each stimulation pulse leads to further T cell expansion.
[0327] In some embodiments, cytokines can be withdrawn after day 5 but added back when TCR stimulation is introduced. Alternatively, and as shown above, cytokines can be present throughout for transient reprogramming. In some embodiments, IL-2 is an essential T cell survival and proliferation factor. The other cytokines are optional and combinations other than IL-2 / -7 / -15 are effective. Such alternate gamma-chain cytokines as well as other factors are described elsewhere herein.Example 8: Down Titration of OSKM Factors Results in Intermediate Differentiation of CD8T Cells
[0328] As described above, human CD8 T cells were tested to determine whether they could be transiently reprogrammed to a stem-like CD8 T cell without losing lineage identity. Because Sendai-OSKM does not integrate and is progressively lost with proliferation, down titration of OSKM factors was tested to determine whether transient reprogramming could be achieved. OSKM factors are packaged in three vectors and given in a 5:5:3 ratio of c-Myc : KLF4-Oct3 / 4-Sox2 : KLF4 (CYTOTUNE™-iPS 2.0 Sendai Reprogramming Kit (THERMO FISHER[UCLA 2024-240] P-638467-PC SCIENTIFIC INC.™)). Ratios of 3:3:2 and 1:1:1 of c-Myc : KLF4-Oct3 / 4-Sox2 : KLF4 were also tested.
[0329] Cultures were harvested at different times (post OSKM day 2, 4, 7, 10, and 15) and subjected to flow cytometry as shown in FIGURE 11, time course graphs depicting the results of a flow cytometry with protein expression assessed by MFI. It was found that CD3 expression is maintained until day 10 and is progressively lost thereafter, suggesting loss of T cell lineage after day 10 (FIGURE 11B). CD8 expression begins to decline between day 7 and day 10 and is lost by day 15 suggesting loss of CD8 T cell commitment may begin between day 7 and 10 (FIGURE 11C). The frequency of central memory T cells remains relatively constant until day 7, then begins to decline (FIGURE 11D). The frequency of stem-central memory T cells increases until day 10, more so in the 3:3:2 and 1:1:1 transduction conditions, then drops at day 15 corresponding to the loss in CD8 expression at that time (FIGURE HE). The early iPSC marker SSEA421 increases at day 15, which, in conjunction with decrease in CD3 and loss of CD8 expression at that time, suggests loss of T cell lineage and gain of stem cell features (FIGURE HF). Because CD3 and CD8 expression decrease between days 10 and 15 and expression of the stem cell marker SSEA421 increases in that interval, we enumerated emergence of iPSC colonies by morphology under light microscopy at day 12 (an intermediate time between day 10 and 15). FIGURE 11G is a bar graph depicting the number of induced pluripotent stem cell colonies (or iPSC-like appearing colonies which continue to develop into iPSC at later time points) at day 12. The results show that the 5:5:3 OKSM transduction formed the most colonies at this time point (mean 32), exhibiting the most rapid kinetics, while the 3:3:2 condition formed about half as many colonies (mean 16) and the 1:1:1 condition forming the least (mean 1.5). These results indicate that the 5:5:3 OSKM transduction condition forms iPSC colonies with the fastest kinetics and greatest efficiency, while down titration of OSKM (3:3:2 or 1:1:1 conditions) results in fewer infected CD8 T cells able to “fully reprogram” into iPSC. We reasoned that down titration of OSKM instead led cells to arrest de-differentiation at intermediate stages, prior to formation of iPSC. To investigate this, we next performed bulk RNA sequencing of cells from each culture condition over time — CD8 T cells infected with Sendai-OSKM at 5:5:3, 3:3:2, or 1:1:1 ratio harvested at day 3, day 4, day 6, day 10, and day 15 — and performed principle component analysis as shown in FIGURE 11H. This demonstrated minimal difference in-between conditions at days 3, 4, and 6. Between day 6 and 10 differences began to emerge between conditions and these became more notable by day 15. Notably, at these later time points (day 10 and day 15), the 5:5:3 and 3:3:2[UCLA 2024-240] P-638467-PC conditions were largely similar to each other but increasingly dissimilar from the 1 : 1 : 1 condition. This suggests that CD8 T cells infected with 5:5:3 or 3:3:3 Sendai-OSKM are able to “fully reprogram” into iPSC (though the rate and efficiency are greater in the 5:5:3 condition, as in FIGURE 11G). In contrast, the 1:1:1 generates incompletely reprogrammed intermediate populations that have lost T cell lineage (FIGURE 11B-C) but have not gained stem cell features (FIGURE 11F-G). Therefore, the 3:3:2 condition appears to increase de-differentiation of CD8 T cells to Tscm at day 7 and 10; however, these cells may be able to continue de-differentiating to iPSC over time. Collectively, down titration of OSKM can at least temporarily achieve “transient reprogramming” but this may not be durable.Example 9: Reprogramming of CD8 T Cells Can Be Halted at a Desired Time in Culture to Achieve “Transient Reprogramming”
[0330] We next performed a series of experiments to determine if de-differentiation following OSKM transduction could be indudbly stopped at a desired time — specifically when T cells dedifferentiate to Tcm or Tscm and prior to losing lineage identity and forming iPSC — to achieve durable “transient reprogramming”. This might be done in conjunction with down titration of OSKM, as described above. We hypothesized that T cell receptor signaling delivered at appropriate times could reinforce lineage identity and abort reprogramming at a defined timepoint / differentiation stage.
[0331] TCR signaling induces NF-kappaB (NFkB , NF-kB , NF-KB ; nuclear factor kappa-light-chain-enhancer of activated B cells), NFAT (nuclear factor of activated T-cells), AP-1 (activator protein 1), Runxl / 3 (Runt-related transcription factor- 1 / 3), GATA3 (GATA binding protein 3), and other transcription factors (e.g., Spl, BATF [basic leucine zipper transcription factor], Jun, IRF4 [interferon regulatory factor 4], and others) (Li et al. Front. Immunol. 22:9:2738 (2018)). In addition to effector vs. memory programs, these transcription factors participate in lineage commitment and differentiation. Because “full reprogramming” includes loss of lineage identity and TCR signaling induces transcription factors that promote T cell lineage identity, we anticipated that TCR signaling will oppose Sendai-OSKM induced de-differentiation. Additionally, TCR signaling can be introduced at any time after OSKM transduction (or during re-programming), which in some embodiments may entail placing cells on a culture surface with anti-CD3 and anti-CD28 or adding antigen presenting cells (APC) loaded with cognate antigens.[UCLA 2024-240] P-638467-PC
[0332] Addition of TCR signaling prior to loss of T cell identity was explored in order to preserve the lineage identity of the T cell and achieve “transient reprogramming”. This would avoid the need for re-differentiation and possible loss of antigen specificity (e.g., via RAG [recombination activating gene] reactivation). Reprogramming was tested to determine whether it could be stopped at a desired time in culture. Several key transcription factors known to oppose reprogramming in fibroblasts (e.g., activating protein-1 [AP-1], Nair, 2023, BioRxiv, https: / / doi.org / 10.! 101 / 202,3.10.04.560808) are downstream of T cell receptor signaling.
[0333] The addition of T cell receptor (TCR) stimulation was tested to determine whether it would halt de-differentiation (FIGURE 12). Based on our previous findings (FIGURE 11), T cell lineage may start to be lost between day 7 and day 10 after OSKM transduction. We therefore tested addition of TCR stimulation at several time points on or before day 7.
[0334] CD8 T cells were transduced with Sendai-OSKM and TCR stimulation added at either 4, 6, or 7 days after transduction (FIGURE 13). Again, CD8 T cells were infected with Sendai-OSKM at a 5:5:3, 3:3:2, or 1 : 1 : 1 ratio of c-Myc:KOS:KLF4 plasmids. Cells were initially cultured as described in FIGURE 4 to permit initial de-differentiation. At indicated time points (day 4, day 6, or day 7 after Sendai-OSKM infection), cells were transferred to T cell conditions, which, in some embodiments, entails media comprising interleukin-2 (IL-2, 10-3000 lU / mL), interleukin-7 (IL-7, 10-20 ng / mL), interleukin- 15 (IL-15, 10-20 ng / mL), and antibodies to CD-3 (1-10 ug / mL) and CD-28 (1-10 ug / mL) (anti-CD3 / anti-CD28, provided as soluble antibodies [e.g., 30ng / mL] or adhered to the cell culture surface [e.g., l-10pg / mL coating concentration) for two weeks (or longer for continued expansion). TCR stimulation may also entail addition of antigen presenting cells (APC) loaded with cognate antigens / tumor lysate or whole tumor cells. Upon harvesting, cells were aliquoted and subjected to one of three experiments to test the canonical features of T cells. As in FIGURE 13A (top right experiment), cells were stained with cell trace violet (CTV), cultured for an additional 5 days in T cell conditions, then subjected to flow cytometry to assess cellular divisions / proliferation. In FIGURE 13A (middle right experiment), cells were stimulated with PMA / ionomycin for 6 hrs and intracellular cytokine production measured by flow cytometry to assess canonical T cell cytokine production and cytotoxicity. In FIGURE 13A (bottom right experiment), cells were immediately stained for immunophenotyping by flow cytometry to characterize their differentiation state.
[0335] In another design for arresting de-differentiation as shown in FIGURE 13B, CD8+ T[UCLA 2024-240] P-638467-PC cells are sorted from patient tumors. T cells are partially reprogrammed with sendai-OSKM at various ratios for 2-8 days. Cells are then transferred to T cell conditions to halt de-differentiation and cultured to expand to clinically relevant numbers. T cell conditions are adapted from a “rapid expansion protocol,” wherein T cells are co-cultured with irradiated peripheral blood mononuclear cells (PBMCs), anti-CD3 antibody, IL-2, IL-7, and IL- 15. IL-21 , TLR agonists, and Notch ligands can additionally be added to culture media (e.g., irradiated PBMCs, anti-CD3 antibody, IL-2, IL-7, IL- 15 , IL-21 , TLR agonist and Notch ligand) . Partially reprogrammed T cells are cultured under these conditions for an additional 1-2 weeks, or as needed to achieve necessary cell numbers. Additional assays testing partially reprogrammed T cell cytokine production and immunophenotype can be performed.Example 10: Proliferation and Morphology of T Cells after “Transient Reprogramming”
[0336] Flow cytometry results following CTV staining and additional 5 day culture are shown in FIGURE 14 for CD8 T cells infected with Sendai-OSKM then harvested on day 4 (FIGURE 14A), day 6 (FIGURE 14B), or day 7 (FIGURE 14C). Here, flow cytometry for CTV staining is shown as stacked histograms, and decreased staining intensity corresponds to increased cellular proliferation (top). Also shown is cellular morphology under tight microscopy at 4X magnification (bottom). Cells retain a morphology consistent with T cells (small and round) that are undergoing proliferation (forming rosettes or clusters). Cell counts are shown in Table 3.
[0337] Table 3. FACS Cell Counts for CD8 at Day 4, Day 6, and Day 7.Day Figure Graph Ratio Subset Count 4 15A Top 5:5:3 CD8 128587Middle 3:3:2 CD8 89607 Bottom 1:1:1 CD8 131640 6 15B Top 5:5:3 CD8 251669Middle 3:3:2 CD8 275250 Bottom 1:1:1 CD8 246186 7 15C Top 5:5:3 CD8 35972Middle 3:3:2 CD8 115656Bottom 1:1:1 CD8 185584
[0338] These results demonstrate that CD8 T cells transduced with Sendai-OSKM and cultured in de-differentiating conditions (FIGURE 4) can be transferred to T cell conditions at an[UCLA 2024-240] P-638467-PC early time point (for example, day 4, day 6, or day 7) and retain the ability to proliferate in response to TCR stimulation with characteristic T cell morphology. Importantly, after transfer, cells were cultured in T cell conditions for 2 weeks followed by an additional 5 days after staining with CTV (FIGURE 13A). In total, cells are at that time more than 3 weeks since OSKM transduction (4+14+5=23 days, 6+14+5=25 days, or 7+14+5=26 days). As previously shown (FIGURE 11), iPSC begin to form at approximately day 10-15 (depending on differentiation status of starting cell population); therefore, if de-differentiation was not aborted, cultures would be expected to be predominantly iPSC (or iPSC-like intermediates) by day 23 (FIGURE 14A), day 25 (FIGURE 14B), or day 26 (FIGURE 14C). In contrast, no cells or colonies with iPSC(-like) morphology were observed under this culture protocol, but rather, cells retained characteristic appearance and ability to respond to TCR stimulation consistent with preserved T cell lineage identity.Example 11: Function of T Cells after “Transient Reprogramming”
[0339] To measure the functional capabilities of the reprogrammed T cells, after two weeks of culture under T cell conditions, as described above, the cells were harvested and stimulated for 6 hours in stimulation cocktail (PMA / ionomycin, per manufacturer instructions, eBioscience™, Cell Stimulation Cocktail (500X)), in tandem with a sample of peripheral blood mononuclear cells (PBMC) (negative control), and subjected to flow cytometry. Here, T cell function is measured by production of canonical cytokines IFNg and granzyme B after 6 hour stimulation. Results are shown in FIGURES 15 for T cells initially transduced with ratios of 5:5:3 (FIGURE 15A), 3:3:2 (FIGURE 15B), or 1:1:1 (FIGURE 15C) or non-transduced PBMCs for negative control (FIGURE 15D). Numbers in each comer of the flow plot represent frequencies of each quadrant.
[0340] The results show that CD8 T cells transduced with Sendai-OSKM and cultured in dedifferentiating conditions (FIGURE 4) can be transferred to T cell conditions at an early time point (for example, day 4, day 6, or day 7) and retain the ability to produce canonical T cell cytokines, for example IFNg and granzyme B.Example 12: Phenotype of T Cells after Transient Reprogramming
[0341] To characterize the phenotype of T cells subjected to “transient reprogramming” followed by culturing under T cell conditions, testing was performed on T cells reprogrammed at aratios of 5:5:3, 3:3:2, and 1:1:1 (as above), as well as on PBMC (negative control). Cell samples were subjected to flow cytometric analysis, and the results are shown in FIGURES 16A-B.[UCLA 2024-240] P-638467-PC FIGURE 16A is a reference schematic depicting T cell differentiation stages, including naive, stem central memory, central memory, effector, and exhausted T cells. FIGURE 16B is a series of flow cytometry plots depicting phenotype of Tcm (CCR7+, CD45RO+) and Tern (CCR7-, CD45RO+) (left) as well as naive T cells (CCR7+, CD95-) and Tscm (CCR7+, CD95+) (right) with results from top to bottom for T cells transduced at a 1 : 1: 1 ratio, T cells transduced at a 3:3:2 ratio, T cells transduced at a 5:5:3 ratio, and PBMC (negative control). Numbers indicate the frequency of respective populations. The results show that CD8 T cells transduced with Sendai-OSKM and cultured in de-differentiating conditions (FIGURE 4) can be transferred to T cell conditions at an early time point (for example, day 4, day 6, or day 7), then cultured in T cell conditions for an additional two weeks, and primarily express phenotypes characteristic of less differentiated memory T cells. Specifically, the frequency of Tscm in culture was significantly increased following “transient reprogramming” when T cells were initially transduced with a 1:1:1, 3:3:2, or 5:5:3 ratio.Example 13: “Transient Reprogramming” of polyclonal, exhausted CD8 T cells harvested from patient tumors
[0342] To further investigate “transient reprogramming” of exhausted CD8 T cells these experiments were then repeated using CD8 T cells isolated from a patient tumor (soft tissue sarcoma). CD8 T cells within a tumor are predominantly tumor-specific. Collectively, all the T cells in a tumor have many different TCRs that recognize many different tumor antigens, that is, it is a polyclonal T cell population. We isolated polyclonal CD8 T cells from a patient tumor and used FACS to sort out terminally differentiated, exhausted PD1+ TIM3-I- cells and used these for “transient reprogramming” with OSKM as described above. FIGURE 17A shows the phenotype of the exhausted, starting population of CD8 T cells. On flow cytometric analysis, these cells are PD1+ and TIM3hi (left panel), are mostly CCR7- CD45RO+, and have essentially no stem central memory cells. These cells were “transiently reprogrammed” using a 5:5:3 ratio of c-Myc:KOS:KLF4 (as described above) and cultured with small molecules as listed (CHIR99021 5uM, DOT1L 5uM, VPA 2mM, and / or Vitamin C 50ug / mL). Importantly, “transient reprogramming” is able to proceed with or without small molecules in culture and small molecules in some embodiments may include the small molecules described herein or other small molecules and may be at the concentrations listed or at other concentrations. Cells were transferred to T cell conditions with TCR stimulation provided by anti-CD3 (2ug / mL) and anti-CD28 (5ug / mL) antibodies on day 7 post sendai-OSKM infection. FIGURE 17B demonstrates T cell phenotypes[UCLA 2024-240] P-638467-PC at day 7 determined by flow cytometry. After 7 days of “transient reprogramming”, CD8 T cells retain PD1 expression (indicative of activated T cells) and have generally less TIM3 expression (left panel) compared to day 0. After “transient reprogramming” CD8 T cells are predominantly Tcm and Tscm phenotypes, staining for CCR7+ CD45RO+ or CCR7+ CD45RO-, respectively (middle panel). Following 7 days of “transient reprogramming”, a relatively large population of stem central memory CD8 T cells is now present, whereas these cells are absent from the starting population of exhausted CD8 T cells (right panel). Thus, a polyclonal population of exhausted, tumor-specific CD8 T cells harvested from a patient tumor can be “transiently reprogrammed” into central memory and stem central memory CD8 T cells.
[0343] Collectively, these results (FIGURE 13 - FIGURE 17) demonstrate that T cells can be “transiently reprogrammed”, wherein transduction with OSKM induces T cell dedifferentiation to a less differentiated T cell subset (e.g., effector T cells to memory T cells) without loss of T cell lineage identity, which can be stopped at a desired time point with addition of TCR stimulation / signaling. CD8 T cells “transiently reprogrammed” in this way retained the ability to proliferate robustly in response to TCR stimulation, maintained characteristic culture morphology, robustly produced canonical T cell cytokines e.g., interferon-gamma (IFN-gamma; interferon-y [IFN-y]; interferon-g [IFN-g]) granzyme B and TNF-a, and expressed phenotypes consistent with less differentiated memory subsets (i.e., Tcm and Tscm).Example 14: Analysis of Differences in Transcriptional and Epigenetic Programs Influencing the Ability of T Cells to De-differentiate Into iPSC and to Subsequently Redifferentiation into Mature T Cells
[0344] It is desirable to understand transcriptional and epigenetic programs that either promote or inhibit CD8 T cell reprogramming, therefore, a time course of next generation sequencing techniques will be performed. Time points include CD8 T cell de-differentiation to iPSC and then re-differentiation to mature CD8 T cells using ATO, as described above. Because during reprogramming to iPSC, cells can become trapped at intermediate stages (Long et al. Molecular Therapy Nucl. Acids 34:102044 (2023)), single-cell / nuclear resolution is used to understand successful reprogramming. Paired single-nuclear RNA sequencing (snRAN-seq) and single nuclear ATAC sequencing (snATAC-seq) of multiplexed samples is performed. Data are analyzed using the Seurat extension R package Signac (Stuart et al. Nature Methods 18: 1333-1341 (2021)). First, FACS sorting of CD8 T cell subsets (naive, stem central memory, central[UCLA 2024-240] P-638467-PC memory, effector memory, effector, exhausted) from matched blood and tumor of patients with STS is performed. Sorted cells are transduced with Sendai-OSKM, and cultures are harvested at 4, 7, 10, 15, and 30 days. After 30 days, CD8-iPSC are re-differentiated into CD8ab T cells using ATO, as described above, and cultures again undergo paired snRNA-seq and snATAC-seq. Analysis of formation of iPSC from less differentiated CD8 T cells vs. more differentiated CD8 T cells will reveal the efficiency and ability of each of these CD8 T cell subsets to de-differentiate and subsequently re-differentiate into mature CD8 T cells. Moreover, integrative analysis of snRNA-seq and snATAC-seq is used to observe and analyze the impact of key genes, their regulation, and how T cell exhaustion is deconstructed with OSKM reprogramming. Analysis of cells trapped at intermediate stages versus those able to reprogram demonstrates targets for more efficient T cell reprogramming.Example 15: Analysis of Epigenetic and Transcriptional Programs Enforcing CD8 T Cell Exhaustion to Restore Sternness of Tumor-Specific T Cells
[0345] Human CD8 T cell subsets are again FACS sorted from matched blood and tumor of patients undergoing STS resection. Aliquots will be taken at time 0 for baseline comparison. CD8 T cells are transduced with Sendai-OSKM at a 5:5:3 ratio. On day 7 post-transduction, cells are transferred to anti-CD3 / anti-CD28 coated plates to provide TCR stimulation with media containing low-dose IL-2, IL-7, and IL- 15. This strategy represents an example of “transient reprogramming”. An aliquot is taken for single-nuclear preparation. T cell cultures are then allowed to proliferate for an additional 14 days (day 21 post-transduction), at which time cultures are harvested and subjected to paired snRNA-seq and snATAC-seq. Time course data are analyzed, e.g., with respect to regulation of transcriptional and epigenetic programs during restoration of tumor-specific CD8 T cell sternness without loss of lineage identity.
[0346] These studies are initially performed using matched blood and tumor tissue of three patients with STS (n=3 separate patients). To confirm findings are not cancer type specific, studies are repeated using matched blood and tumor of patients with advanced melanoma (n=3 separate patients). Because TCR signal strength impacts memory versus effector differentiation (Chin et al. Nature Commun. 13: 2240 (2022)), different strengths of anti-CD3 / CD28 are tested, as well as co-stimulation to further enrich for Tscm. The exhausted CD8 T cell program is recalcitrant (Beltra et al. Immunity 52: 825-841. e828 (2020),), so the addition of small molecules and media[UCLA 2024-240] P-638467-PC components to improve yield (e.g., vitamin C, valproic acid, DOT IL [disruptor of telomeric silencing 1-like]) is also tested.Example 16: Durability of Anti-Tumor Immunity From Transfer of Transiently or Fully Reprogrammed CD8 T Cells
[0347] Durability of anti-tumor immunity from transfer of transiently or fully reprogrammed CD8 T cells is tested using mouse models.
[0348] STEMCCA mice, possessing OSKM under tetracycline-dependent promoter control (Stadtfeld et al., Nature Methods 7:53-55 (2010),), are crossed with R26-M2rtTA mice, harboring reverse tetracycline-controlled transactivator protein, both on a B6 background generating progeny with doxycycline-inducible OSKM in all cells. These mice are given TAO1 tumor cells — a murine STS (soft tissue sarcoma) model — in the subcutaneous flank (FIGURE 18A).Tumors are harvested at day 21 and tumor-infiltrating exhausted CD8 T cells (PD1+, TIM3+) FACS sorted. Tumor control of fully (FIGURE 3) versus transiently (FIGURE 12) reprogramed cells is then compared. Fully reprogrammed cells have continuous doxycycline in ex vivo culture for 30 days until stable iPSC colonies are established, then subjected to re-differentiation with ATO, as described above. Transiently reprogrammed cells are exposed to doxycycline for 7 days, then doxycycline is removed and plate-bound anti-CD3 / CD28 and IL-2, IL-7, and IL- 15 are added. Tumor-specific killing is quantified by co-culture of reprogrammed cells with TAO1 cells in vitro, staining tumor cells (CD45-) for Annexin V and 7-aminoactinomycin D (7-AAD) for flow cytometric analysis. IxlO6reprogrammed CD8 T cells are then transferred to secondary, sub-lethally irradiated B6 mice with established TAO1 tumors. Tumor growth is measured biweekly using calipers.
[0349] This line of experimentation is repeated with human tissues. Exhausted CD8 T cells and tumor cells are two-way FACS sorted from resected STS. T cells undergo “full” or “transient reprogramming”. Tumor cells are injected into SCID mice to develop patient-derived xenografts (PDX) (FIGURE 18B). 1-lOxlO6reprogrammed CD8 T cells are injected into PDX-bearing mice, and tumor growth is measured biweekly with calipers.
[0350] Tumor control of “fully reprogrammed” CD8 T cells vs. “transiently reprogrammed” CD8 T cells is comparatively observed. Engraftment of reprogrammed cells is compared by enumerating human CD8 T cells recovered from harvested PDX tumors. Cellular differentiation[UCLA 2024-240] P-638467-PC state and functional status (e.g., production of IFNg, granzyme B, TNFa) are measured by flow cytometry. Each of these are important components for clinical translation.Example 17: Persistence of Restored Sternness of Reprogrammed CD8 T Cells and Reconstitution of Memory and Effector Subsets in Tumor-Bearing Hosts
[0351] To evaluate persistence of restored sternness of reprogrammed CD8 T cells, competitive and serial transfer experiments to test persistence are performed. Mouse CD8 T cells infiltrating TAO1 tumors in STEMCCA mice are harvested and “fully” or “transiently reprogrammed”, as described above. During culture, reprogrammed CD8 T cells are labeled with BrdU, while non-reprogrammed controls are not. For competitive transfer, reprogrammed CD8 T cells and controls (both CD45.2+) are transferred in a 1:1 ratio into a sub-lethally irradiated CD45.1+ Pepboy mouse bearing a TAO1 tumor (FIGURE 18C). Tumor, draining lymph node, and spleen are harvested 3 weeks later and analyzed for reprogrammed (CD45.2+, BrdU+) and control CD8 T cells (CD45.2+, BrdU-), revealing which is better able to engraft in niches and persist. Similarly, this experiment is repeated to compare persistence of “fully” versus “transiently reprogrammed” CD8 T cells. “Fully reprogrammed” T cells are labeled with BrdU during culture, while “transiently reprogrammed” T cells are not. “Fully” and “transiently reprogrammed” T cells (both CD45.2+) are transferred in a 1 : 1 ratio into a sub-lethally irradiated CD45.1 + Pepboy mouse bearing a TAO1 tumor. Tumor, draining lymph node, and spleen are harvested 3 weeks later and analyzed for “fully reprogrammed” (CD45.2+, BrdU+) and “transiently reprogrammed” CD8 T cells (CD45.2+, BrdU-), revealing which is better able to engraft in niches and persist. For serial transfer, CD45.2+ reprogrammed and control CD8 T cells are transferred into separate sub-lethally irradiated TAOl-bearing CD45.1+ Pepboy mice (FIGURE 18D). Reprogrammed and control CD8 T cells are then isolated from each mouse 3 weeks later and transferred into a second TAOl-bearing mouse. These experiments are then repeated comparing “fully” (labeled BrdU+) versus “transiently reprogrammed” (BrdU-) CD8 T cells.
[0352] Performance of fully and transiently reprogrammed cells is compared, including reconstitution of all memory and effector subsets, as well as comparing the results to those of control cells. Recognition of antigens in the tumor of a secondary mouse (despite originating from genetically identical tumor cells) by polyclonal CD8 T cells harvested from TAO1 tumors will be measured and analyzed. If antigen specificity is altered during “full reprogramming”, as RAG 1 / 2 reactivation can initiate another round of recombination (Minagawa et al. Cell Stem Cell 23: 850-[UCLA 2024-240] P-638467-PC 858.e854 (2018), RAG 1 / 2 in iPSCs is knocked out. Timing of RAG1 / 2 reactivation using a RAG-activated green fluorescent protein (GFP) reporter (Trancoso et al. Front Immunol. 4: 110 (2013)) is also tested. If necessary, TAO1 cells are stably transfected with ovalbumin (TAOl-ova), providing a dominant antigen to which a polyclonal response is still generated. If persistence of fully and / or transiently reprogrammed CD8 T cells is less than expected then TCR sequencing of recovered, long-lived CD8 T cells are then compared with snRNA-seq of the input CD8 T cell pool, identifying transcriptional profiles conferring greater persistence.Example 18. CD8+ PD1+ TIM3+ T cells sorted from patient tumors partially reprogrammed with sendai-OSKM
[0353] Exhausted CD8+ PD1+ TIM3+ T cells from a melanoma and liposarcoma were partially programmed to achieve manifold expansions, as shown in FIGURE 19. PD1+ TIM3+ exhausted T cells were sorted from patient tumors, melanoma (left) or liposarcoma (right). T cells were partially reprogrammed with sendai-OSKM at 5:5:3, 3:3:2, or 2:2:1 ratios for 4 days. Cells were then transferred to T cell conditions to halt de-differentiation and cultured for an additional 2 weeks. Samples were taken after 7 or 14 days to measure cell proliferation. Fold expansion is calculated as (number of cells in culture at each timepoint) / (number of cells put into culture).
[0354] Partial / and or fully reprogrammed CD8 T cells have also been obtained from the following tumors; patient demographics are included.w sxx4S: Mss H€ ™3.............. M _ WO IPS, r&mrem _M ©sxxfyi ti mnigntS3 H WO- LFSj w33. F 14^ prmwyF WO - iPO wnw ( WO 4 DO )| 43 F WB / OO-tfS, psimfy (00)33 UPS (high grads), wUWatk:mw t&c msDxsxsa ta LN si nwtxsWiX '“xxxxxxxxs ta LN[UCLA 2024-240] P-638467-PC
[0355] Thus, significant and clinically relevant expansion using partially reprogrammed, stem-like T cells can be readily achieved by the methods disclosed herein.
[0356] While certain features of the disclosure and methods of use thereof have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the invention.
Claims
[UCLA 2024-240] P-638467-PC CLAIMSWhat is claimed is:
1. A method for treating a solid tumor in a subject comprising the steps of:a. isolating CD8 T cells from the tumor, tumor environment, tumor microenvironment or blood;b. exposing the CD8 T cells to de-differentiation-inducing conditions; c. inducing de-differentiation of the CD8 T cells;d. halting de-differentiation of the CD8 T cells at temporally and / or phenotypically defined time at which stem-like memory features are reacquired;e. administering the CD8 T cells to the subject;whereby the solid tumor is treated.
2. The method of claim 1, wherein the solid tumor is melanoma, a mesenchymal cancer such as a sarcoma or an epithelial cancer such as pancreatic cancer.
3. The method of claim 1, wherein exposing the CD8 T cells to de-differentiationinducing conditions comprises exposing the T cells to OSKM, such as Sendai-OSKM, optionally at a 5:5:3, 3:3:2, 2:2:1 or 1:1:1 ratio of c-Myc:KLF4-Oct3 / 4-Sox2:KLF4.
4. The method of claim 1, wherein the inducing de-differentiation comprises exposing cells to OSKM in 100% T cell medium on days 0-1, then over the next 5-6 days reducing the percent (v / v) T cell medium and increasing the percent (v / v) stem cell medium with cytokines, followed by 100% stem cell medium with cytokines.
5. The method of claim 1, wherein the inducing de-differentiation comprises exposing cells to 100% T cell medium with cytokines, such as from about day 2 to about day 8.[UCLA 2024-240] P-638467-PC 6. The method of claim 4 or 5, wherein the cytokines comprise IL-2, IL-7 and / or IL-15, such as such as 10-3000 IU / mLIL-2, 10-20 ng / mLIL-7 and / or 10-20 ng / mLIL-15, for example, 12 lU / mL IL-2, 10 ng / mL IL-7 and 10 ng / mL IL- 15.
7. The method of claim 1, wherein inducing de-differentiation of the CD8 T cells comprisesa. exposing the CD8 T cells to Sendai-OSKM and 100% T cell medium on days 0-1;b. exposing the CD8 T cells to 75% T cell medium, 25% stem cell medium and cytokines on about day 2;c. exposing the CD8 T cells to 50% T cell medium, 50% stem cell medium and cytokines on about day 3d. exposing the CD8 T cells to 25% T cell medium, 75% stem cell medium and cytokines on about day 4;e. exposing the CD8 T cells to 100% stem cell medium and cytokines on about day 5; andf. exposing the CD8 T cells to 100% stem cell medium and cytokines starting on about day 6.
8. The method of any one of claims 1-7, wherein during and / or after any one or more steps, the CD8 T cells are expanded.
9. The method of claim 8, wherein the expansion occurs in T cell medium.
10. The method of claim 1, wherein the halting de-differentiation is carried out when the majority of tumor-specific T cells have gained stem-like T cell features, such as any one or more of: positive CD3, positive CD8, high %Tcm (CD45RO+, CD62L+, CD95+, CCR7+ and / or IL-2Rb+), low SSEA421, and / or high %Tscm (CD45RA+, CD62L+, CD95+, CCR7+ and / or fL-2Rb+); and / or at a defined time point corresponding with acquisition of stem-like T cell features without loss of T cell lineage identity.[UCLA 2024-240] P-638467-PC 11. The method of claim 1, wherein the halting de-differentiation is carried out after about day 2 and before about day 21, such as on any one of days 2-8, such as on day 2, 3, 4, 6 or 8.
12. The method of claim 1, wherein the halting de-differentiation comprises exposing the T cells to T cell stimulation conditions.
13. The method of claim 12, wherein the T cell stimulation conditions comprises TCR signaling with or without costimulation, with or without T cell medium, or T cell medium with or without cytokines.
14. The method of claim 12, wherein the TCR signaling comprises exposure to one or more small molecules, peptides, cytokines, growth factors, and / or antibodies, such as anti-CD3 antibodies, anti-CD28 antibodies, irradiated PBMCs, TLR agonist such as R848, Notch ligand such as DLL4-Fc, cognate peptide, tumor cells, tumor lysate, antigen presenting cells, or any combination thereof, to achieve T cell stimulation, such as the combination of irradiated PBMCs, anti-CD3, IL-2, IL-7, IL-15, optionally including IL-21, TLR agonist and / or Notch ligand.
15. The method of claim 1, wherein the halted de-differentiation comprises expression of NFkB, NFAT, AP-1, Runxl / 3 and / or GATA3, and continued expression of CD3 and CD8; and / or lack of upregulation of canonical iPSC markers, such as SSEA3, SSEA4, CD30, Tra-1-60, Tra-1-81, or any combination thereof.
16. The method of claim 8 or 9, wherein the expanding of the T cells comprises further incubation of the T cells in T cell stimulation conditions.
17. The method of claim 1, wherein the T cells are infused into the subject.
18. The method of claim 1, wherein the CD8 cells isolated from the tumor express CD39, CD69, CD103, CD137, PD-1, TIM3, or any combination thereof.
19. The method of claim 1, wherein inducing de-differentiation of the CD8 T cells further comprises including at least one epigenetic modifier.[UCLA 2024-240] P-638467-PC 20. The method of claim 1, wherein inducing de-differentiation of the CD8 T cells further comprises including vitamin C, a histone deacetylase inhibitor such as valproic acid (VPA), ahistone methyltransferase inhibitor, such as a DOT IL inhibitor, optionally EPZ-5676 (pinometostat), and / or a GSK3b inhibitor such as CHIR99021.
21. The method of claim 1, further comprising a modulator of signal strength of the TCR.
22. Transiently reprogrammed, tumor-specific CD8 T cells prepared by:a. exposing CD8 T cells obtained from a tumor, a tumor microenvironment or blood to de-differentiation-inducing conditions;b. inducing de-differentiation of the CD8 T cells; andc. halting de-differentiation of the CD8 T cells at a temporally or phenotypically defined time at which stem-like memory features are reacquired.
23. The transiently reprogrammed CD8 T cells of claim 22, wherein the cells are expanded.
24. The transiently reprogrammed CD8 T cells of claim 22, wherein exposing the CD8 T cells to de-differentiation-inducing conditions comprises transducing the T cells with OSKM, such as Sendai-OSKM, optionally at a 5:5:3, 3:3:2 or 1:1:1 ratio of c- Myc:KLF4-Oct3 / 4-Sox2:KLF4.
25. The transiently reprogrammed CD8 T cells of claim 22, wherein the inducing de- differentiation comprises exposing cells to OSKM in 100% T cell medium on days 0- 1, then over the next 5-6 days reducing the percent (v / v) T cell medium and increasing the percent (v / v) stem cell medium with cytokines, followed by 100% stem cell medium with cytokines.
26. The transiently reprogrammed CD8 T cells of claim 22, wherein the inducing de- differentiation comprises exposing cells to 100% T cell medium with cytokines, such as from about day 2 to about day 8.[UCLA 2024-240] P-638467-PC 27. The transiently reprogrammed CD8 T cells of claim 23 or 24, wherein the cytokines comprise IL-2, IL-7 and / or IL-15, such as 10-3000 IU / mLIL-2, 10-20 ng / mLIL-7 and / or 10-20 ng / mL IL-15, for example, 12 lU / mL IL-2, 10 ng / mL IL-7 and 10 ng / mL IL-15.
28. The transiently reprogrammed CD8 T cells of claim 22, wherein inducing dedifferentiation of the CD8 T cells comprisesa. exposing the CD8 T cells to Sendai-OSKM and 100% T cell medium on days 0-1;b. exposing the CD8 T cells to 75% T cell medium, 25% stem cell medium and cytokines on about day 2;c. exposing the CD8 T cells to 50% T cell medium, 50% stem cell medium and cytokines on about day 3d. exposing the CD8 T cells to 25% T cell medium, 75% stem cell medium and cytokines on about day 4;e. exposing the CD8 T cells to 100% stem cell medium and cytokines on about day 5; andf. exposing the CD8 T cells to 100% stem cell medium and cytokines starting on about day 6.
29. The transiently reprogrammed CD8 T cells of any one of claims 22-28, wherein during and / or after any one or more steps, the CD8 T cells are expanded.
30. The transiently reprogrammed CD8 T cells of claim 29, wherein the expansion occurs in T cell medium.
31. The transiently reprogrammed CD8 T cells of claim 22, wherein the halting dedifferentiation is carried out when the majority of tumor-specific T cells have gained stem-like T cell features, such as any one or more of: positive CD3, positive CD8, high %Tcm (CD45RO+, CD62L+, CD95+, CCR7+ and / or IL-2Rb+), low SSEA421, and / or high %Tscm (CD45RA+, CD62L+, CD95+, CCR7+ and / or fL-2Rb+); and / or at a defined time point corresponding with acquisition of stem-like T cell features without loss of T cell lineage identity.[UCLA 2024-240] P-638467-PC 32. The transiently reprogrammed CD8 T cells of claim 22, wherein the halting dedifferentiation is carried out after about day 2 and before about day 21, such as on any one of days 2-8, such as on day 2, 3, 4, 6 or 8.
33. The transiently reprogrammed CD8 T cells of claim 30 or 31 , wherein the T cell medium comprises TCR signaling.
34. The transiently reprogrammed CD8 T cells of claim 33, wherein the TCR signaling comprises exposure to anti-CD3 antibodies, anti-CD28 antibodies, irradiated PBMCs, TLR agonist such as R848, Notch ligand such as DLL4-Fc, cognate peptide, tumor cells, tumor lysate, antigen presenting cells, or any combination thereof, to achieve T cell stimulation, such as the combination of irradiated PBMCs, anti-CD3, IL-2, IL-7, IL-15, optionally including IL-21, TLR agonist and / or Notch ligand.
35. The transiently reprogrammed CD8 T cells of claim 22, wherein the halted dedifferentiation comprises expression of NFkB, NFAT, AP-1, Runxl / 3 and / or GATA3, with continued expression of CD3 and CD8; and / or lack of upregulation of canonical iPSC markers, such as SSEA3, SSEA4, CD30, Tra-1-60, Tra-1-81, or any combination thereof.
36. The transiently reprogrammed CD8 T cells of claim 27, wherein the expanding T cells in step e. comprises further incubation of the T cells in T cell medium.
37. The transiently reprogrammed CD8 T cells of any one of claims 22-36, wherein the transiently reprogrammed CD8 T cells are prepared for infusion into a subject.
38. The transiently reprogrammed CD8 T cells of claim 22, wherein the CD8 cells are obtained from a tumor, tumor environment, tumor microenvironment or blood.
39. The transiently reprogrammed CD8 T cells of claim 38, wherein the CD8 cells isolated form the tumor, tumor environment, tumor microenvironment or blood express CD39, CD69, CD103, CD137, PD-1, TIM3, or any combination thereof.
40. A method for treating a solid tumor in a subject comprising the steps of:[UCLA 2024-240] P-638467-PC a. isolating CD8 T cells from the tumor, tumor environment, tumor microenvironment or blood;b. exposing the CD8 T cells to de-differentiation-inducing conditions; c. inducing full de-differentiation of the CD8 T cells to iPSCs;d. maturing the iPSCs back into CD8 T cells; ande. administering the CD8 T cells to the subject;whereby the solid tumor is treated.
41. The method of claim 40, wherein the solid tumor is melanoma, a mesenchymal cancer such as a sarcoma or an epithelial cancer such as pancreatic cancer.
42. The method of claim 40, wherein exposing the CD8 T cells to de-differentiationinducing conditions comprises exposing the T cells to OSKM, such as Sendai-OSKM, optionally at a 5:5:3, 3:3:2, 2:2:1 or 1:1:1 ratio of c-Myc:KLF4-Oct3 / 4-Sox2:KLF4.
43. The method of claim 40, wherein the inducing de-differentiation comprises exposing cells to OSKM in 100% T cell medium on days 0-1, then over the next 3-4 days reducing the percent (v / v) T cell medium and increasing the percent (v / v) stem cell medium with cytokines, followed by 100% stem cell medium without cytokines.
44. The method of claim 43, wherein the inducing de-differentiation comprises exposing cells to 100% T cell medium with cytokines from about day 2 to about day 5.
45. The method of claim 43 or 44, wherein the cytokines comprise IL-2, IL-7 and / or IL- 15, such as such as 10-3000 IU / mLIL-2, 10-20 ng / mLIL-7 and / or 10-20 ng / mL IL- 15, for example, 12 lU / mL IL-2, 10 ng / mL IL-7 and 10 ng / mL IL- 15.
46. The method of claim 40, wherein the T cells are exposed to 100% T cell medium without cytokines starting about day 6.
47. The method of claim 40, wherein inducing de-differentiation of the CD8 T cellscomprises[UCLA 2024-240] P-638467-PC a. exposing the CD8 T cells to Sendai-OSKM and 100% T cell medium on days 0-1;b. exposing the CD8 T cells to 75% T cell medium, 25% stem cell medium and cytokines on about day 2;c. exposing the CD8 T cells to 50% T cell medium, 50% stem cell medium and cytokines on about day 3d. exposing the CD8 T cells to 25% T cell medium, 75% stem cell medium and cytokines on about day 4;e. exposing the CD8 T cells to 100% stem cell medium and cytokines on about day 5; andf. exposing the CD8 T cells to 100% stem cell medium without cytokines starting on about day 6; andg. exposing the CD8 T cells to 100% stem cell medium without cytokines for the reminder of culture.
48. The method of any one of claims 40-47, wherein the full de-differentiation occurs over about 1-2 months.
49. The method of any one of claims 40-47, wherein during and / or after any one or more steps, the iPSC are expanded.
50. The method of claim 49, wherein the expansion occurs in stem cell medium.
51. The method of claim 40, wherein the maturing of the iPSCs to T cells is carried out by culturing the iPSCs in an ATO.
52. The method of claim 51 , wherein the culturing is carried out for about 3-4 months.
53. The fully reprogrammed CD8 T cells of claims 51-52, wherein the expanding T cells in step e. comprises further incubation of the T cells in T cell medium.
54. The method of any one of claims 40-53, wherein the T cells are infused into the subject.[UCLA 2024-240] P-638467-PC 55. The method of claim 40, wherein the CD8 cells isolated from the tumor, tumor environment, tumor microenvironment or blood express CD39, CD69, CD103, CD 137, PD-1, TIM3, or any combination thereof.
56. The method of claim 40, wherein inducing de-differentiation of the CD8 T cells further comprises including at least one epigenetic modifier.
57. The method of claim 40, wherein inducing de-differentiation of the CD8 T cells further comprises including vitamin C, a histone deacetylase inhibitor such as valproic acid (VPA), a histone methyltransferase inhibitor, such as a DOT1L inhibitor, optionally EPZ-5676 (pinometostat), and / or a GSK3b inhibitor such as CHIR99021.
58. The method of claim 40, wherein the iPSC are induced or matured into mesodermal progenitors, followed by induction into hematopoietic progenitors, and then into differentiated into naive or stem-like T cells.
59. The method of claim 58, wherein the iPSCs are sequentially exposed toa. Activin A, BMP4, VEGF, and FGF (mesodermal induction);b. aggregating mesodermal progenitors with a MS5-DLL4 cells and culturing resultant organoids initially in EGM2 media with a TGFb inhibitor then EGM2 media with a TGFb inhibitor plus SCF, FLT3L, and TPO (hematopoietic induction); andc. cultured in RPMI media supplemented with ascorbic acid, B27 supplement, SCF, FLT3L, IL-7 (T cell differentiation).
60. Fully reprogrammed, tumor-specific CD8 T cells prepared by:a. exposing CD8 T cells isolated from a tumor, a tumor microenvironment or blood to de-differentiation-inducing conditions;b. inducing full de-differentiation of the CD8 T cells to iPSCs; andc. re-maturing or re-differentiating the iPSCs to CD8 T cells.
61. The fully reprogrammed CD8 T cells of claim 60, wherein the cells are expanded.[UCLA 2024-240] P-638467-PC 62. The fully reprogrammed CD8 T cells of claim 60, wherein exposing the CD8 T cells to de-differentiation-inducing conditions comprises transducing the T cells with OSKM, such as Sendai-OSKM, optionally at a 5:5:3, 3:3:2, 2:2:1 or 1:1:1 ratio of c- Myc:KLF4-Oct3 / 4-Sox2:KLF4.
63. The fully reprogrammed CD8 T cells of claim 60, wherein the inducing dedifferentiation comprises exposing cells to OSKM in 100% T cell medium on days 0- 1, then over the next 5-6 days reducing the percent (v / v) T cell medium and increasing the percent (v / v) stem cell medium with cytokines, followed by 100% stem cell medium without cytokines.
64. The fully reprogrammed CD8 T cells of claim 60, wherein the inducing dedifferentiation comprises exposing cells to 100% T cell medium with cytokines from about day 2 to about day 5.
65. The fully reprogrammed CD8 T cells of claim 64, wherein the cytokines comprise IL- 2, IL-7 and / or IL-15, such as 10-3000 IU / mLIL-2, 10-20 ng / mLIL-7 and / or 10-20 ng / mL IL-15, for example, 12 lU / mL IL- 2, 10 ng / mL IL-7 and 10 ng / mL IL-15.
66. The fully reprogrammed CD8 T cells of claim 60, wherein the T cells are exposed to 100% T cell medium without cytokines starting about day 6.
67. The fully reprogrammed CD8 T cells of claim 60, wherein inducing de-differentiation of the CD8 T cells comprises:a. exposing the CD8 T cells to Sendai-OSKM and 100% T cell medium on days 0-1;b. exposing the CD8 T cells to 75% T cell medium, 25% stem cell medium and cytokines on about day 2;c. exposing the CD8 T cells to 50% T cell medium, 50% stem cell medium and cytokines on about day 3d. exposing the CD8 T cells to 25% T cell medium, 75% stem cell medium and cytokines on about day 4;[UCLA 2024-240] P-638467-PC e. exposing the CD8 T cells to 100% stem cell medium and cytokines on about day 5; andf. exposing the CD8 T cells to 100% stem cell medium without cytokines starting on about day 6; andg. exposing the CD8 T cells to 100% stem cell medium without cytokines for the reminder of culture.
68. The fully reprogrammed CD8 T cells of claim 60, wherein the de-differentiation occurs over about 2 months.
69. The fully reprogrammed CD8 T cells of claim 60, wherein during and / or after any one or more steps, the iPSC are expanded.
70. The fully reprogrammed CD8 T cells of claim 60, wherein the expansion occurs in stem cell medium.
71. The fully reprogrammed CD8 T cells of claim 60, wherein the re-maturing of the iPSCs to T cells is carried out by culturing the iPSCs in an ATO.
72. The fully reprogrammed CD8 T cells of claim 71, wherein the culturing is carried out for about 3-4 months.
73. The fully reprogrammed T cells of any one of claims 60-72, wherein the T cells are prepared for infusion into a subject.
74. The fully reprogrammed T cells of claim 60, wherein the CD8 cells isolated from the tumor, tumor microenvironment or blood express CD39, CD69, CD103, CD137, PD1, TIM3, or any combination thereof.
75. A method for partially reprogramming T cells comprising the steps of:a. isolating CD8 T cells from a tumor, tumor environment, tumor microenvironment or blood;b. exposing the CD8 T cells to de-differentiation-inducing conditions;[UCLA 2024-240] P-638467-PC c. inducing de-differentiation of the CD8 T cells;d. and halting de-differentiation of the CD8 T cells at temporally and / or phenotypically defined time at which stem-like memory features are reacquired.
76. The method of claim 75, wherein the solid tumor is melanoma, a mesenchymal cancer such as a sarcoma or an epithelial cancer such as pancreatic cancer.
77. The method of claim 75, wherein exposing the CD8 T cells to de-differentiationinducing conditions comprises exposing the T cells to OSKM, such as Sendai-OSKM, optionally at a 5:5:3, 3:3:2, 2:2:1 or 1:1:1 ratio of c-Myc:KLF4-Oct3 / 4-Sox2:KLF4.
78. The method of claim 75, wherein the inducing de-differentiation comprises exposing cells to OSKM in 100% T cell medium on days 0-1, then over the next 5-6 days reducing the percent (v / v) T cell medium and increasing the percent (v / v) stem cell medium with cytokines, followed by 100% stem cell medium with cytokines.
79. The method of claim 75, wherein the inducing de-differentiation comprises exposing cells to 100% T cell medium with cytokines, such as from about day 2 to about day 8.
80. The method of claim 78 or 79, wherein the cytokines comprise IL-2, IL-7 and / or IL- 15, such as such as 10-3000 IU / mLIL-2, 10-20 ng / mLIL-7 and / or 10-20 ng / mL IL- 15, for example, 12 lU / mL IL-2, 10 ng / mL IL-7 and 10 ng / mL IL- 15.
81. The method of claim 75, wherein inducing de-differentiation of the CD8 T cells comprisesa. exposing the CD8 T cells to Sendai-OSKM and 100% T cell medium on days 0-1;b. exposing the CD8 T cells to 75% T cell medium, 25% stem cell medium and cytokines on about day 2;c. exposing the CD8 T cells to 50% T cell medium, 50% stem cell medium and cytokines on about day 3[UCLA 2024-240] P-638467-PC d. exposing the CD8 T cells to 25% T cell medium, 75% stem cell medium and cytokines on about day 4;e. exposing the CD8 T cells to 100% stem cell medium and cytokines on about day 5; andf. exposing the CD8 T cells to 100% stem cell medium and cytokines starting on about day 6.
82. The method of any one of claims 75-81, wherein during and / or after any one or more steps, the CD8 T cells are expanded.
83. The method of claim 82, wherein the expansion occurs in T cell medium.
84. The method of claim 75, wherein the halting de-differentiation is carried out when the majority of tumor-specific T cells have gained stem-like T cell features, such as any one or more of: positive CD3, positive CD8, high %Tcm (CD45RO+, CD62L+, CD95+, CCR7+ and / or IL-2Rb+), low SSEA421, and / or high %Tscm (CD45RA+, CD62L+, CD95+, CCR7+ and / or fL-2Rb+); and / or at a defined time point corresponding with acquisition of stem-like T cell features without loss of T cell lineage identity.
85. The method of claim 75, wherein the halting de-differentiation is carried out after about day 2 and before about day 21, such as on any one of days 2-8, such as on day 2, 3, 4, 6 or 8.
86. The method of claim 75, wherein the halting de-differentiation comprises exposing the T cells to T cell stimulation conditions.
87. The method of claim 86, wherein the T cell stimulation conditions comprises TCR signaling with or without costimulation, with or without T cell medium, or T cell medium with or without cytokines.
88. The method of claim 75, wherein the TCR signaling comprises exposure to one or more small molecules, peptides, cytokines, growth factors, and / or antibodies, such as anti-CD3 antibodies, anti-CD28 antibodies, irradiated PBMCs, TLR agonist such as[UCLA 2024-240] P-638467-PC R848, Notch ligand such as DLL4-Fc, cognate peptide, tumor cells, tumor lysate, antigen presenting cells, or any combination thereof, to achieve T cell stimulation, such as the combination of irradiated PBMCs, anti-CD3, IL-2, IL-7, IL-15, optionally including IL-21, TLR agonist and / or Notch ligand.
89. The method of claim 75, wherein the halted de-differentiation comprises expression of NFkB, NFAT, AP-1, Runxl / 3 and / or GATA3, and continued expression of CD3 and CD8; and / or lack of upregulation of canonical iPSC markers, such as SSEA3, SSEA4, CD30, Tra-1-60, Tra-1-81, or any combination thereof.
90. The method of claim 82 or 83, wherein the expanding of the T cells comprises further incubation of the T cells in T cell stimulation conditions.
91. The method of claim 75, wherein the CD8 cells isolated from the tumor express CD39, CD69, CD103, CD137, PD-1, TIM3, or any combination thereof.
92. The method of claim 75, wherein inducing de-differentiation of the CD8 T cells further comprises including at least one epigenetic modifier.
93. The method of claim 75, wherein inducing de-differentiation of the CD8 T cells further comprises including vitamin C, a histone deacetylase inhibitor such as valproic acid (VPA), a histone methyltransferase inhibitor, such as a DOT1L inhibitor, optionally EPZ-5676 (pinometostat), and / or a GSK3b inhibitor such as CHIR99021.
94. The method of claim 75, further comprising a modulator of signal strength of the TCR.
95. A method for fully reprogramming T cells comprising the steps of:a. isolating CD8 T cells from a tumor, tumor environment, tumor microenvironment or blood;b. exposing the CD8 T cells to de-differentiation-inducing conditions; c. inducing full de-differentiation of the CD8 T cells to iPSCs; and[UCLA 2024-240] P-638467-PC d. maturing the iPSCs back into CD8 T cells.
96. The method of claim 95, wherein the solid tumor is melanoma, a mesenchymal cancer such as a sarcoma or an epithelial cancer such as pancreatic cancer.
97. The method of claim 95, wherein exposing the CD8 T cells to de-differentiationinducing conditions comprises exposing the T cells to OSKM, such as Sendai-OSKM, optionally at a 5:5:3, 3:3:2, 2:2:1 or 1:1:1 ratio of c-Myc:KLF4-Oct3 / 4-Sox2:KLF4.
98. The method of claim 95, wherein the inducing de-differentiation comprises exposing cells to OSKM in 100% T cell medium on days 0-1, then over the next 3-4 days reducing the percent (v / v) T cell medium and increasing the percent (v / v) stem cell medium with cytokines, followed by 100% stem cell medium without cytokines.
99. The method of claim 95, wherein the inducing de-differentiation comprises exposing cells to 100% T cell medium with cytokines from about day 2 to about day 5.
100. The method of claim 98 or 99, wherein the cytokines comprise IL-2, IL-7 and / or IL- 15, such as such as 10-3000 IU / mLIL-2, 10-20 ng / mLIL-7 and / or 10-20 ng / mL IL- 15, for example, 12 lU / mL IL-2, 10 ng / mL IL-7 and 10 ng / mL IL- 15.
101. The method of claim 95, wherein the T cells are exposed to 100% T cell medium without cytokines starting about day 6.
102. The method of claim 95, wherein inducing de-differentiation of the CD8 T cells comprisesa. exposing the CD8 T cells to Sendai-OSKM and 100% T cell medium on days 0-1;b. exposing the CD8 T cells to 75% T cell medium, 25% stem cell medium and cytokines on about day 2;c. exposing the CD8 T cells to 50% T cell medium, 50% stem cell medium and cytokines on about day 3d. exposing the CD8 T cells to 25% T cell medium, 75% stem cell medium and cytokines on about day 4;[UCLA 2024-240] P-638467-PC e. exposing the CD8 T cells to 100% stem cell medium and cytokines on about day 5; andf. exposing the CD8 T cells to 100% stem cell medium without cytokines starting on about day 6; andg. exposing the CD8 T cells to 100% stem cell medium without cytokines for the reminder of culture.
103. The method of any one of claims 95-102, wherein the full de-differentiation occurs over about 1-2 months.
104. The method of any one of claims 95-103, wherein during and / or after any one or more steps, the iPSC are expanded.
105. The method of claim 104, wherein the expansion occurs in stem cell medium.
106. The method of claim 95, wherein the maturing of the iPSCs to T cells is carried out by culturing the iPSCs in an ATO.
107. The method of claim 106, wherein the culturing is carried out for about 3-4 months.
108. The method of claim 95, wherein the CD8 cells isolated from the tumor, tumor environment, tumor microenvironment or blood express CD39, CD69, CD103, CD 137, PD-1, TIM3, or any combination thereof.
109. The method of claim 95, wherein inducing de-differentiation of the CD8 T cells further comprises including at least one epigenetic modifier.
110. The method of claim 95, wherein inducing de-differentiation of the CD8 T cells further comprises including vitamin C, a histone deacetylase inhibitor such as valproic acid (VPA), a histone methyltransferase inhibitor, such as a DOT1L inhibitor, optionally EPZ-5676 (pinometostat), and / or a GSK3b inhibitor such as CHIR99021.[UCLA 2024-240] P-638467-PC 111. The method of claim 95, wherein the iPSC are induced or matured into mesodermal progenitors, followed by induction into hematopoietic progenitors, and then into differentiated into naive or stem-like T cells.
112. The method of claim 111, wherein the iPSCs are sequentially exposed toa. Activin A, BMP4, VEGF, and FGF (mesodermal induction);b. aggregating mesodermal progenitors with a MS5-DLL4 cells and culturing resultant organoids initially in EGM2 media with a TGFb inhibitor then EGM2 media with a TGFb inhibitor plus SCF, FLT3L, and TPO (hematopoietic induction); andc. cultured in RPMI media supplemented with ascorbic acid, B27 supplement, SCF, FLT3L, IL-7 (T cell differentiation).
